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Abstract
Neuropsychiatric symptoms (NPS) are prevalent in dementia, and it has been estimated 
that up to 90% of people with dementia will experience NPS in the course of their 
dementia. Sometimes NPS in dementia are poorly diagnosed, and the effect of the 
treatment prescribed for the NPS has been poorly documented.
The aim of this thesis was to describe the prevalence, course and treatment of NPS in 
Norwegian nursing homes. We wanted to study whether NPS are transient or persistent. In 
addition, we wanted to investigate the effect of discontinuing treatment with 
antidepressants and antipsychotics on patients in Norwegian nursing homes with dementia 
and NPS. We conducted a small pilot discontinuation study, and a large double blind 
randomised controlled discontinuation trial (DB RCT). Previous DB RCT discontinuation 
studies of antipsychotics have shown that discontinuation of the medication has been 
beneficial for the patients, while the effect of the discontinuation of antidepressants in 
patients with dementia and NPS has not previously been studied in a DB RCT. To obtain
good assessments of the cognitive function of the patients in the study, most of them 
having moderate or severe dementia, we translated the Severe Impairment Battery (SIB) 
into Norwegian and validated this instrument.
Four studies were conducted. In the validation study of the SIB 59 patients from three 
nursing homes in Hedmark and Oppland were included. In the study on the prevalence and 
the course of NPS in nursing homes, 210 patients from seven nursing homes in Hedmark 
and Oppland were included. In the pilot discontinuation study, 23 patients from seven 
nursing homes in Hedmark and Oppland were included, while in the DB RCT 
discontinuation study of antidepressants 128 patients from 52 nursing homes in 14 
counties of Norway were included.
The Severe Impairment Battery (SIB) is a cognitive test for patients with moderate to 
severe dementia (minimum score 0 and maximum score 100). In the SIB validation study, 
three psychiatrists/doctors drafted the cognitive questionnaire into Norwegian before a 
psychiatrist made a final Norwegian translation from the three drafts. A colleague born in 
Newcastle, who has lived in Norway for several decades, translated the Norwegian 
version of the SIB back into English, and this version corresponded well with the original 
English version. The patients' cognition and degree of dementia were examined with the 
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SIB and the Clinical Dementia Rating scale (CDR), while the patients were diagnosed 
with dementia according to the International Classification of Diseases (ICD-10). A nurse 
and a doctor used the SIB to assess the patients within seven days of each other. The 
average SIB score was 72.10 points. In the reliability study Cronbach's alpha was 0.97, 
indicating a good internal reliability of the test. Spearman's rho correlation coefficient 
between the two testers was 0.85 for the total SIB score, and ranged between 0.46 and 
0.76 for the sub-items of the test, which indicated a good inter-rater reliability. Scoring 
results on the SIB were compared with the CDR scores of patients. Spearman's rho 
correlation coefficient between the SIB score and the CDR score was 0.55. The groups of 
patients with CDR 1, 2 and 3 were significantly different from each other as measured by 
the SIB. By using Receiver Operating Characteristic (ROC) curve analysis we found that 
the SIB score of 87/88 best discriminated between CDR <2 and CDR 2, while the SIB 
score of 80/81 best discriminated between the CDR 2 and CDR 3 The study indicated that 
the Norwegian version of the SIB is reliable and valid, and can be used to evaluate 
cognition in patients with moderate and severe dementia.
In the study of the prevalence and the course of NPS, patients were examined at baseline 
(T0) and after four (T1) eight (T2), twelve (T3) and sixteen (T4) months with the 
Neuropsychiatric Inventory (NPI), CDR, the Mini-Mental State Examination (MMSE) and 
the Quality of Life in late-stage dementia (QUALID) scale. The NPI examines NPS, and 
we reported the prevalence and course of the NPS identified with the NPI. At baseline, the 
average age of the patients included was 84.9 years, 69.2% were female and the median 
length of stay in the nursing home was 673 days. The three most prevalent NPS were 
irritability, agitation/aggression and apathy (T0 and T1), irritability, agitation/aggression
and disinhibition (T2 and T3) and depression, disinhibition and irritability (T4). Irritability
had the highest cumulative prevalence (63.5%), followed by agitation/aggression (51.0%) 
and disinhibition (50.0%). In total, 91.7% of patients had at least one NPS during the 16 
months period. Irritability (42.6%), disinhibition (37.8%) and depression (31.5%) had the 
highest cumulative incidence. The most persistent NPS were agitation/aggression,
irritability and disinhibition (T0-T1) and (T1-T2), disinhibition, apathy and irritability 
(T2-T3) and hallucinations, depression and anxiety (T3-T4). The NPS with highest 
resolution rate were euphoria, appetite and eating disorders, and sleep and night-time 
behaviour disorders (T0-T1) and (T1-T2), appetite and eating disorders, hallucinations and 
delusions (T2-T3) and appetite and eating disorders, euphoria and apathy (T3-T4). The 
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conclusion of this study is that almost all patients included in this study have one or more 
NPS in the course of sixteen months, but individual symptoms fluctuate, which should 
affect the treatment which patients are given.
In the small pilot study where we investigated the effect of the discontinuation of 
antidepressants and antipsychotics, 23 patients with dementia, but without a depressive 
disorder, were included. Twelve patients used antipsychotics of different types and 11 
patients used selective serotonin reuptake inhibitor (SSRI) antidepressants. Patients were 
examined at baseline with the CDR, the NPI, the Cornell Scale for Depression in 
Dementia (CSDD), a sub-scale of the Unified Parkinson's Disease Rating Scale (UPDRS), 
the SIB, the Lawton and Brody's Physical Self-Maintenance Scale (PSMS) and the Quality 
of Life-Alzheimer's Disease (QoL-AD) scale. At three, six and 12 weeks, patients were 
examined with the NPI and the UPDRS, and after 24 weeks the same assessment scales as 
at baseline were used. At inclusion the average age was 84.1 years and 91.3% were 
women. At three and six weeks, we found a small increase in the NPI and the UPDRS 
scores of patients in both groups, but at 12 and 24 weeks the scores on both scales were 
back to baseline levels. The SIB scores (cognition) at 24 weeks showed a slight decrease 
in the group who discontinued antidepressant medication and a small increase in the group 
who discontinued antipsychotics. The CSDD scores were unchanged in the antipsychotic 
group, but showed a small decrease in the antidepressant group. None of the results were 
statistically significant, but suggested that discontinuation of antidepressants and 
antipsychotics were safe in the patients with dementia and NPS, and could even be 
beneficial for the patients.
In the randomised double-blind RCT discontinuation study of antidepressants, the 128 
patients were assessed with the same assessment tools as in the pilot study and the 
assessments were done at baseline and after four, seven, 13 and 25 weeks. The 128 
patients used escitalopram, citalopram, sertraline or paroxetine at inclusion. In half of the 
patients the antidepressive medication was discontinued, while in the other half of the 
patients the medication was continued. The study was double blind and placebo-
controlled, meaning that in patients who discontinued medication the antidepressant was 
substituted by placebo tablets or capsules identical in appearance to the study medication 
in those who continued with medication. Neither the patients, the relatives, employees at 
the nursing home or the study management knew which patients were in the 
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discontinuation group and which were in the active medication group, as randomisation 
and distribution of the study medication was made by the hospital pharmacy at Innlandet 
Hospital Trust, Gjøvik. Randomisation was by a computer-generated 1:1 allocation 
sequence. Sixty-three patients were allocated to the antidepressants discontinuation group 
(ADG), out of which 27 patients (42.9%) had to discontinue the study within 25 weeks. 
Sixty-five patients were allocated to the antidepressants continuation group (ACG), out of 
which 18 patients (27.7%) had to discontinue the study within 25 weeks. At baseline, the 
groups were comparable in terms of age, gender, NPI score, CSDD score and all the other 
measured variables. At 25 weeks, the ADG group had an increase of 2.53 points on the 
CSDD from 5.03 points while the ACG group had a decrease of -0.43 point from 5.89 
points. The difference between the groups was statistically significant. A post hoc analysis 
showed that the difference in the total CSDD score between the groups were statistically 
significant different as early as at week 7 (visit 3). Measured with the NPI the ADG group 
had an increase of 5.93 points from 17.79 points while the ACG group had a decrease of -
1.39 points from 17.63 points. When analysing the results with ANCOVA, and correcting 
for the baseline values of the CSDD, the difference between groups was still statistically 
significant. We analysed the mood sub-scores of the CSDD, based on a Norwegian factor 
analysis (Barca et al., 2008), and the affective subscales of the NPI (NPI-depression + NPI 
Anxiety) to examine the mood symptoms of the patients. This analysis also showed 
statistically significant differences between the groups. For the other assessment tools –
the CDR, the UPDRS, the QoL-AD and the PSMS – there were no statistically significant 
changes between baseline and 25 weeks. We concluded that discontinuation of 
antidepressants in patients who have dementia and NPS, but no depressive disorder, led to 
an increase in depressive symptoms.
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Sammendrag
Nevropsykiatriske symptomer (NPS) er hyppig forekommende ved demens, og det er blitt 
estimert at opp mot 90 % av alle personer med demens vil oppleve NPS i løpet av sin 
demenssykdom. NPS ved demens er dessverre til dels dårlig diagnostisert, og effekten av
behandlingen vi tilbyr ved NPS har vært dårlig dokumentert. 
Målet med denne forskningen har vært å beskrive forekomst, forløp og behandling av NPS 
i norske sykehjem. Vi ønsket å undersøke hvilke nevropsykiatriske symptomer som var 
flyktige og hvilke symptomer som var vedvarende. I tillegg ønsket vi å undersøke effekten 
av å seponere antidepressiva hos pasienter på norske sykehjem med demens og NPS. Vi 
gjennomførte en liten pilotseponeringsstudie og en større dobbeltblind randomisert 
kontrollert seponeringsstudie (DB RCT). Tidligere DB RCT seponeringsstudier av 
antipsykotika har vist at seponeringen av medisinen har gagnet pasientene, mens effekten 
av å seponere antidepressiva hos pasienter med demens og NPS aldri tidligere har vært 
undersøkt i en DB RCT. For å ha et godt mål på den kognitive funksjonen hos pasientene i 
studien, som for det meste hadde moderat og alvorlig demens, oversatte vi the Severe 
Impairment Battery (SIB) til norsk, og validerte og reliabilitetstestet dette 
måleinstrumentet.
Fire studier ble gjennomført. I valideringsstudien av SIB ble 59 pasienter inkludert fra tre 
sykehjem i Hedmark og Oppland. I forekomst og forløpsstudien av NPS i sykehjem, ble 
210 pasienter fra syv sykehjem i Hedmark og Oppland inkludert. I pilotseponeringsstudien 
ble 23 pasienter fra syv sykehjem i Hedmark og Oppland inkludert, og i DB RCT 
seponeringsstudien av antidepressiva ble 128 pasienter fra 52 sykehjem i 14 fylker av 
Norge inkludert.
The Severe Impairment Battery (SIB) er en kognitiv test som er tilrettelagt for pasienter 
med moderat til alvorlige demens. Minimum skåre på testen er 0 og maksimum skåre er 
100. I valideringsstudien av SIB ble testen oversatt fra engelsk til norsk av tre 
psykiatere/leger før en fjerde psykiater laget en felles norsk versjon av de tre forslagene. 
En kollega født i Newcastle, som har bodd i Norge i flere tiår, oversatte den norske 
versjonen tilbake til engelsk, og denne versjonen var i overensstemmelse med den 
opprinnelige engelske versjonen. Pasientenes kognisjon og grad av demens ble undersøkt 
med SIB og the Clinical Dementia Rating scale (CDR), og pasientene ble diagnostisert 
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med demens i henhold til International Classification of Diseases (ICD-10). Testing med 
SIB ble gjort av en sykepleier og en lege med maksimum syv dagers mellomrom. 
Gjennomsnittlig SIB poengsum hos pasientene var 72,10 poeng. Cronbach’s alfa var 0,97,
som indikerer en god intern reliabilitet for testen. Spearman’s rho korrelasjonskoeffisient 
mellom de to testerne var 0,85 for total SIB skåre, og varierte mellom 0,46 og 0,76 for 
underskårene i testen, noe som indikerte en god inter-rater reliabilitet. Skåringsresultatene 
på SIB ble sammenholdt med CDR skåre for pasientene. Spearman’s rho korrelasjons 
koeffisient mellom SIB skåre og CDR var 0,55. Gruppene av pasienter med CDR 1, 2 og 3 
var signifikant forskjellig fra hverandre målt med SIB. Ved hjelp av Receiver Operating 
Characteristic (ROC) kurve analyser fant vi at en SIB skåre på 87/88 best skilte mellom 
CDR<2 og CDR 2, mens en SIB skåre på 80/81 best skilte mellom CDR 2 og CDR 3. 
Studien indikerte at den norske versjonen av SIB er reliabel og valid, og kan benyttes til å 
evaluere kognisjonen hos pasienter med moderat og alvorlig grad av demens.
I forekomst- og forløpsstudien ble pasientene undersøkt ved baseline (T0) og etter fire 
(T1) åtte (T2), tolv (T3) og seksten(T4) måneder med Neuropsychiatric Inventory (NPI), 
CDR, Mini-Mental Status Evaluering (MMSE) og Quality of life in late-stage dementia 
(QUALID) skala. NPI undersøker NPS. Ved baseline var gjennomsnittsalder på de 
inkluderte pasientene 84,9 år, 69,2 % var kvinner og median lengde på 
sykehjemsoppholdet var 673 dager. De tre mest hyppige NPS ved de ulike 
måletidspunktene var irritabilitet, agitasjon og apati ved T0 og T1, irritabilitet, agitasjon 
og manglende hemninger ved T2 og T3, og depresjon, manglende hemninger og 
irritabilitet ved T4. Høyest kumulativ forekomst hadde irritabilitet (63.5 %), agitasjon 
(51.0 %) og manglende hemninger (50.0 %). Hele 91.7 % av pasientene hadde minst et 
NPS i løpet av 16 måneders perioden. Irritabilitet (42.6 %), manglende hemninger (37.8 
%) og depresjon (31.5 %) hadde høyest kumulativ insidens. De mest vedvarende NPS var 
agitasjon, irritabilitet og manglende hemninger (T0–T1) og (T1–T2), manglende 
hemninger, apati og irritabilitet (T2–T3) og hallusinasjoner, depresjon og angst (T3–T4). 
De mest flyktige NPS var eufori, endringer i spisemønsteret og endret nattvaner (T0–T1) 
og (T1 – T2), endringer i spisemønsteret, hallusinasjoner og vrangforestillinger (T2–T3) 
og endringer i spisemønsteret, eufori og apati (T3–T4). Konklusjonen på denne 
undersøkelsen er at nesten alle pasienter innlagt på de sykehjem vi undersøkte har en eller 
flere NPS i løpet av seksten måneder, men de enkelte symptomene er flyktige, noe som 
burde ha innvirkning på behandlingen som pasientene tilbys.
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I den lille pilotstudien hvor vi undersøkte effekten av seponering av antidepressiva og 
antipsykotika ble 23 pasienter med demens, uten en depressiv lidelse inkludert. I alt 12 
pasienter brukte antipsykotika av forskjellige typer og 11 pasienter brukte antidepressiva 
av typen Selektive Serotonin Reopptak Inhibitor (SSRI). Pasientene ble undersøkt ved
baseline med CDR, NPI, the Cornell Scale of Depression in Dementia (CSDD), en 
underskala av the Unified Parkinson’s Disease Rating Scale (UPDRS), SIB, Lawton and 
Brody’s Physical Self Maintenance Scale (PSMS) og Quality of Life- Alzheimer’s 
Disease (QoL-AD). Ved tre, seks og 12 uker ble pasientene undersøkt med NPI og 
UPDRS, og etter 24 uker ble samme kartleggingsverktøy som ved baseline brukt. Ved 
inklusjon var gjennomsnittelig alder 84,1 år og 91,3 % var kvinner. Ved tre og seks uker 
fant vi en liten økning i NPI og UPDRS skåre hos pasientene i begge gruppene, men 
skåringene på begge skalaene gikk ved 12 og 24 uker tilbake igjen til utgangsverdien. SIB 
skåringene (kognisjon) viste ved 24 uker en liten nedgang i gruppen som seponerte 
antidepressiva og en liten økning i gruppen som seponerte antipsykotika. CSDD 
skåringene var uforandret i antipsykotika gruppa, men viste en nedgang i antidepressiva 
gruppa. Ingen av resultatene var statistisk signifikante, men antydet at seponering av 
antidepressiva og antipsykotika hos pasienter med demens og NPS var trygt, og til og med 
kunne være en fordel for pasientene.
I den dobbelblinde randomiserte seponeringsstudien av antidepressiva ble de 128 
pasientene undersøkt med de samme kartleggingsverktøyene som i pilotstudien. Det ble 
gjort undersøkelser ved baseline og etter fire, sju, 13 og 25 uker. De 128 pasientene brukte 
enten escitalopram, citalopram, sertraline eller paroksetin ved inklusjon. Hos halvparten 
av pasientene ble medisinen seponert, mens den andre halvparten fortsatte med sin 
opprinnelige medisin. Studien var dobbelblind og placebokontrollert, dvs. at pasientene 
som fikk seponert antidepressiva fikk erstattet medikasjonen med placebotabletter eller 
kapsler med identisk utseende som den aktive medikasjonen. Verken pasienter, pårørende, 
ansatte på sykehjemmet eller studieledelsen visste hvilke pasienter som var i 
seponeringsgruppen eller hvilke som var i gruppen med aktiv medikasjon, da 
randomiseringen og utsending av studiemedikasjon ble gjort av sykehusapoteket på 
Gjøvik (og ble holdt hemmelig). Randomiseringen ble gjort med en datamaskin i henhold 
til en 1:1 randomiseringsliste. Seksti-tre pasienter fikk seponert antidepressiva 
(Antidepressiva Discontinuation Group - ADG), 27 (42.9 %) av dem måtte avbryte 
studien før 25 uker. Seksti-fem pasienter fortsatte med antidepressiva (Antidepressiva 
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Continuation Group - ACG), 18 (27.7 %) av dem måtte avbryte studien før 25 uker. Ved 
baseline var det ingen signifikante forskjeller mellom gruppene i forhold til alder, kjønn, 
NPI skåring, CSDD skåring eller alle andre målte variabler. Ved 25 uker hadde ADG-
gruppen en økning på 2,53 poeng på CSDD fra 5,03 mens ACG-gruppen hadde en 
nedgang på -0,43 fra 5,89. Forskjellen mellom gruppene var statistisk signifikant. En post 
hoc analyse viste at forskjellen mellom gruppene målt med CSDD var statistisk signifikant 
forskjellig allerede etter 7 uker (besøk 3). Målt med NPI hadde ADG-gruppen en økning 
på 5,93 fra 17,79 mens ACG-gruppen hadde en nedgang på -1,39 fra 17,63. Ved en 
ANCOVA-analyse, der vi korrigerte for baselineverdier av CSDD, var forskjellen mellom 
gruppene fremdeles statistisk signifikante. Vi analyserte underskårer av CSDD og NPI for 
å se nærmere på effekten på de affektive symptomene. Også disse analysene viste 
statistisk signifikante forskjeller mellom gruppene. For de andre kartleggingsverktøyene; 
CDR, UPDRS, QoL-AD og Lawton og Brody ADL skjema (PSMS) fant vi ingen statistisk 
signifikante forskjeller mellom de to gruppene. Vi konkluderte at seponering av 
antidepressiva hos pasienter som har demens og NPS, men ingen depressiv lidelse, førte til 
en økning i depressive symptomer. 
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1 Introduction
Although Alois Alzheimer’s description of Auguste D and her disease, included in a 
lecture in November 1906, marks the beginning of dementia research, ”dementia” is an 
ancient term first used more than 2,000 years ago. The Roman poet and philosopher 
Lucretius used the term ”dementia” back in 50 B.C.E. in the sense of ”being out of one's 
mind”. At that time dementia was used to describe the condition of anyone who had lost 
their ability to reason, and was applied to patients with mental illness, infections involving 
the nervous system, and dementia experienced in old age. Dementia caused by old age 
was called ”demences senilis”, a term used in the first classification of mental diseases in 
1838. Arnold Pick was a German neurologist and psychiatrist best known for identifying 
the syndrome named after him (Pick’s disease), but in 1891 he used the term ”dementia 
praecox” to describe patients with loss of cognitive function following a psychosis. Later 
”Dementia Praecox” was altered to schizophrenia, which is today’s name for that disease.
Dementia is a syndrome including a decline in cognition to an extent that leads to 
functional impairment and a range of psychological and behavioural symptoms, such as 
hallucinations, delusion, anxiety, depression, agitation and disinhibition. The focus of
research on dementia has been on symptoms, risk factors and treatment, both in nursing 
home patients and patients living at home. 
The development of cognitive tests for patients with dementia has focused on tests for 
patients with mild to moderate cognitive impairment. Many of these cognitive tests, such 
as the Mini Mental State Examination (MMSE) and the Clock drawing  (CDT) test are 
both valid and have excellent reliability, but they have a ”floor effect”, which means that 
the tests are not able to differentiate between patients below a certain threshold of 
cognitive impairment. The Clinical Dementia Rating scale (CDR) categorises the level of 
dementia into no dementia (CDR<1), mild dementia (CDR 1), moderate dementia (CDR 
2) and severe dementia (CDR 3). Most of the patients with dementia in Norwegian nursing 
homes have moderate dementia (33.2%) or severe dementia (41.8%) (Selbaek et al.,
2007). To assess the changes in cognitive function in these patients more accurately, 
assessment tools for moderate to severe dementia have to be applied. The Severe 
Impairment Battery (SIB) was developed by Panisset and colleagues to overcome the floor 
effect (Panisset et al., 1994), and can be applied among patients with moderate and severe 
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degree of dementia. We translated the SIB into Norwegian, validated the scale and tested 
it for reliability. This leads us to paper I of the thesis.
Neuropsychiatric Symptoms (NPS) are frequent in dementia. According to a previous 
study 81% of patients in Norwegian nursing homes have dementia, and 72% of patients 
with dementia have NPS (Selbaek et al., 2007). The course of NPS fluctuates, and this has 
been demonstrated in several studies from different countries. The course of NPS in 
Norwegian nursing home patients has not been well studied. The only longitudinal study
is at twelve month follow up study on a cohort of 1,163 patients (Selbaek et al., 2008).
Internationally, the study with the longest follow-up time on the course of NPS in nursing 
homes was made by Wetzels et al. in the Nederland, which included 290 nursing home 
residents with a follow-up of two years (Wetzels et al., 2010b). We hypothesized that the 
NPS have a fluctuating course with rapid cycles and that a study of the course of NPS in 
Norwegian nursing homes with frequent assessments was necessary. This is covered in 
paper II of the thesis.
The treatments of NPS could be pharmacological and non-pharmacological. Studies on 
pharmacological treatment in Norwegian nursing homes have revealed that 75% of 
patients are prescribed psychotropic drugs (Selbaek et al., 2007). Thirty-nine percent of 
the patients in the study by Selbaek et al were prescribed antidepressants, and 26% of the 
patients were prescribed antipsychotics (Selbaek et al., 2007). In light of the lack of 
evidence for treating NPS and depression in dementia with antidepressants, we concluded 
that the prescription rate of antidepressants in Norwegian nursing homes was too high. We 
were curious to find out what the effect of antidepressant discontinuation in patients with 
dementia and NPS would be. An antidepressant discontinuation study in nursing homes 
would be the world’s first DB RCT discontinuation study of antidepressants in patients 
with dementia and, no matter whether the results would support or discourage the 
discontinuation of antidepressants; the conclusion would be of interest to clinicians 
throughout the world. This is covered in papers III and IV of the thesis.
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2 Background
2.1 Dementia
2.1.1 Definition, diagnosis, prevalence and risk factors
Dementia is not one illness or disease, but a clinical syndrome or a group of symptoms 
characterised by a decline in cognitive function to an extent that leads to functional 
impairment, as well as the occurrence of behavioural and psychological symptoms. 
Decline in cognition is the main symptom in most of the patients with dementia, although 
the first symptom of some of the dementia diseases is a behavioural or psychological 
symptom. Diagnosis of dementia is in two steps. Step one is to diagnose the dementia
syndrome; step two is to diagnose the specific disease causing the dementia syndrome. 
Dementia is normally diagnosed according to the criteria of the International 
Classification of Diseases, version 10 (ICD-10), published by the World Health 
Organisation (WHO) in 1993, or the criteria of Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition, Text Revision, (DSM-IV-TR), published by the American 
Psychiatric Association (APA) in 1994. The ICD-10 is in use in Norway, and textbox 1 
displays the ICD-10 research criteria for dementia. Although a large number of diseases 
may cause dementia, 95% of the dementias are caused by five diseases. The most frequent 
cause of dementia is Alzheimer’s Disease (AD), followed by Vascular Dementia (VaD), 
Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD), and dementia 
caused by excessive use of alcohol. Dementia is directly caused by neuronal dysfunction 
of the brain, and neuronal degeneration is found in AD, DLB and FTD. Depositions of 
extracellular -amyloid plaques and neurofibrillary tangles intracellular in neurons in the 
brain are found in AD. In DLB, Lewy bodies are found in the brain stem and also in 
cortical areas. FTD can be caused by a variety of disorders, which lead to cell death in 
frontal and temporal lobes of the brain. Depositions of Pick’s cells are seen in Pick’s 
disease, but most often other causes of neurodegeneration are seen in FTD. A
cerebrovascular infarct, caused by a thrombosis with loss of blood flow to brain areas or a 
hemorrhagic stroke, will cause cell death in neurons in VaD. In alcoholic dementia a 
combination of thiamine malnutrition and a neurotoxic effect of the alcohol on brain cells 
contributes to the dementia (Joyce, 1994).
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The differences in the clinical pictures of different types of dementia are best seen early in 
the course of the disease. Later the clinical picture is blurred and a precise diagnosis is 
difficult to make. In patients with AD the dementia in most cases presents with a memory 
decline as the first sign, but also dysfunction in other cognitive functions, such as 
attention, problem solving and orientation occurs. In FTD the memory of the patients is 
normally intact in the early stages. Instead these patients have decreased executive 
function, inattention, lack of motivation and socially aberrant behaviour as the first 
presenting symptoms. AD, DLB and FTD exhibit a gradual progression of the disease. 
Textbox 1 
Definition of the dementia syndrome, according to the ICD-10 research criteria
I. Evidence of each of the following:
a. A decline in memory. The decline should be objectively verified.
b. A decline in other cognitive abilities characterised by deterioration in judgement 
and thinking, such as planning and organising, and in the general processing of 
information.
- Mild. The decline in cognitive abilities causes impaired performance in daily 
living, but not to a degree making the individual dependent on others.
- Moderate. The decline in cognitive abilities makes the individual unable to 
function without the assistance of another in daily living. 
- Severe. The decline is characterised by an absence, or virtual absence, of 
intelligible ideation.
II. Preserved awareness of the environment (i.e. absence of clouding of consciousness). 
When there are superimposed episodes of delirium the diagnosis of dementia should 
be deferred.
III. A decline in emotional control or motivation, or a change in social behaviour, 
manifest as at least one of the following:
a. Emotional lability;
b. Irritability;
c. Apathy;
d. Coarsening of social behaviour.
IV. For a confident clinical diagnosis, G1 should have been present for at least six 
months; if the period since the manifest onset is shorter, the diagnosis can only be 
tentative.
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Patients with DLB have parkinsonism, visual hallucinations and fluctuation in cognitive 
function as markers of the disease, and two of the three symptoms should be present for a 
diagnosis of DLB to be made. Patients with VaD are a heterogeneous group, whose 
disease can be classified into post-stroke dementia, vascular dementia (cortical and sub-
cortical multi-infarct dementia, hypoperfusion and haemorrhagic dementia), mixed 
AD/VaD and vascular MCI (O'Brien et al., 2003). Some patients with VaD go through an 
acute onset of symptoms at first (F01.0, VaD with acute onset) related to the 
cerebrovascular incident, while other patients have a gradual onset (F01.1, multi-infarct 
dementia). Structural images of their brains show vascular pathology, but the dementia 
symptoms will vary according to where in the brain the cerebral infarcts are located. 
Dementia caused by excessive alcohol use is recognisable by a decline in memory, 
confabulation and decreased motivation, but some patients demonstrate frontal pathology 
such as disinhibition. Secondary dementia caused by other diseases, such as thyroid
dysfunction, infections, subdural hematomas and brain tumours are rare but should be 
excluded by a diagnostic assessment.
There are no exact prevalence numbers for the different dementia diagnoses in the 
literature, but a meta-analysis suggests that 60-70% of dementias are caused by AD, 20-
30% are caused by VaD and the rest are caused by other types of dementias (Lobo et al.,
2000). The introduction of the new criteria for DLB (McKeith et al., 2005) has focused 
attention on the disease, and in a Norwegian study of patients with mild dementia referred 
to geriatric and old-age psychiatric out-clinics the prevalence of DLB was 20% (Aarsland
et al., 2008). Dementia is a chronic condition that eventually leads to the death of the 
patient (Sachs et al., 2011).
The only population-based prevalence studies on dementia in Norway were done twenty-
five years ago, and are from Oslo (Engedal et al., 1988;Engedal, 1993). In this study the 
prevalence of dementia in elderly aged 75 years and above and living in their own home  
was 10.5% (severe dementia 3.8% and mild dementia 6.7%) (Engedal et al., 1988). For 
patients living in nursing home the prevalence of dementia was 71.6% (Engedal, 1993).
In a study of 4,736 elderly persons receiving in-home care or living in nursing homes in 
Norway, 24.8% of the persons living at home and 74.9% of nursing-home patients had
dementia (Nygaard et al., 1987). A study on the prevalence of dementia in a non-
representative sample of Norwegian nursing homes has been conducted, showing a 
26
prevalence of dementia in nursing homes of 82% (Nygaard et al., 2000). When estimating 
the number of patients with dementia in Norway we have to include information from 
studies in related countries and extrapolate the numbers (Harvey et al., 2003;Ott et al.,
1998;Ott et al., 1995). Table 1 shows the prevalence of dementia in Oslo, Rotterdam and 
England.
Table 1. Prevalence of dementia in Norway extrapolated from other studies
Age
(years)
London Rotterdam Oslo
Estimates of number 
of persons with dementia 
in Norway
45-64 0.08 – 0.12% 900-1300
65-69 0.9% 1 468
70-74 2.1% 3 369
75-79 6.1% 10.1% 9 198
80-84 17.6% 16.7% 20 115
85-89 31.7% 26.2% 19 127
90+ 40.7% 28.3% 10 920
Total 65 000
Adapted from (Engedal and Haugen, 2004)
It is estimated that 24.3 million people worldwide have dementia, and the number is 
expected to increase to approximately 81.1 million by 2040 (Ferri et al., 2005). The one-
year incidence of dementia worldwide is 4.6 million. Most of the patients with dementia 
are living in the developing countries, which have the highest incidence rate as well. 
The economic costs for dementia are difficult to estimate. According to a report from the 
World Health Organisation (WHO), assessing disability with the Global Burden of 
Disease, dementia is the disease which contributes to most years of disability (11.2%), 
followed by stroke, musculoskeletal disorders and cardiovascular disease (World Health 
Organization, 2003).
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Major risk factors for dementia are old age (Lobo et al., 2000), vascular risk factors and 
genetic polymorphism. Vascular risk factors such as high blood pressure, Diabetes 
Mellitus and hypercholesterolemia have been intensively studied, indicating a plausible 
positive association (Skoog et al., 1996;Ott et al., 1999;Kivipelto et al., 2002).
Nevertheless, double blinded randomised placebo controlled trials (DB RCT) intervening 
on the vascular risk factor did not decrease the risk of dementia (Ligthart et al., 2010).
Lately the attention has been drawn to genetic research, and the strongest correlation is 
found between persons being a homozygotic APOE-	
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
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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
(Farrer et al., 1997), although there is evidence for APOE- being a risk factor for VaD 
as well (Jones et al., 2011). Large genetic studies with more than 5000 included AD 
patients and controls have found associations between AD and other loci as the ApoJ, 
PICALM and CR1 (Harold et al., 2009;Lambert et al., 2009).
Recent studies have concluded that a socially active life, physical activity, a healthy diet, 
and mentally and intellectually stimulating activities are protective factors against 
dementia (Kivipelto and Solomon, 2008;Fratiglioni and Qiu, 2009;Fratiglioni et al., 2004).
A recent meta-analysis concluded that physical activity was protective against VaD 
(Aarsland et al., 2010).
2.1.2 Cognitive Assessment scales and diagnostic procedure
A wide selection of cognitive tests is available for the assessment of patients with 
suspected dementia. Some tests are screening tests for declining cognitive function; some 
tests are for the examination of global cognitive function, while others are for the 
assessment of specific cognitive functions. The Mini Mental State Examination is one of 
the world’s most used screening tests for cognitive dysfunction (Folstein et al., 1975), and 
is useful in differentiating between persons with dementia of moderate or severe degree 
and  persons without dementia. However, the MMSE does not differentiate very well 
between persons with mild cognitive impairment (MCI) and those with a mild degree of 
dementia (Edhag and Norlund, 2006;SBU, 2008). The clock-drawing test is a screening 
test for executive function and visuospatial capacity (Sunderland et al., 1989). The Trail-
Making Test A (TMT-A) and Trail-Making Test B (TMT-B) are assessment scales which 
evaluate attention, speed and mental flexibility (Reitan RM, 1955). The Ten Word recall 
test from the Consortium to Establish a Registry for Alzheimer’s disease (CERAD) 
battery of tests is a visual and verbal memory test, and other parts of the CERAD battery 
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of neuropsychological tests are the Boston naming test for aphasia and Constructional 
Praxis. The Controlled Oral Word Association Test (COWAT) is a verbal fluency test.
The Rey Auditory Verbal Learning Test (AVLT), California Verbal Learning Test 
(CVLT) and the Kendrick Object Learning Test are other examples of memory tests 
(Morris et al., 1989;Kendrick DC et al., 1979;Rey A, 1964;Delis et al., 1988).
Cognitive assessment in the later stages of dementia
In the later stages of dementia the cognitive tests used in investigations in the early stages 
do not work well to measure the degree of cognitive impairment, due to floor effects. 
Therefore, other methods are used. One way to measure degree of cognition is to obtain 
proxy information from carers or relatives and use this information together with 
information from interviews with the patients to rate the degree of dementia. The Clinical 
Dementia Rating Scale (CDR) is a six-item questionnaire (memory, orientation, 
judgement and problem solving, community affairs, homes and hobbies and personal care) 
(Hughes et al., 1982), where the patients’ degree of dementia is scored based on all 
available information. The CDR categorises the severity of the dementia as no dementia 
(CDR=0), possible dementia (CDR=0.5), mild (CDR=1), moderate (CDR=2) or severe 
dementia (CDR=3). The Global Deterioration Scale for the Assessment of Primary 
Degenerative Dementia (GDS) categorises the dementia into seven stages according to the 
cognitive decline (Reisberg et al., 1982), while the Functional Assessment Staging Test 
(FAST) consists of 16 stages and sub-stages (Reisberg, 1988). The Severe Impairment
Battery (SIB) is a cognitive test with 51 items (minimum score zero, maximum score 
100), especially developed for patients with moderate and severe dementia (Saxton and 
Swihart, 1989). The SIB consists of both multiple choice questions and tests for practical 
skills, which makes the questionnaire feasible for patients with moderate and severe 
dementia.   
Other examinations
A diagnostic investigation of patients with suspected cognitive decline or dementia 
should, in addition to the evaluation of cognition, include a structural and in many cases 
also a functional imaging of the brain, as well as blood tests. Biological tests will 
contribute to the investigation both to find treatable causes of dementia, such as brain 
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tumours and pathological thyroid function, but also in the differentiation of dementia 
types. 
Conventional Computer Tomography (CT) of the brain in patients with AD shows loss of 
brain substance in the temporal and parietal parts of the brain cortex, but the changes are 
not visible in all the patients with a very mild degree of AD. Magnetic Resonance Imaging 
(MRI) will, as the CT, show structural changes in the brain, but is more sensitive to show 
decreased volumes of the hippocampus area in patients with AD, DLB, FTD and VaD
(Firbank et al., 2011;Barber et al., 2000;Galton et al., 2001). Ppatients with AD have a 
bigger reduction in their hippocampus volume than patients with VaD and DLB (Burton et 
al., 2009). Both MRI and CT will be useful in diagnosing VaD by detecting
cerebrovascular infarcts. Patients with FTD have loss of brain substance in the frontal and 
temporal area of the brain cortex which is often visible on MRI scans (but not always in 
the very mild cases). 
Functional imaging of the brain by Single-Photon Emission-Computed Tomography 
(SPECT) shows decreased blood flow in the frontal and temporal areas of the brain in 
FTD and in the temporal and parietal area in AD, and may be useful to distinguish FTD 
and AD more accurately, (Ballard et al., 2011b). Positron emission tomography (PET) is a 
widely used method for functional imaging of tissue, not only in the brain. If the 
biologically active molecule chosen for PET is an analogue of glucose (FDG), the 
concentrations of tracer that appear on the image give the metabolic activity of the tissue. 
The FDG-PET scan of the brain is useful in discriminating AD from other dementias 
(Berti et al., 2011). The newly developed method of amyloid imaging with pathology 
specific A-PET will improve early detection of AD (Mosconi et al., 2010). Elevated 
levels of amyloid plaque in brain tissue, assessed with PET-scans, are found in patients 
with AD and DLB compared to controls and patients with FTD, and the amyloid 
deposition is especially prevalent early in the course of the disease (Quigley et al., 2011).
In AD lower concentration of beta-amyloid and higher concentration of phosphorylated 
tau is found in the cerebrospinal fluid (CSF), and analyses of spinal fluid may be helpful 
in the diagnostic investigation (Hansson et al., 2006).
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2.1.3 Treatment
At the moment there is no cure for any types of dementia, and the current available 
medical treatment for dementia, cognitive enhancers, can only modify the symptoms of 
the dementia in patients with AD, Parkinson’s disease with Dementia (PDD) and DLB,
VaD and mixed AD/VaD. Two classes of cognitive enhancers are licensed for use in 
Norway, but neither the acetylcholinesterase inhibitors (AchEI) nor memantine have 
demonstrated more than a modest effect on cognition, performance of ADL or a clinical 
global impression of change  (McShane et al., 2006;Birks and Harvey, 2003). The effect 
of AchEI on NPS has been studied on several occasions, but the results are contradictory. 
Best evidence is for the effect of AchEI in reducing apathy, depression and aberrant motor 
behaviour (Gauthier et al., 2010). One study has reported a reduction in agitation in 
patients with AD in nursing homes using donepezil (Tariot et al., 2001). In recent decades 
a variety of research groups have worked to develop and study the effects of active 
immunisation as a therapy to reduce amyloid plaque in transgenic mice. The trials have 
been successful in reducing the amyloid deposit in mice brains, but the memory did not 
improve (Morgan, 2011). Passive immunisation with antibodies has been tested out in 
patients with Alzheimer’s Disease, and has led to amyloid plaque clearance, but no 
improvement in cognition (Morgan, 2011). Immunisation has possible dangerous side 
effects, such as microhaemorrhages, encephalitis and vasogenic intracranial oedemas.
2.2 Neuropsychiatric Symptoms
2.2.1 Definitions and diagnosis
The recognised symptom of dementia is cognitive impairment and especially a decline in 
memory. However, the accompanying symptoms of dementia such as apathy, depression, 
agitation and delusion, are often more devastating and create more discomfort for the 
patients and cause more distress for the carers than the cognitive deficit. Defining the 
group of behavioural and psychological symptoms into a specific syndrome has been 
challenging, and different names for this group of symptoms have been applied. Due to 
the diversity of the symptoms, it has been difficult to agree upon one term that describes 
the whole group of symptoms. As this group of symptoms are symptoms associated with 
dementia, but different from cognitive dysfunction, “non-cognitive symptoms of 
dementia” has been proposed as a term for the group of symptoms. Other terms, such as 
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“behavioural disturbances” and “challenging behaviour”, refer to the altered behaviour
(such as apathy, agitation or aggression), while “neuropsychiatric symptoms” refer to the 
more psychological symptoms, for example delusions, hallucinations, depression and 
anxiety. The term “Behavioural and Psychological Symptoms of Dementia” (BPSD) was 
first presented at the International Psychogeriatric Association’s (IPA) Initial Consensus 
Conference on BPSD in 1996, and BPSD was defined as “Signs and symptoms of 
disturbed perception, thought content, mood or behaviour that frequently occur in patients 
with dementia” (Finkel et al., 1996). The IPA established a task force to define the 
concept, presented at the Update Consensus Conference, entitled “Behavioural and 
Psychological Symptoms of Dementia (BPSD): A Clinical and Research Update”, held in 
May 1999. Over the next decade “BPSD” was frequently used to describe the group of 
symptoms. The problems of aggregating several distinct symptoms into one syndrome or 
concept soon were apparent, and criticism strengthened. Problems escalated even more 
when clinical trials on the treatment for BPSD often used the total score on assessment 
scales for BPSD when evaluating efficacy of psychotropic medications. It has been argued 
that the symptoms of BPSD should be treated individually, and not as a syndrome. In 
recent years more and more researchers and clinicians have used the term 
“neuropsychiatric symptoms of dementia (NPS)”, or even divided the group of symptoms 
into distinct individual symptoms, such as depression in dementia. For the rest of this 
thesis I will use the term “NPS” when talking about behavioural or psychological 
symptoms of dementia. Some of the individual neuropsychiatric symptoms have naturally 
been classified into sub-syndromes, e.g. psychosis consisting of delusion and 
hallucinations. Factor analyses of the assessment scales for NPS have supported the 
aggregation of single symptoms of NPS into sub-syndromes.
2.2.2 Clinical presentation
The definition and classification of the individual neuropsychiatric symptoms are 
important to ensure that we all discuss the same symptoms, but the classification may be 
challenging. For most of the NPS neither the ICD-10 nor the DSM-IV provides good and 
reliable definitions for NPS, and there are no specific diagnoses for NPS. The definition of 
individual NPS is mostly based on the various assessment scales that are used to classify 
and quantify NPS. In any case, some individual symptoms or signs of NPS, or specific 
sub-syndromes, do need specific consideration.
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2.2.2.1 Delusion
Delusions in patients with dementia are often simple in their presentation. Paranoid types 
of delusion are common, best described as fear of being robbed, fear that their spouse is 
cheating on them or fear of being persecuted. More complex and bizarre delusions, as may 
be seen in patients with schizophrenia, are seldom seen in patients with dementia (Jeste 
and Finkel, 2000). Delusions is frequent in AD.
2.2.2.2 Hallucinations
Visual hallucinations are by far the most common type of hallucinations in patients with 
dementia, both in patients with AD and in patients with DLB (Jeste and Finkel, 2000). In 
patients with DLB visual hallucinations are frequent. The hallucinations in DLB are 
recurrent in nature, are usually present early in the disease and are persistent throughout
course of the disease (Weisman and McKeith, 2007).
Misidentification is common in patients with dementia, and should be distinguished from 
delusions and hallucinations. They are usually visual in their nature, e.g. misidentification 
of close relatives or misidentification of the patients’ own mirror reflection.
2.2.2.3 Depressive symptoms
Depressive symptoms occur frequently in dementia, but should be distinguished from a 
depressive disorder in patients with dementia. Depressive disorders are defined in the 
ICD-10, and the same diagnostic criteria are applied to patients with dementia as to 
patients without dementia. Diagnosis of a depressive disorder in patients with dementia is 
difficult, and a discussion of symptoms and assessment scales will be covered in chapter 
2.3. It is important for the treatment of patients with dementia to differentiate a diagnosis 
of a depressive disorder in dementia from depressive symptoms in dementia, as the choice 
of treatment depends on this difference. The cut off between a depressive disorder in 
dementia and depressive symptoms in dementia is unclear and precise diagnosis is 
challenging, due to variety in the expression of symptoms, overlap between dementia and 
depression symptoms, as well as the patients’ communications and language problems. 
Depressive symptoms are frequent in VaD and DLB.
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2.2.2.4 Anxiety
Patients with dementia are often concerned about the future and worry about forthcoming 
events and plans. As a natural reaction to their loss of memory and cognitive decline, the 
patients lose track of their belongings, and are then concerned that their belongings may 
be lost. There is no exact definition of anxiety in dementia, although some argue for using 
DSM-IV or ICD-10 criteria for anxiety. One important consideration is how anxiety in 
patients with dementia is expressed, and it has been suggested that other NPS, such as 
agitation, irritability and aggression, could be interpreted as signs of anxiety (Clive-Reed 
and Gellis, 2011). This broadened definition of anxiety in dementia that some researchers 
have adopted is also reflected in the prevalence number for anxiety in dementia, which 
varies from 25 to 70% (Ballard et al., 2000;Teri et al., 1999).
2.2.2.5 Apathy
Apathy in dementia is one of the most prevalent NPS, and causes distress for the patients 
and reduces their Quality of Life. Apathy may be a sign of lack of internal motivation or a 
sign of behavioural inactivity (Brodaty and Burns, 2011). Several definitions of apathy in 
dementia have been formulated, but most of them include points such as diminished 
response to reward and lack of goal-directed behaviour (Brown and Pluck, 2000). Apathy 
is frequent in AD, FTD and VaD.
2.2.2.6 Agitation
Agitation in dementia is often recognised as wandering, restlessness, repetitive behaviour, 
attention seeking, screaming, plucking and pacing. A widely used definition is the 
classification of agitation by Cohen-Mansfield as aggressive behaviour, physically 
nonaggressive behaviour and verbally agitated behaviour (Cohen-Mansfield et al., 1989).
2.2.2.7 Irritability/aggression
Physically aggressive behaviour in dementia is widely seen, and causes a lot of distress for
the patients, the carers and the relatives. A wide definition of physical aggression is given 
by Patel and Hope: “an overt act involving delivery of a noxious stimulus to another 
person which was clearly not accidental” (Patel and Hope, 1992).
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2.2.2.8 Disinhibition
Disinhibition is one of the core symptoms in FTD, leading to impulsive or inappropriate 
behaviour, swearing, and outbursts of frustration or lack of social tact. Patients may also 
lack inhibition with regard to handling their finances, shop lifting or aberrant sexual 
behaviour. 
2.2.3 Assessment scales
There are methodological challenges related to the assessment scales for NPS. Due to the 
patients’ cognitive decline, loss of insight and decline in language and communication 
abilities most of the patients are unable to describe the symptoms themselves. Hence, 
several assessment scales for NPS are based on observations made by either the carers or 
the relatives, but the observation-based assessment scales rely on different aspects of the 
patient–carer relationship as well as the carer’s personal experiences and attitude to the 
patient. The challenge has been to develop assessment scales that are both valid and 
reliable. The validity of the questionnaire has to be strong, that is that the assessment 
scales are assessing what they are meant to assess. Further, the assessment scales should 
assess the patients in a similar way if rated by two or more persons (inter-rater reliability), 
as well as at different time points (test–retest reliability). Assessment scales for 
neuropsychiatric symptoms may be global (assessing different symptoms within the NPS 
spectrum) or a specific scale especially developed to rate one single NPS. The 
Neuropsychiatric Inventory (NPI) is a well-known global assessment scale widely used in 
both research and in clinical practice (Cummings et al., 1994). The NPI originally 
consisted of 10 different items: delusions, hallucinations, depression/dysphoria, anxiety, 
agitation/aggression, euphoria, disinhibition, irritability/lability, apathy and aberrant motor 
activity. Later, two neurovegetative items, sleep and night-time behaviour disorders, and 
appetite and eating disorders, were added to the NPI and this version is often referred to as 
the NPI-12 as opposed to the original NPI-10 version (Cummings, 1997). Each symptom 
in the NPI is first rated as present or not during the last four weeks, and if present the 
frequency is rated on a scale from 1 to 4 where 4 is most frequent, while the severity of 
the symptom is rated on a scale from 1 to 3 where 3 is most severe. Each symptom is rated 
alone, without taking into account the other NPS. The frequency score and the severity 
score are multiplied together and thereafter the scores of all 12 symptoms are added 
together giving a maximum score of 144. A score above three on an individual NPS is 
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regarded as a clinically significant symptom (Steinberg et al., 2004). As the NPI consists 
of symptoms that are phenomenologically different, the total score on the NPI is not 
always the best way to quantify the burden of NPS on the patients. Several studies have, 
therefore, through a factor analysis, divided the NPI scale into sub-syndromes (Aalten et 
al., 2003;Selbaek and Engedal, 2011).
Another widely used global assessment scale for NPS is the Behavioural Pathology in 
Alzheimer’s Disease (BEHAVE-AD) (Reisberg et al., 1996;Reisberg et al., 1987). The 
BEHAVE-AD was developed in 1987 as an attempt to overcome the problem of the rating 
scales of NPS used at that time, where assessments of cognition, functionality and NPS 
were done on the same assessments scale (Reisberg et al., 1996). The motivation for the 
development of a questionnaire solely assessing NPS has to be seen in the light of the 
definition of the BPSD at that time. The 25 items of the BEHAVE-AD are grouped into 
seven major categories (Paranoid and delusional ideation, Hallucinations, Activity 
disturbances, Aggressiveness, Diurnal rhythm disturbances, Affective disturbances and 
Anxieties and phobias). The severity of each symptom is scored on a 4-point scale, where 
0 = not present, 1 = present, 2 = present, generally with an emotional component, and 3 =
present, generally with an emotional and physical component. In addition the BEHAVE-
AD contains a 4-point global assessment of the overall magnitude of the NPS. 
For individual symptoms, such as depression, anxiety and agitation, assessment scales 
tailored for specific symptoms have been developed. Assessment scales for depression are 
the Cornell Scale of Depression in Dementia (CSDD) (Alexopoulos et al., 1988a), the 
Geriatric Depression Scale (GDS) (Yesavage et al., 1982), the Hamilton Depression 
Rating Scale (HAM-D) (Hamilton, 1960) and the Montgomery Asberg Depression Rating 
Scale (MADRS) (Montgomery and Asberg, 1979). Among those scales the only ad proxy 
based scale is the CSDD, which for this reason is the most feasible assessment scale for 
depression in patients with dementia.
Agitation has been of particular interest to researchers. The Cohen-Mansfield Agitation 
Inventory (CMAI) (Cohen-Mansfield, 1996) is a questionnaire for agitation in dementia. 
and the Brief Agitation Rating Scale (BARS) is a sub-scale of the CMAI (Finkel et al.,
1993).
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2.2.4 NPS and different dementia types
The differences in symptoms and signs between different types of dementia are largest at 
the start of the various dementia disorders. In the severe stage, regardless of which 
dementia disorder is present, most patients experience more or less all the symptoms of 
dementia and the clinical picture is blurred. 
2.2.4.1 Alzheimer’s disease
In AD NPS are frequently found, especially in the severe stages of the disease, and 
patients are characteristically identified with anxiety, apathy and depression (Spalletta et 
al., 2010). A recent review concluded, by using weighted means from three studies, that 
apathy (55.5%), depression (45.9%) and anxiety (42.0%) were the three most prevalent 
NPS in AD (Gauthier et al., 2010). While the prevalence rate of depression is stable across 
the severity of the dementia, prevalence rates for apathy increases with increasing severity. 
If psychotic symptoms are present delusions are more prevalent than hallucinations.
2.2.4.2 Dementia with Lewy Body (DLB)/Parkinson’s disease with dementia (PDD)
DLB is associated with hallucination, delusion, depression, irritability and aggression. In a 
Norwegian prospective study over twelve years almost 60% of the patients with DLB had 
developed psychosis (Forsaa et al., 2010). Hallucination in the DLB is usually of the 
visual type, and is regarded as a mark of the disease and is one of the criteria for DLB 
(McKeith et al., 1996). As many as 50 to 80% of patients with DLB and 78% of patients 
with Parkinson’s disease and dementia have visual hallucinations (Harding et al.,
2002;Gold, 2009). Disinhibition is frequent in DLB, found in 65% of the patients 
(Engelborghs et al., 2005), while in a study with 339 patients with DLB, 63.1% of the 
patients had sleep disturbances assessed with NPI-Q (Bliwise et al., 2011). Significantly 
more sleep disturbances were found in patients with dementia (71%) than in patients 
without dementia (55.7%), and most sleep disturbances were found in patients with DLB 
(Rongve et al., 2010). Depression is more prevalent in patients with DLB/PDD than in 
patients with AD (Fritze et al., 2011).
2.2.4.3 Vascular Dementia (VaD)
Patients with vascular dementia are a heterogeneous group, ranging from patients with one 
large single infarct to patients with sub cortical ischemic cerebrovascular dementia.
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Depression, emotional lability and apathy is common in VaD, especially depression, while 
psychosis is less prevalent in VaD than other types of dementias (O'Brien, 2003).
Depression and anxiety are found to be equally common in VaD as in AD (Ballard et al.,
2000).
2.2.4.4 Frontotemporal Dementia (FTD)
Patients with FTD seldom experience cognitive decline at the beginning of their disease, 
while NPS such as apathy, disinhibition, irritability and aberrant social behaviour 
dominate their dementia (Engelborghs et al., 2005). Psychotic symptoms are very rare in 
patients with FTD. 
2.2.4.5 Dementia due to excessive alcohol use
Patients with dementia due to excessive alcohol use usually present with apathy and loss 
of attention, in addition to confabulation. Some of the patients have disinhibition, if they 
have damage in the frontal lobes of their brain.
2.2.5 Prevalence of NPS
Prevalence rates of NPS are available from studies from different geographical areas and 
from different settings. Estimates of the overall prevalence of NPS for patients with 
dementia, defined as expressing at least one individual NPS at a given time, range from 25 
to 80% according to the cohort studied. This variation in prevalence rates is most likely 
caused by methodological issues, such as differences in the cohorts studied, both in level 
of care, diagnosis of dementia, time frame of data collection, assessment tools and 
threshold for defining a symptom as present. The prevalence of some individual NPS 
differs according to the severity of the dementia and type of dementia disease, while the 
prevalence of other individual NPS are stable across type of dementia and severity. This is 
reflected in different prevalence rates in patients living at home and in institutions.
2.2.5.1 Population based studies
Population based studies (recruiting patients from the community and not through clinical 
settings) are important to the description of the prevalence of NPS, in that they reduce the 
bias found in studies that assess patients referred from a clinical setting. Prevalence of any 
NPS in patients with Mild Cognitive Impairment (MCI) is from 35 to 85% (Monastero et 
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al., 2009). Interestingly enough, the prevalence of NPS has been reported to be as high as 
27-29% in persons without cognitive decline, with depression (11.4%), aberrant night time 
behaviour (10.9%) and irritability (7.6%) being the most frequent symptoms (Geda et al.,
2008;Chan et al., 2010). Geda and colleagues reported a significant difference in the 
prevalence of NPS in persons without cognitive decline and in patients with MCI. Apathy, 
agitation, anxiety, irritability and depression were all more prevalent in patients with MCI, 
having an OR above 2.5 compared to persons without any cognitive impairment (Geda et 
al., 2008). The most prevalent NPS in patients with MCI were depression/dysphoria 
(27.0%), apathy (18.5%) and irritability/lability (19.4%). For patients with dementia, the 
prevalence of NPS in population based studies ranges from 61 to 88%, with apathy (27–
57%) and depression (24-38%) being the most frequent (Lyketsos et al., 2000;Ikeda et al.,
2004;Tatsch et al., 2006).
2.2.5.2 Clinical out-patient studies
Several studies have used the NPI as an assessment scale for NPS, but nevertheless 
prevalence estimates in out-patients vary from 74% to 96%, indicating differences in the 
samples as well as in the dementia diagnosis (Steffens et al., 2005;Benoit et al.,
1999;Petrovic et al., 2007). One of the problems with prevalence studies in clinical 
settings is that some of the patients have been prescribed psychotropic medication, which 
may alter to what extent they express their symptoms. One study from Italy tried to avoid 
this problem, by including only patients with newly diagnosed AD who had not been 
prescribed any psychotropic medication. They reported a prevalence of 59.4% for at least 
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patients having clinically significant apathy and 29.3% of the patients having an affective 
sub syndrome (NPI-depression + NPI-anxiety) (Spalletta et al., 2010).
2.2.5.3 Long term care
Prevalence rates of NPS for patients in long term care settings have been presented in 
several studies in recent decades. Eighty-one percentage of patients in Norwegian nursing 
homes have dementia, and 72 % of the patients with dementia have a clinically significant 
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(Selbaek et al., 2007). The most prevalent 
NPS in Norwegian nursing homes are irritability (present in 29.3% of the patients), apathy 
(29.1%) and aggression (26.6%). Zuidema estimated prevalence of NPS in 1,322 patients 
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in Dutch nursing homes, and measured with the NPH-NH they found that 
agitation/aggression, apathy and irritability were the most frequent symptoms (30–35%). 
Assessed by the CMAI, 85% of the patients had symptoms of agitation (Zuidema et al.,
2007). In 1990 Burns and colleagues published four studies describing the prevalence of 
NPS in 178 patients from nursing homes and outpatient clinics with AD, assessed by the 
Geriatric Mental State Schedule (GMSS) (Copeland et al., 1976). They reported 
prevalence rates for delusion (10.7%), hallucination (11.3%), aggression (19.7%), 
wandering (18.5%) and apathy (40.5%) (Burns et al., 1990d;Burns et al., 1990c;Burns et 
al., 1990b;Burns et al., 1990a).
Prevalence rates can also be estimated from baseline data in longitudinal studies. Ballard 
et al. included 206 patients in a longitudinal study of NPS, 136 of them with a second 
assessment after one year (Ballard et al., 2001a). Overall 76% of the patients had at least 
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hallucinations, 40% expressed aggression, 32% had aberrant motor behaviour and 18% 
had depression. Wancata et al. included 249 patients 60 years and older, and assessed 
them at baseline and after six months with the Clinical Interview Schedule (CIS) 
(Goldberg et al., 1970). Thirty-eight percentages of the patients experienced some NPS at 
baseline, 30% had at least one depressive symptom while 12.7.5% had at least one 
symptom in the aggressive-psychotic syndrome (Wancata et al., 2003). In a longitudinal 
study with 299 patients in long term care institutions from the Netherlands, the most 
prevalent NPS at baseline were irritability (28.2%), aberrant motor behaviour (23.1%) and 
agitation (20.5%) (Wetzels et al., 2010b).
2.2.6 Course of the NPS
Several studies report the course of NPS, and they show heterogeneity in the course of the 
symptoms (Wetzels et al., 2010a). Overall it has been estimated that up to 90% of patients 
with dementia will experience at least one NPS through the course of the disease (Robert
et al., 2005). The course of the NPS may be studied by categorising the patients with 
dementia according to dementia severity, or by following a cohort of patients with 
dementia with repeated assessments of NPS. 
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Prevalence of NPS according to the severity of the dementia
Most of the prevalence studies on NPS report an increased prevalence of NPS as the 
dementia becomes more severe. In a large study on NPS in Norwegian nursing homes, 
Selbæk et al. report an overall prevalence of NPS (any NPI item > 3) of  54.5% in mild 
dementia (CDR = 1), 69.7% in moderate dementia (CDR = 2) and 83.6% in severe 
dementia (CDR = 3) (Selbaek et al., 2007). There was a statistically significant increase in 
the prevalence of delusions, hallucinations, aggression, apathy, disinhibition and aberrant 
motor behaviour as the dementia became more severe. In a study by Ballard et al. patients 
were assessed at baseline and after one year. At follow up the overall trend was that fewer 
patients expressed a clinically significant NPS, although hallucination (7%) and any NPS 
(82%) showed an increasing trend (Ballard et al., 2001b).
Recurrence, persistence and resolution
Several studies have assessed NPS in a cohort of patients over the course of time, and so 
were able to record recurrence, persistence and resolution of NPS. “Persistence” is defined 
as the ratio of patients with Clinically Significant NPS (CS-NPS) at follow-up to patients 
with CS-NPS at the previous assessment, and “resolution” is the ratio of patients without 
CS-NPS at follow-up to the patients with CS-NPS at the previous assessment. 
“Recurrence” is the ratio of patients with symptoms at follow up to the patients with CS-
NPS at one of the previous assessments. Studies on the course of NPS have been on both 
outpatients and those in long term care (Aalten et al., 2005;Devanand et al., 1997;Ballard
et al., 2001a;Wancata et al., 2003;Wetzels et al., 2010b;Selbaek et al., 2008). Although 
the prevalence rate of symptoms remains stable, with only minor changes in the 
percentage of patients with NPS, the symptoms for each patient show an intermittent 
course. The studies report an overall high resolution rate of the NPS, with resolution rate 
from 57% to 87% (agitation sub-syndrome), from 56% to 75% (psychotic sub-syndrome), 
from 37% to 85% (depressive sub-syndrome) and 48% (apathy) (Wetzels et al., 2010a).
The fluctuation in resolution rate is caused by differences in the assessment tools, the time 
between assessments, the dementia diagnosis and the severity of the disease. 
2.2.7 Possible causes and risk factors for NPS in dementia
The possible underlying causes for NPS in patients with dementia are many: biological 
and personal factors in the patient, alteration of neurotransmitters, genetic factors, brain 
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morphology and environmental factors, such as the attitudes and perhaps hostility in carers 
and relatives, and the physical environment of the patient’s home or the institution in 
which they are living. The interactions between the causes are complex, and for an 
individual patient it is not possible to identify one single cause of NPS.
2.2.7.1 Neurochemical factors
Patients with dementia are found to have alterations in their neurotransmitter systems, due 
to increased or decreased levels of neurotransmitters, neuron loss or receptor loss, changes 
in the density of receptors, in the up-and-down regulation of receptors or a combination of 
the above mechanisms. Understanding the pathology of the neurotransmitter system in 
patients with dementia may direct the development of treatment options for NPS, as well 
as explaining the underlying causes of NPS. 
Norepinephrine
Norepinephrine (NE) is a neurotransmitter both in the central nervous system (CNS) and 
in the peripheral nervous system. The NE concentration as well as the density of 
noradrenergic neurons are decreased in many areas of the brain in patients with AD, 
(Herrmann et al., 2004). A correlation has been found between the severity of the AD and 
the level of NE dysfunction (Bondareff et al., 1982), but the results are contradictory. 
Decreased function of the NE system is associated with such NPS as depression and 
anxiety, while increased levels of NE have been found in AD patients with aggression and 
agitation (Herrmann et al., 2004). Loss of NE neurons in AD may lead to an acceleration 
of NE metabolism and hence an increase in NE activity (Hoogendijk et al., 1999) .
Serotonin
Low levels of serotonin in the CNS are known to be associated with depression or anxiety 
in patients without dementia. This association is the basis for treating anxiety and 
depressive disorders with Selective Serotonin Reuptake Inhibitor (SSRI), which will 
increase the concentration of extracellular serotonin in the brain. The association between 
serotonin depletion and depression/anxiety is not as clear in patients with dementia. 
Studies with functional neuroimaging demonstrate serotonergic dysfunction both in 
patients with AD and FTD, but the location of the serotonergic dysfunction in the brain 
varies between studies (Salmon, 2007). In AD the numbers of 5HT2 receptors are often 
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decreased, which in studies have been associated with behavioural symptoms, but the 
effect of serotonin on cognition and depression in AD is less clear (Salmon, 2007). In FTD 
loss of serotonin receptors is found in the frontal and temporal cortex as well as in the 
nucleus raphe dorsalis. The serotonin dysfunction in FTD is linked with increased 
impulsivity and irritability, affective change, and changes in eating behaviour (Weder et 
al., 2007).
Acetylcholine
Low levels of acetylcholine in patients with AD are associated with cognitive decline 
(Winkler et al., 1998), which is the theoretical basis for the use of Acetylcholinesterase 
inhibitors (AchEI) in AD and DLB. Unfortunately, the effect of AchEI on cognition is 
limited (Clegg et al., 2002). Acetylcholine has also been associated with NPS in patients 
with dementia. The limbic system and the nucleus basalis of Meynert are involved in the 
mediation of emotion, mood and motivation, and decreased levels of acetylcholine in 
these areas are found in AD and may be associated with NPS in patients with AD 
(Grossberg, 2005). Increased muscarinic M2 binding in the temporal and frontal cortex, 
inhibiting Ach–binding, were found to be associated with psychosis in a small sample of  
26 patients with AD (Lai et al., 2001), while decreased cholinergic function assessed post-
mortem in brains of patients with AD were found to be associated with aggression 
(Garcia-Alloza et al., 2005).
Gamma-aminobutyric acid (GABA) and Glutamate
Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the 
human brain. GABA is present in the neocortex and the hippocampus, modulating the 
cholinergic and glutamatergic activity and thereby participating in the neuropathology of 
NPS, especially depression and apathy in AD (Limon et al., 2011;Garcia-Alloza et al.,
2006). Glutamate is an excitatory neurotransmitter in the brain. In a small study (21 
patients with AD) the regulation of glutamate was found to be affected in patients with 
dementia and a high anxiety score (Tsang et al., 2008), but affection of the regulation of 
glutamate has not been demonstrated in patients with AD and depressive symptoms 
(Garcia-Alloza et al., 2006). Although not demonstrated in clinical settings, there is a 
hypothetical possibility that a low concentration of glutamate in frontal and cingulated 
cortices correlates with agitation and irritability in dementia (Francis, 2009).
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2.2.7.2 Genetic factors
Due to the strong familial aggregation of symptoms implicating genetic variation as a 
mediating factor in the development of those symptoms, many NPS studies in recent years 
have employed designs to study genetic association. Associations have been found 
between genetic factors and psychosis (Sweet et al., 1998) and between genetic factors 
and agitation and depression (Tunstall et al., 2000). Identification of genetic risk factors 
provides clinicians with the possibility of screening and targeting therapeutic strategies 
(Holmes et al., 1998). Moreover, a few studies have reported preliminary findings 
positively associating a response to treatment with antipsychotics with polymorphisms 
already associated with the NPS themselves (Angelucci et al., 2009;Dombrovski et al.,
2010), indicating a possible role for these polymorphisms in the cost effectiveness as well 
as the therapeutic effectiveness of treatment. A recent review shows that the results are 
contradictory (Michele-Sweet and Sweet, 2010). From a methodological perspective these 
differences are likely to be in part the result of four principal concerns: 1) small sample 
sizes; 2) differing definitions of syndromes; 3) differing criteria for a symptom to be 
recognised as ”clinically significant”; and 4) in those studies which use a cross-sectional 
method it is not always clear whether the phenotype under investigation will have had 
enough time to emerge as clinically significant.  
Apolipoprotein E (ApoE) is a well established risk factor for AD. Persons with 
	^-allelles have an increased risk of developing AD compared to 
	^*-allelles (OR=14.9) (Farrer et al., 1997). Persons with heterozygote 
epsilon2/epsilon4 (OR=2.6) and epsilon3/epsilon4 (OR=3.2) also have an increased risk, 
while people with genotypes epsilon2/epsilon2 (OR=0.6) and epsilon2/epsilon3 (OR=0.6) 
have a decreased risk (Farrer et al., 1997). Whether the ApoE 4 polymorphism is related 
to NPS or not has been examined in several studies lately. Some studies indicating that 
^-allelles carriers are at risk of developing depression and apathy during the course 
of their AD, but other studies report no association between ApoE 4 and depression in 
patients with dementia (Hirono and Cummings, 1999;Butters et al., 2003;Cacabelos et al.,
1997). An association between AD, depression and ApoE 4 was found in a recent study 
of 322 older patients, divided into three groups; patients with AD and NPS (N=93), 
patients with AD but without NPS (N=108), and patients with no cognitive impairment 
(No CI: N=121). Overall, they found no significant difference in the distribution of ApoE 
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genotypes between AD patients with and without NPS, but they reported that patients 
carrying ApoE 	

	_depression and apathy (D'Onofrio et al., 2011).
A Norwegian study found the same association, reporting that AD patients carrying an 
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 (Fritze et al., 2011).
Different receptor polymorphisms and transporter polymorphisms for serotonin and 
dopamine have been associated with NPS. One polymorphism of a serotonin transporter 
gene has been associated with psychosis in AD; one polymorphism of a dopamine 
transporter gene has been associated with agitation while a polymorphism in a dopamine 
receptor gene has been associated with mood symptoms in dementia (Proitsi et al., 2010).
Decreased density of serotonin transporters (SERT) is found in the prefrontal cortex of the 
brain in patients with AD, but no differences in transporter density was found between AD 
patients with and without severe depression (Thomas et al., 2006). Polymorphisms of the 
dopamine receptors and transporter genes have also been associated with behavioural 
symptoms, such as sleep disturbance and aberrant motor behaviour (Proitsi et al., 2010).
The likelihood of depression is increased by five times in patients with AD and a 
polymorphism of the serotonin receptor genes (5HT2A and 5HT2C), compared to patients 
without a polymorphism (Holmes et al., 2003). In a small study patients with DLB/PDD 
and depression had higher density of Serotonin 1A receptors in the temporal cortex than 
DLB/PDD patients without depression (Sharp et al., 2008).
2.2.7.3 Structural and functional brain changes
The evolution of new technologies in brain imagining has allowed studies on the 
relationship between structural changes in the brain of patients with dementia and the NPS 
of the patients. Structural changes can be assessed with Computerised Tomography (CT) 
and Magnetic Resonance Imaging (MRI), while functional changes in patients with 
dementia can be assessed with Single-Photon Emission Computed Tomography (SPECT), 
functional MRI (fMRI) and Positron Emission Tomography (PET). Nevertheless, the 
results in different studies are contradictory, probably caused by small sample size, 
heterogeneity in patients in terms of dementia diagnosis and severity, different assessment 
techniques and other methodological problems.
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Cerebrovascular factors and depressive symptoms
Depression in dementia is associated with decreased blood flow in the prefrontal areas, the 
superior frontal and anterior cingular region, as demonstrated in two studies using PET 
technology (Hirono et al., 1998;Holthoff et al., 2005). Assessed by MRI, white 
matter hyperintensities in the frontal and right parietal lobe are strongly correlated with 
apathy and depression in Alzheimer's disease (Malloy et al., 2007;O'Brien et al.,
1996;Starkstein et al., 2009). Assessed by MRI, the same dysfunction in the fronto-
subcortical circuits is found in patients with VaD and FTD with apathy (Malloy et al.,
2007). In a study of 116 persons with AD, VaD or DLB, the medial temporal lobe width 
on CT scanning was significantly greater in patients with depression than in patients with 
dementia, but there was no difference in width between patients with different dementia 
diagnoses (O'Brien et al., 2000). Many articles report structural differences in the brains of 
patients expressing apathy and patients expressing depression. Assessed by MRI, 
structural brain dysfunction in patients with depressive symptoms and dementia is more 
located in the frontal deep white matter and basal ganglia, while patients with apathy have 
dysfunctions in the superior frontal and anterior cingular region (Malloy et al., 2007).
There are also convincing evidences for the association between cardiovascular risk 
factors early in life and depression later in life (Almeida et al., 2007).
Functional brain changes
Functional dysfunction in the brain may be assessed by SPECT. Aggression in patients 
with dementia is in one study associated with decreased perfusion in the left anterior 
temporal lobe (Hirono et al., 2000) and in another study associated with dysfunction in the 
right middle temporal lobe (Lanctot et al., 2004), which makes the interpretation of the 
results difficult. The evidence is more convincing for FTD, where several studies 
assessing patients with SPECT have concluded that a dysfunction in the right frontal and 
temporal lobe is associated with aggression, antisocial behaviour or other socially 
undesirable behaviour (Mychack et al., 2001).
Psychosis in dementia has been studied in patients with AD and DLB. Several studies 
have demonstrated, with the use of PET scans, dysfunction in the frontal, parietal, and 
temporal lobes in AD patients with psychosis, more specific hypoperfusion in the regions 
of the right parietal and left dorsolateral prefrontal cortex (Meeks et al., 2006). Structural 
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imaging (CT) has also revealed an asymmetry in the frontal and temporal lobe in 
psychosis of AD (Geroldi et al., 2002).
2.2.7.4 Environmental factors
Several environmental factors have to be considered as possibly contributing to the NPS 
of patients with dementia, but obviously there are methodological challenges when 
studying these factors. Much attention has been paid to the patient’s physical environment 
in their home or in an institution. The development from nursing homes with large units to 
smaller Special Care Units (SCU) with fewer patients has been appraised by care givers 
and relatives, but research in the field is controversial. No DB RCT has been performed on 
the effect of SCU compared to ordinary nursing home units, but several non-RCTs 
comparing SCU with ordinary nursing home units have been published. Nevertheless, the 
results are difficult to interpret as only one study has examined the effect of SCU on one 
primary outcome (Bellelli et al., 1998). Bellelli et al. report differences in symptoms seen 
in patients after admission to SCU. They reported a decrease in affective symptoms and 
agitation but no difference in psychotropic drug use after three months (Bellelli et al.,
1998). Overall, a favourable effect of SCU on affective symptoms, agitation, psychotropic 
drug use and use of physical restraints compared to ordinary nursing home units was 
reported in a recent Cochrane review, but no effect was found on the quality of life of the 
patients (Lai et al., 2009).
The carers’ influence on the patients and vice versa has been extensively studied, in an 
attempt to clarify the interaction between the carer and the patient. Professional carers
obviously express different emotions towards the patients than relatives living with the 
patients do, but the interaction and emotions expressed between professional carers and 
the patients are important for the treatment of the patients. The Unmet Needs Model 
proposes that people with dementia are unable to articulate their needs and therefore react 
to adverse situations with behaviour that may be disturbing to others (Cohen-Mansfield, 
2001).
2.2.7.5 Cognition
Cognition is connected to NPS, and the association is best understood as the prevalence of 
NPS increasing as the dementia becomes more severe (Selbaek et al., 2007). As the 
cognitive function declines, in combination with loss of vision and hearing, the patients 
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with dementia will have problems interpreting input from the surroundings in which they 
live, which may lead to NPS. Loss of cognitive functions, such as motivation and 
executive functions, may also lead to inactivity, mimicking NPS such as apathy and 
depressive symptoms. In a cross-sectional study, examining 125 probably AD-patients 
with cognitive tests and NPI, García-Alberca et al. found that decline in cognitive function 
predicted NPS (Garcia-Alberca et al., 2011). Although García-Alberca’s study was small 
and is supported by few other studies, the finding is interesting and should encourage 
further research in the field.
2.2.7.6 Somatic diseases
NPS may be caused by, or worsened as a result of, somatic diseases. Hypothyroidism, for 
example, manifests itself with apathy, decreased energy, depressive symptoms and 
cognitive decline, which may be interpreted as NPS in dementia. Somatic diseases, such 
as urinary tract infections, constipation, anaemia or a broken bone may cause delirium in 
the patient. The clinical picture of delirium is fluctuating consciousness, hyper- or hypo 
activity, disturbances in day-night rhythm and disorganisation of behaviour, which may be 
difficult to differentiate from dementia with NPS. Delirium is more prevalent in patients 
with dementia than in patients without dementia, which could further complicate the 
separation of dementia with NPS from delirium. Pain in patients with dementia may be 
interpreted as a NPS. The verbal expression of pain is difficult for patients with moderate 
and severe dementia, and pain could manifest itself or be expressed as a NPS. In a RCT of 
352 nursing home residents in western Norway, the group of patients receiving individual 
pain treatment had a significant reduction of agitation and other NPS compared to the 
group not receiving pain treatment (Husebo et al., 2011). The strong association between 
cerebrovascular risk factors, stroke, dementia and depression later in life is discussed in 
chapter 2.2.7.6. NPS symptoms as apathy and depression is common after cerebrovascular 
incidents, and 30-50% of patients experience depressive symptoms post-stroke (Berg et 
al., 2003;Hackett et al., 2005).
2.2.8 Consequences of NPS
Neuropsychiatric symptoms are risk factors for the development of dementia. In a Chinese 
study with 321 patients, patients with Mild Cognitive Impairment (MCI) who showed 
NPS had an increased risk of progression to dementia compared to patients with MCI but 
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without NPS, most highly correlated in patients with depression accompanying the MCI 
(Chan et al., 2011). Previous studies have also reported an increased risk of cognitive 
decline in patients with dementia and depressive symptoms (Wilson et al., 2002). Other 
studies have reported that hallucination is a risk factor for progression to dementia caused 
by AD (Burns et al., 1990b;Scarmeas et al., 2005;Wilson et al., 2000).
Different kinds of NPS have been associated with functional impairment. In a study of 523 
patients with AD, anxiety was reported to be associated with ADL impairment (Teri et al.,
1999). Aggression was associated with functional impairment (Haupt et al., 2000) in a 
study of 60 patients with AD, and in a study with 456 patients with AD followed for up to 
14 years, psychosis was a risk factor for decline in both ADL function and cognition 
(Scarmeas et al., 2005).
The concept of Quality of Life (QoL) in patients with dementia has been difficult to 
describe and therefore it has been difficult to agree upon a common definition of QoL in 
dementia. Several assessment scales have been developed to assess QoL in dementia.
They have been used to study the association between NPS and QoL, but there is a 
discrepancy in the results. One study has reported an inverse association between NPS and 
QoL, increased prevalence of NPS being associated with a decreased QoL in a study of
101 patients with AD (Banerjee et al., 2006), but other studies have shown no association 
between NPS and QoL (Ballard et al., 2001c). In a systematic review of studies on the 
association between dementia and QoL, they found no association between decline in 
cognition or functional impairment and QoL, but they found an association between 
depression and lowered QoL (Banerjee et al., 2009). A Norwegian study also reported an 
association between low QoL and severe depression (Barca et al., 2011).
NPS cause distress for the carer and relatives of patients with dementia (Ulstein et al.,
2007;Black and Almeida, 2004). Several studies have studied the association between 
depression in carers of patients with dementia and NPS in the patient, but the results are 
contradictory (Black and Almeida, 2004;Donaldson et al., 1997) showing a poor to 
moderate association. In patients with newly diagnosed PDD, relatives of the patients 
reported apathy, depression, anxiety and irritability caused most distress (Leiknes et al.,
2010).
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Patients with dementia need nursing home placement earlier than persons without 
dementia (Luppa et al., 2010), but also factors such as increased age of the patient or the 
carer, living alone and male gender contribute to institutionalisation. In patients with 
dementia cognitive impairment is associated with institutionalisation, but there is also an 
association between NPS and nursing home placement (Luppa et al., 2008). Aggression 
had the highest hazard ratio for time to nursing home placement (HR 4.17), followed by 
hallucination (HR 2.54) and depression (HR 1.07) (Gilley et al., 2004). NPS are also 
found to increase the cost of care for patients with dementia, estimated at an increased cost 
of $30 per month for each additional point on the NPI (Herrmann et al., 2006).
2.2.9 Treatment
NPS cause distress for the patients and the carers, and much effort has been put into 
finding the best treatment for the different NPS. While research into pharmacological 
treatments for NPS dominated the field in the 1990s, the interest in research into non-
pharmacological treatments for NPS increased in the following decade. The separation of 
treatment into pharmacological and non-pharmacological alternatives has been criticised, 
as the terms indicated that the non-pharmacological treatment is inferior to the 
pharmacological treatment (Cohen-Mansfield, 2001). It has been argued that the term non-
pharmacological treatment should be replaced by the term psychosocial intervention. The 
term psychosocial intervention is unfortunately not perfect either, as some interventions 
are neither psychological nor founded on social theory, but the term psychosocial 
intervention will be used in this thesis. 
2.2.9.1 Psychosocial interventions 
Recently, reviews of the treatment of the NPS have stated that the treatment of choice for 
NPS is psychosocial intervention (Ballard and Corbett, 2010). As the gold standard for a 
double blinded randomised placebo controlled trial (DB RCT) is difficult to apply in 
studies of psychosocial interventions, most of the research into psychosocial intervention 
is by means of open trials or observational studies. The best evidence for the effect of 
psychosocial intervention in the treatment of NPS is for hand massage and touch therapy 
(Viggo et al., 2006). Music therapy for patients with NPS may potentially reduce agitation 
in patients with dementia in the short term (Sung and Chang, 2005), although a Cochrane 
review using stricter criteria for the inclusion of studies in their meta-analysis concluded 
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that music therapy was of no effect for NPS (Vink et al., 2004). Exercise is effective in 
increasing physical strength and balance, and the most consistent evidence in elderly 
patients with and without dementia showed that exercise increased sleep duration and 
decreased night-time awakenings (Heyn et al., 2004). Conversely, a Cochrane review 
concluded that physical exercise was of no benefit in treating NPS for patients with 
dementia and NPS (Forbes et al., 2008). For other psychosocial interventions, such as 
acupuncture, reminiscence therapy, validation therapy, aromatherapy, animal assisted 
therapy and light therapy, the evidence for its effect is poor (O'Neil et al., 2011). The lack 
of evidence for psychosocial interventions might be caused by the study design, small 
study cohorts and methodological issues, but might also be caused by the lack of efficacy 
of the intervention. As well as intervening on the patient level, intervention on the staff 
level has been tried to improve the patients’ NPS. Intervention may focus on the 
motivation of the staff, their knowledge of dementia as well as their attitude towards the 
patients. Several studies on staff education lack a control group, and their results should be 
treated with caution. Burgio et al. systematically trained nursing home staff in the 
treatment of NPS. Compared to a control group of nursing homes without specific 
behavioural management techniques, patients in the intervention nursing homes showed 
reduced agitation (Burgio et al., 2002). It has also been demonstrated that learning non-
verbal communication both reduced symptoms in patients and increased the well-being of 
the care givers (Magai et al., 2002). Person-Centred Care (PCC) is a new way of thinking 
about dementia care, where the person with dementia is in focus, not the dementia disease. 
PCC was developed by Tom Kitwood and the relation to dementia is found in his book: 
”Dementia reconsidered: the person Comes First” (Kitwood T., 1997). Dementia-care 
mapping (DCM) is a method of implementing PCC in persons with dementia (Brooker, 
2005). There are a couple of high quality studies on PCC. In a study from Australia, 324 
patients with dementia from 15 sites were allocated to one of three treatment options: 1: 
DCM, 2: PCC; and 3: usually care (Chenoweth et al., 2009). The analysis showed a 
statistically significant reduction in agitation and the use of antipsychotic drugs over time 
for patients receiving PCC and DCM compared to patients receiving the usual care. In 
another smaller RCT study of the effect of PCC used with patients in a bathing situation (a 
towel bath or usual care), the group of patients receiving the PCC or towel bath had 
significantly reduced agitation and aggression compared to that in the group of patients 
receiving the usual care (Sloane et al., 2004). Other studies on PCC have been of poorer 
quality and the studies have had methodological limitations (Edvardsson et al., 2008).
51
2.2.9.2 Pharmacological interventions
There has been extensive research on the effect of psychotropic drugs for NPS. Studies on 
the cause of NPS have revealed deficits in the neurotransmitter system of patients with 
dementia and NPS, which have been the theoretical basis for pharmacological 
interventions. Finding one psychotropic drug which is effective for all kinds of NPS is 
probably not possible, and clinicians should be encouraged to tie intervention to specific 
symptoms in their patients. 
Antipsychotic medication
The experience with the effect of antipsychotic medication for psychosis in patients with 
Schizophrenia and other psychiatric diseases, induced optimism in treating psychosis in 
patients with dementia with antipsychotic medication. The effectiveness of antipsychotic 
medication for psychosis, agitation and aggression in dementia has been demonstrated in 
some studies (Brodaty et al., 2003;Cummings et al., 2002;De Deyn et al., 2004), but the 
results are contradictory as other studies have reported no effect of antipsychotic 
medication for NPS (Schneider et al., 2006). In reviews and meta-analyses the effect of 
atypical antipsychotic medication was demonstrated for risperidone (reducing aggression 
and psychosis) and aripiprazol (reducing aggression and psychosis), but the effect of the 
medication has to be balanced by the side effects of the medication (Ballard and Corbett, 
2010). Studies on olanzapine and quetiapine did not indicate benefit of the treatment on 
NPS (Ballard and Corbett, 2010). Side effects in patients using antipsychotics are extra 
pyramidal side effects (EPS), decreased cognitive function, sedation and metabolic side 
effects. Newer atypical antipsychotics are believed to have fewer EPS than old typical 
antipsychotics, but atypical antipsychotics have been found to increase the risk of death 
and cerebrovascular disease in patients with dementia (Schneider et al., 2005;Ballard et 
al., 2011a). Cohort studies published thereafter indicated that typical antipsychotics might 
have even higher mortality rates than atypical antipsychotics (O'Brien, 2008;Gill et al.,
2005;Gill et al., 2007). There are some indications of an association between agitation, 
aggression and psychosis in patients with dementia, which may have encouraged the use 
of antipsychotic medication for other NPS than psychosis in dementia (Rapoport et al.,
2001). Discontinuation studies of antipsychotic medication in patients with dementia and 
NPS have been beneficial to the patients (Bridges-Parlet et al., 1997;Cohen-Mansfield et 
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al., 1999;van Reekum et al., 2002;Ballard et al., 2004;Ruths et al., 2004;Ruths et al.,
2008;Ballard et al., 2008;Ballard et al., 2009).
Antidepressive medication
There are a few studies of the effect of antidepressants on NPS. Citalopram was reported 
to be effective in reducing all kinds of NPS in a study of 98 patients (Nyth and Gottfries, 
1990). In a DB RCT study of 85 patients treated with citalopram, perphenazine or a 
placebo for up to 17 days, citalopram was found to be superior to a placebo in treating 
psychosis and behavioural symptoms (Pollock et al., 2002). Nevertheless, four other 
studies reported that antidepressants were not more effective than a placebo for NPS 
(Auchus and Bissey-Black, 1997;Teri et al., 2000;Lyketsos et al., 2003;Finkel et al.,
2004), and a review concluded that antidepressants were not very effective in the 
treatment of NPS (Seitz et al., 2011). Two studies have reported similar effects for 
citalopram as for risperidone in reducing agitation and psychosis in patients with dementia 
(Pollock et al., 2007;Barak et al., 2011). The side effects of antidepressants vary between 
the classes of antidepressants. Tricyclic antidepressants (TCA) are known to cause 
cognitive decline, sedation and cholinergic symptoms as dry mouth, while SSRI may 
cause symptoms from the gastro-intestinal tract (GI-tract). Traditionally, SSRI has been 
regarded as having fewer side effects than TCA, but a recent study reported that SSRI 
antidepressants have more severe side effects (death and cerebrovascular incidents) than 
classical TCA (Coupland et al., 2011).
Cognitive enhancers
The effect of cognitive enhancers for NPS is controversial, as there are published studies 
with positive and negative effects (Ballard et al., 2005;Finkel, 2004;Howard et al., 2007).
Best evidences are for the use of Acetylcholinesterase inhibitors (AchEI) for psychosis in 
patients with AD and DLB, as summarised in several meta-analysis and reviews 
(Grossberg, 2005;Sink et al., 2005;Trinh et al., 2003). Nevertheless, it has been 
commented that the small effect of AchEI on the treatment of NPS is of little clinical 
interest, although there is a statistically significant difference between the AchEI groups 
and the placebo groups (Sink et al., 2005). The main side effects of AchEI are from the 
GI-tract, the AchEI are generally well tolerated in the elderly, and may therefore be the
drug of choice in the treatment of psychosis in dementia. Memantine has been 
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demonstrated to be effective in treating symptoms of irritability/lability and 
agitation/aggression in patients with AD and NPS in patients with VaD (Ballard and 
Corbett, 2010). There are few studies on the effect of memantine for clinically significant 
agitation and aggression, and the evidence for the effect of memantine on psychosis is 
weak (Ballard and Corbett, 2010).
Antiepileptic drugs
With regard to antiepileptic drugs, the best evidence is for carbamezepine, with possible 
positive effect on agitation demonstrated in two small studies (Tariot et al., 1998;Olin et 
al., 2001). A Norwegian DB RCT with 103 patients found no differences in agitation or 
aggression between the oxcarbazepine and placebo group after 8 weeks treatment 
(Sommer et al., 2009). The effect of other antiepileptic drugs has not been demonstrated 
(Ballard and Corbett, 2010).
2.3 Depression in the elderly
2.3.1 Depression in patients without dementia
The prevalence of depression increases with older age, see table 2 (Stordal et al., 2001).
Risk factors for depression in older age are solitude, somatic co-morbidity, previous 
episodes of depression, being female, experience of losses, having sleep disturbances, 
bereavement, functional impairments and low socio-economic status (Crown et al.,
2002;Cole and Dendukuri, 2003). Depression in old age is categorised as early-onset 
depression and late-onset depression, referring to whether the first episode of depression 
was before or after the age of 65 years. There is reason to believe that there is a substantial 
difference in early-onset and late-onset depression, in terms of epidemiology, pathology 
and the neurotransmitters involved in the disease, which should be taken into account 
when treating the depression, because later life depression is often linked to physical 
health (Alexopoulos et al., 2002).
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Table 2. Prevalence of depression in Norway, categorised according to age
Age Men Women
20-29 years 4.1 % 4.3 %
30-39 years 6.9 % 7.0 %
40-49 years 10.5 % 9.3 %
50-59 years 14.1 % 12.2 %
60-69 years 14.4 % 14.6 %
70-79 years 17.2 % 17.4 %
80-89 years 23.4 % 18.3 %
2.3.2 Depression in patients with dementia
Depressive symptoms, as part of the NPS syndrome, are found in up to 50 % of patients 
with dementia (Lyketsos and Olin, 2002). Even a depressive disorder, as defined in the 
DSM IV, ICD-10 or Provisional Criteria for Depression in Dementia, is frequent in 
patients with dementia as up to 20-25 % has the disorder (Lyketsos and Olin, 
2002;Lyketsos et al., 1997). The distinction between depressive symptoms of dementia, 
such as loss of interest and decreased initiative, and a depressive disorder is difficult for 
even an experienced geriatric psychiatrist to make. Depressive disorder in dementia is 
especially prevalent in patients with vascular dementia and in patients with Parkinson’s 
disease. Up to 40% of patients with Parkinson’s disease experience depression or 
depressive symptoms at least once during the course of their Parkinson’s disease 
(Hanagasi and Emre, 2005). It has been suggested that depressive disorders in patients 
with dementia have a different clinical presentation than depressive disorders in patients 
without dementia, such as lack of interest and motivation, slowness of motor function and 
thoughts, and decreased response to pleasurable activities (Janzing et al., 2002), but the
hypothesis is contradictory as other studies have reported similarities in the depressive 
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symptoms in elderly patients with and without dementia (Engedal et al., 2011;Starkstein et 
al., 2005).
2.3.3 Assessment scales
Patients with dementia of moderate or severe degree may have problems in expressing 
their emotions, fear, and affections due to language problems and cognitive decline. The 
cognitive problems may even increase in patients with depression, which is problematic in 
the interpretation of their score on a depression rating scale based on interviews with the 
patients. Ordinary, well-known assessment scales for depression, such as the 
Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 
1979), are therefore of limited use in patients with moderate or severe dementia. A couple 
of assessment scales have been designed for the elderly, including the Geriatric 
Depression Scale (GDS) (Yesavage et al., 1982) and the Cornell Scale for Depression in 
Dementia (CSDD) (Alexopoulos et al., 1988a). The GDS is not primarily developed for 
patients with dementia, and it fails to maintain validity in patients with mild to moderate 
dementia (Montorio and Izal, 1996). While the GDS is based on interviews with the 
patients, who have to respond with Yes/No answers, the CSDD is primarily based on 
observation by the carers. The CSDD is a questionnaire consisting of nineteen different 
items, each item is scored 0 (no symptoms), 1 (moderate symptoms) and 2 (severe 
symptoms). The CSDD has been translated into Norwegian, and is validated for patients 
living in Norwegian nursing homes (Barca et al., 2010). According to the same study a 
cut-off point >8 for depression and a cut-off point >13 for severe depression are 
recommended (Barca et al., 2010). Based on a factor analysis by Barca et al. the CSDD 
has been separated into a mood factor (sadness, anxiety, pessimism, suicidal thoughts, 
poor self esteem and delusion), a physical factor (appetite loss, weight loss, lack of energy 
and loss of interest), a cyclic factor (multiple night-time awakening, difficulty falling 
asleep and early morning awakening), a retardation factor (retardation and lack of joy) and 
behavioural factor (diurnal variation, irritability and agitation). One symptom, multiple 
physical complaints, did not load on any factor (Barca et al., 2008). It is feasible to divide 
the factors into a mood sub-score and non-mood sub-score (Barca et al., 2008). The 
original sub-scales suggested by Alexopoulos et al. contain different items, but these sub-
scales were not based on a factor analysis (Alexopoulos et al., 1988a). The CSDD is 
widely used both in clinical settings and in research, and has been found valid in patients 
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without dementia as well as in patients with dementia (Alexopoulos et al., 1988b). The 
Hamilton rating scale for depression (HAM-D) (Hamilton, 1960) is not developed for the
elderly or patients with dementia, but is still in use in the nursing home population. The 
HAM-D is a semi-structured 21-item questionnaire, with a cut-off point of 10/11 for 
depression. As the HAM-D is influenced by somatic symptoms and diseases, the use of 
HAM-D in the elderly population has been criticised. Nevertheless the HAM-D
demonstrated its validity in a study of patients with terminal cancer (Olden et al., 2009).
2.3.4 Treatment of depression
The treatment options for patients with depression and coexisting dementia are the same 
as for patients without dementia; psychosocial treatment, Electroconvulsive Treatment 
(ECT) and antidepressant medication. While the evidence for psychosocial treatment for 
depression in elderly patients without dementia is strong (Cuijpers et al., 2006), the 
evidence for psychosocial treatment for depression in dementia is weak (Verkaik R et al.,
2005). However, one review has suggested that psychosocial treatment for depression is 
effective even in patients with dementia (Wilkins et al., 2009). Electroconvulsive therapy 
(ECT) is often used as the last treatment option for depression when treatment with 
antidepressant medication has failed or been proven ineffective. Most of the evidence for 
ECT in elderly patients with depression is from patients without cognitive impairment, but 
one small study of patients with depression comparing patients with no cognitive 
impairment, MCI and dementia, demonstrated that ECT was equally effective in all three 
groups of patients (Hausner et al., 2011). All three patient groups had transient cognitive 
decline after the ECT treatment, but even the patients with dementia regained pre-ECT 
cognition scores 6 months after the final treatment with ECT.
Antidepressants are frequently prescribed to patients with dementia. Almost 40 percentage
of patients in Norwegian nursing homes are prescribed antidepressants on a regular basis 
(Selbaek et al., 2007). The indication for the use of antidepressants is sometimes unclear 
or poorly documented. The evidence for the use of antidepressants for depression in 
patients with dementia is weak. Several DB RCTs have studied the effect of 
antidepressants on depression in patients with dementia, and they are all summarised in 
table 3. Most of the studies are against medication, but the results diverge. This 
inconsistency in the results and conclusions are caused by the heterogeneity of the studies, 
in terms of number of included patients, type and severity of the dementia, the severity of 
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Table 3. Randomised controlled trials of antidepressants on depression in patients with 
dementia
Study No of participants Study drug
1. Reifler et al 1989 n=28 imipramine = placebo
2. Nyth et al 1992 and 1994 n=98/29 citalopram > placebo
3. Roth et al 1996, n=694 moclobemid > placebo
4. Petracca et al 1996 n=21 clomipramine > placebo
5. Magai et al 2000 n=31 sertraline = placebo
6. Petracca et al, 2001 n=41 fluoxetine = placebo
7. Lyketsos et al 2003 n=44 sertraline > placebo
8. V. Cunha et al 2007 n=31 venlafaxine = placebo
9. Rosenberg et al 2010 n=133 sertraline = placebo
10. Weintraub et al 2010 n=133 sertraline = placebo
11. Banerjee et al 2011 n=326
mirtazapine
sertraline
= placebo
= placebo
the depression, the type and dosage of the medication, the assessment methods and the 
duration of the study period. The lack of evidence of the effect of antidepressants for 
depression in dementia is confirmed in meta-analysis. The conclusions of two meta-
analyses are against the use of antidepressants (Bains et al., 2002;Nelson and Devanand, 
2011), while one meta-analysis concludes that antidepressants are more effective than a 
placebo (OR = 2,32, CI 1,04 - 5,16 and NNT = 5 for response and OR = 2,75, CI 1,13 –
6,65 and NNT = 5 for remission) (Thompson et al., 2007). The selection of studies in 
Thompson’s meta-analysis is, however, slightly different from the other two meta-
analyses, explaining the discrepancy in the conclusion. The three latest published DB 
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RCTs on the effect of antidepressants for depression in patients with dementia are of good 
quality and cover a large number of patients. All three studies are against the use of 
sertraline compared to a placebo, and one study is against the use of mirtazapine compared 
to a placebo as well (Rosenberg et al., 2010;Weintraub et al., 2010;Banerjee et al., 2011).
At the moment there is no evidence that the use of antidepressants is superior to a placebo 
in the treatment of depression in patients with dementia.  
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3. Previous studies related to the four papers of this thesis
3.1 The validation of the Norwegian version of the Severe Impairment 
Battery
In recent decades several cognitive tests for patients with dementia have been developed 
and are in clinical use. Some of them are used for screening for cognitive dysfunction, 
such as the Mini Mental State Examination, while other cognitive tests have been 
developed to assess more specific cognitive functions, such as the Trail Making Test A 
and B (Folstein et al., 1975;Reitan RM, 1955), comprehensively described in chapter 
2.1.2.
Most of the cognitive tests for patients with dementia are developed for patients with mild 
to moderate dementia. When testing patients with severe dementia the psychometric 
properties of the tests do not allow observation of changes in cognitive function over time, 
nor will they be able to separate differences in cognitive function in different patients.
This so-called floor effect of cognitive tests inspired a research group at the McGill Centre 
for Studies on Aging, St Mary's Hospital, Montreal, to develop a new cognitive test 
especially for patients with moderate to severe dementia (Panisset et al., 1994). The 
original Severe Impairment Battery (SIB) is a 57-item questionnaire, minimum score zero 
and maximum score 133, which can be divided into nine cognitive domains: social 
interaction, memory, orientation, language, attention, praxis, visuospatial and 
constructional abilities, and orientation to name. The SIB was later revised into a 51-item 
questionnaire (minimum score zero, maximum score 100) (Schmitt et al., 1997). The SIB 
takes 20-30 minutes to complete, which is the maximum attention span for patients with 
severe dementia. Therefore, a short version of the SIB, the SIB-S, was developed with 
help of exploratory factor analysis (EFA) and consensus meetings, reducing the original 
SIB to a 26-question version (minimum score zero, maximum score 52 (Saxton et al.,
2005). An even shorter version of the SIB, the SIB-8, with eight questions (minimum 
score zero, maximum score 16) was developed by analysing four DB RCT that had been 
using the 100 points version of the SIB to evaluate changes in cognitive function after 
treatment with cognitive enhancers (Schmitt et al., 2009). The eight questions were chosen 
by analysing sensitivity to change and ease of administration. The SIB and its short 
versions have been translated into and validated in several different languages (Suh and 
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Kang, 2006;Ahn et al., 2006;Hugonot-Diener et al., 2003;Pippi et al., 1999;Llinas et al.,
1995;de Jonghe et al., 2009).
3.2 Course of the NPS in nursing homes
There are several studies on the course of NPS in patients with dementia in nursing 
homes, comprehensively reviewed by Wetzels et al. (Wetzels et al., 2010a). They 
identified 18 studies on the course of NPS in nursing homes. The same year, Wetzels and 
colleagues published a study on the course of NPS over a two year period in Dutch 
nursing homes (Wetzels et al., 2010b). Of the nineteen studies identified, only seven 
studies were primarily designed to study the course of NPS in patients with dementia 
(Burton et al., 1995;Wagner et al., 1995;Ballard et al., 2001a;Payne et al., 2002;Wancata
et al., 2003;Selbaek et al., 2008;Wetzels et al., 2010b), and only four of them studied a 
broad range of NPS (Ballard et al., 2001a;Wancata et al., 2003;Selbaek et al.,
2008;Wetzels et al., 2010b).
The seven studies on the course of NPS in patients in nursing homes differed in terms of 
number of patients included, assessment scales, time interval between assessments and 
time from first to last assessment (table 4). Burton et al. described a sample of 201 
patients in a longitudinal cohort study. Of the 201 patients, 79 patients received 
antipsychotics and 122 did not receive antipsychotics. The patients were assessed with the 
Psychogeriatric Dependency Rating Scale (PGDRS), an assessment-scale describing nine 
different disruptive behaviours, at baseline and after one year (Burton et al., 1995). Their 
main conclusion was that in patients prescribed antipsychotics disruptive behaviour was 
more prevalent, more persistent and had a higher incidence rate than in patients not 
prescribed antipsychotics. While persistence of disruptive behaviour in patients not 
prescribed antipsychotics was 4-5% after one year, the persistence of disruptive behaviour 
in patients prescribed antipsychotics was 13-14%. In the study by Wagner et al. 298 
patients with dementia (mostly AD) were assessed three times over a period of four 
months with the Memory Behaviour Problems Checklist-NH (MBPC-NH) (Wagner et al.,
1995). The MBPC-NH is a 24-item assessment tool evaluating behaviour in patients with 
dementia (Teri et al., 1992). The main conclusion in the paper by Wagner et al. was that 
the patients were as likely to experience an occurrence of a new behaviour problem as a 
drop in behaviour problems between baseline and four months. 
61
Table 4. Studies on the course of the NPS in nursing homes
Author (Year) N
Follow 
up
No of 
assessments
Assessment 
Instrument
Residence
Wetzels et al.,
2010
117 2 yrs 5 NPI-NH SCU
Selbaek et al.,
2008
633 1 yr 2 NPI-NH NH
Wancata et al.,
2003
86 6 months 2 CIS NH
Payne et al.,
2002
201 1 year 3 CSDD NH
Ballard et al.,
2001
136 1 year 2 NPI-10 3 SCU/3 NH
Wagner et al., 
1995
298 4 months 3 MBPCNH SCU
Burton et al., 
1995
201 1 year 2 PGDRS NH
N = No of patients, NPI-NH = Neuropsychiatric Inventory – Nursing Home edition, SCU = Special 
Care Unit, NH = Nursing Home, CIS = Clinical Interview Schedule, CSDD = Cornell Scale of 
Depression in Dementia, NPI-10 = Neuropsychiatric Inventory 10 items edition, MBPC-NH = 
Memory Behaviour Problems Checklist-NH, PGDRS = Psychogeriatric Dependency Rating Scale
Ballard et al. assessed 136 patients in three special care units (SCU) and three nursing 
home wards with the NPI-10 assessment scale twice over a period of 12 months (Ballard
et al., 2001a). They reported a persistence rate of 41-43% for agitation symptoms, 25% for 
hallucination, 43% for delusion and 32% for depression. Payne et al. followed a group of 
201 patients with depressive symptoms (CSDD>12) with three assessments over one year, 
and found a persistence rate for depression of 15% (Payne et al., 2002). Wancata et al.
assessed a group of 86 patients with the Clinical Interview Schedule (CIS) at baseline and 
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after 6 months (Wancata et al., 2003). The CIS is a semi-structured interview developed to 
study psychiatric morbidity (Goldberg et al., 1970). After six months the persistence rate 
for depressive symptoms and aggressive-psychotic symptoms were 63.3% and 73.1%, 
respectively. Selbæk et al. included 933 patients with dementia, where 633 patients 
completed the follow-up assessment after one year (Selbaek et al., 2008). The patients 
were assessed with the NPI-NH twice over one year, and persistence rates were calculated;
52.9% for agitation/aggression, 58.0% for irritability, 42.1% for hallucinations, 44.1% for
delusions, 44.5% for anxiety and 52.2% for depression. Finally, in the study by Wetzels et 
al. 117 patients were assessed twice a year for two years with the NPI-NH. The 
persistence rate for the different NPI items were: agitation/aggression (52.9–62.4%), 
disinhibition (9.6–33.6%), irritability (37.6–56.1%), aberrant motor behaviour (41.9–
62.8%), hallucination (50%), delusion (13.2–36.2%), depression (17.6–39.5%), apathy 
(36.0–54.8%), euphoria (17.6–39.5%) night time behaviour (0-56.7%) and eating 
abnormalities (14.2–50.0%) (Wetzels et al., 2010b).
Overall, the studies on the course of NPS in nursing homes differ in their results, but the 
trend is that while the patients’ persistence rate of at least one NPS is high between 
assessments, the individual NPS fluctuate in their nature and show an intermittent course 
(Wetzels et al., 2010a).
3.3 Discontinuation of antidepressants and NPS
Previously, no DB RCT on the discontinuation of antidepressive medication in patients 
with dementia has been published. The only randomised and controlled antidepressant 
discontinuation study in elderly patients was by Ulfvarson et al., who in a single blind 
RCT studied discontinuation of antidepressive medication (SSRI) in 70 patients with no 
dementia or history of depression, and with no anxiety or a major depressive disorder 
(Ulfvarson J et al., 2003). Half of the patients were randomised to discontinuation, and 
there were no differences between the two groups, either at three or at six months in terms 
of depressive symptoms as measured with MADRS, a global assessment of functioning 
and side effects.
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3.4 Discontinuation of antipsychotic medication and NPS
Antipsychotic medications are used for NPS in dementia. In a study by Selbæk et al. 24% 
patients in Norwegian nursing homes were prescribed antipsychotic medication (Selbaek
et al., 2007). The Norwegian Medical Agency (NMA) recommends discontinuing 
antipsychotics after three months’ prescription when used for NPS. Antipsychotics do 
have serious adverse effects, such as cerebrovascular incidents, dizziness, sedation,
decreased cognitive function and Parkinsonism (Felleskatalogen, 2011). In 2004 the NMA 
warned against prescription of risperidone and olanzepine for elderly patients with 
dementia as published data showed a three-fold increase in cerebrovascular incidents in 
patients prescribed risperidone and olanzepine (Schneider et al., 2005;Brodaty et al.,
2003). Later, a similar increased risk of cerebrovascular incidence has been demonstrated 
in typical antipsychotics as in atypical antipsychotics (Gill et al., 2005;Gill et al., 2007).
Multi medication is a problem in geriatric patients, and we know that geriatric patients are 
vulnerable to adverse effects and interactions.
Several studies have reported that the discontinuation of the treatment of antipsychotic 
medication in patients with dementia and NPS is safe and has even been beneficial for the 
patients (Bridges-Parlet et al., 1997;Cohen-Mansfield et al., 1999;van Reekum et al.,
2002;Ballard et al., 2004;Ruths et al., 2004;Ballard et al., 2008;Ballard et al., 2009;Ruths
et al., 2008).
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4 The thesis
4.1 Objectives
The overall objective of the project was to study the neuropsychiatric symptoms (NPS) of 
patients with dementia in nursing homes, the course of the symptoms and the effect of the 
withdrawal of antidepressive medication. To be able to evaluate changes in cognitive 
function over time in patients with moderate and severe dementia, the Severe Impairment 
Battery (SIB) was translated into Norwegian.
The main objectives in this thesis were:
 To investigate the validity and reliability of the Norwegian version of the SIB
 To describe the prevalence and distribution of NPS in patients with dementia in 
Norwegian nursing homes
 To explore the course of the NPS in patients with dementia in Norwegian nursing 
homes
 To study the effect of the discontinuation of antidepressive medication in patients 
with dementia and NPS in Norwegian nursing homes
4.2 The subjects
The four aims of the thesis were examined in four sub studies including different subjects 
and the results are reported in four articles.
4.2.1 Severe Impairment Battery validation study
In the validation and reliability study of the SIB 59 patients from three nursing homes in 
the counties of Hedmark and Oppland were recruited. A non-randomised group of nursing 
home patients were invited to take part in the study, and based on the Clinical Dementia 
Rating Scale (CDR) score, the patients were categorised into mild, moderate and severe 
dementia groups. We ensured that equal numbers of patients with mild, moderate and 
severe dementia were recruited. The patients or their relatives gave their written consent 
before inclusion in the study.
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4.2.2 The course of NPS in Norwegian nursing homes
All of the patients in seven nursing homes in Hedmark and Oppland were invited to take 
part in the study on the course of NPS in patients with dementia. Of the 271 patients 
screened for inclusion 61 patients were not included. Twenty-nine patients declined 
participation, twenty-five relatives declined on behalf of the patients, two patients moved 
out of the nursing home before data collection commenced, one patient had a terminal 
illness, and four patients were not asked to participate because the nursing home staff
deemed it improper to ask for the consent. Of the 210 patients included in the study, 169 
patients were suffering from dementia, defined as a score of one or more on the CDR 
(Hughes et al., 1982).
4.2.3 The withdrawal of antipsychotics and antidepressants from patients with dementia
and BPSD living in nursing homes – an open pilot study
In the small pilot study on the discontinuation of antidepressive or antipsychotic 
medication, patients were recruited from seven nursing homes in Hedmark and Oppland. 
The nursing home doctors screened for eligible patients in the nursing homes or in 
selected wards of the nursing homes, and contacted the patients or relatives to obtain 
written consent. Forty-one patients were screened for inclusion, 18 patients failed the 
screening procedure (14 patients declined participation; four patients did not fulfil the 
inclusion criteria). Of the 23 patients recruited, 11 patients were using antidepressive 
medication and 12 patients were using antipsychotic medication at inclusion. All the 
included patients in the study discontinued the prescribed antidepressive or antipsychotic 
medication. 
4.2.4 Discontinuation of antidepressants in patients suffering from dementia and NPS 
in Norwegian nursing homes – the DESEP study
To ensure representativeness of the cohort, patients in the DESEP study were recruited 
from 52 nursing homes in 14 counties in Norway. The recruitment of patients was done by 
16 study centres, and they were either a department of geriatric psychiatry or a large 
nursing home with a special interest in dementia. Two-hundred-and-five patients were 
assessed for eligibility, 77 patients were excluded for the following reasons: not meeting 
the inclusion criteria (n=25), declined to participate (n=29), depressive disorders (n=19), 
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other psychiatric disease (n=1) and other reasons (n=3). Patients or relatives gave their 
written consent before the patients were included in the study. 
4.3 Methods
4.3.1 Data collection
For all four studies, the assessment of the patients was done in a similar way, although the 
questionnaires used were slightly different. Registered nurses underwent a one-day 
standardised training course to ensure a common way of applying the questionnaire. The 
patients’ cognitive function was assessed by an interview with the patients with a 
standardised cognitive test, the Severe Impairment Battery (SIB) (Saxton and Swihart, 
1989). The patients’ quality of life was assessed by the Quality of Life – Alzheimer 
Disease (QoL-AD) (Logsdon and Albert, 1999), a questionnaire either answered by the 
patient, the carer or both. The degree of dementia, extra pyramidal side-effects (EPS) and 
the level of function were assessed with the CDR (Hughes et al., 1982), the Unified 
Parkinson Disease Rating Scale (UPDRS, six-item version) (Ballard et al., 1997), and the 
Lawton & Brody's Physical Self-Maintenance scale (PSMS) (Lawton and Brody, 1969),
respectively. NPS were assessed by the Neuropsychiatric Inventory (NPI) (Cummings et 
al., 1994) and depressive symptoms were assessed by the Cornell Scale of Depression in 
Dementia (CSDD) (Alexopoulos et al., 1988a).
The Neuropsychiatric Inventory (NPI)
The NPI has been described in detail in chapter 2.2.3, and the study nurses filled in the 
questionnaire about the patient based in information from the carers in the nursing homes. 
In the two discontinuation studies we used the 10-item version of the NPI (NPI-10), while 
in the study on the course of the NPI we used the 12-item version (NPI-12). A clinically 
significant NPS (CS-NPS) was defined as a score >3 on an individual subscore. 
The Cornell Scale of Depression in Dementia (CSDD)
The CSDD has previously been described in chapter 2.3.3, and was filled in based on 
information from the carers in the nursing homes. In the DESEP study we used the factor 
analysis from Barca et al. to divide the CSDD score into a mood-score and a non-mood 
score (Barca et al., 2008).
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The Severe Impairment Battery (SIB)
The SIB has been discussed in chapters 2.1.2 and 3.1. In the small pilot discontinuation 
study and the DESEP study we used the 100-point version of the SIB, and the cognitive 
test was given to the patients.
The Clinical Dementia Rating Scale (CDR)
The CDR is described in chapter 2.1.2, and was administrated to the carers in the nursing 
homes, and filled in based on observations of the patients. The total CDR score was 
obtained by using the scoring rules given by the Washington University CDR-assignment 
algorithm (Morris, 1993).
The Quality of Life – Alzheimer Disease (QoL-AD)
The QoL-AD is a 13-item questionnaire designed to obtain a rating of the patient's Quality 
of Life from both the patient and the carer (Logsdon et al., 1999). The language in the 
questionnaire is straightforward, and the assessment scale is developed for patients with 
dementia (feasible for patients with MMSE scores of 10 or higher) (Logsdon et al., 1999).
Carers completed the measure as a questionnaire, while patients were interviewed about 
their own QoL. During the interview the patients had a written text with the four possible 
answers in front of them, and were given the opportunity to point out their answers. The 
measure consists of 13 items, rated on a four-point scale, with 1 being poor and 4 being 
excellent (minimum total score 13, maximum score 52). 
The Unified Parkinson Disease Rating Scale (UPDRS, six-item version)
The UPDRS is developed to assess the symptoms in patients with Parkinson’s disease, and 
is used to evaluate their response to treatment and the course of the symptoms over time. 
The UPDRS consists of five parts, evaluating mental symptoms, motor symptoms, ADL 
and other symptoms. Ballard et al. isolated six items from the UPDRS that could be used 
to evaluate Parkinsonism in patients with DLB, but could also be used to evaluate Extra 
Pyramidal Symptoms (EPS) in patients using antipsychotics (Ballard et al., 1997). Each 
item is scored on a 5-point scale from 0 (normal) to 4 (severe symptom), and the six items 
are added up to a maximum of 24 points. Ballard et al. reported a specificity of 100% and 
a sensitivity of 85% for significant Parkinsonism in DLB using a cut-off of 7/8 points on 
the UPDRS 6-item version.
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The Lawton & Brody's Physical Self-Maintenance scale (PSMS)
Lawton and Brody's scale for the assessment of ADL was developed for use 
among elderly persons living at home or in institutions. It comes in a self-reporting and 
an observational version; in our studies we used the observational version. The scale is 
based on the theory that activities can be arranged hierarchically, where some activities are 
more complex than others. The PSMS measures physical ADL function, in contrast 
to Instrumental ADL (IADL). The scale consists of 6 items. A 5-point scale for responses 
ranges from total independence (1 point) to total dependence (5 points). The total score 
ranges from six to 30; a higher score indicates greater impairment.
4.3.2 The Severe Impairment Battery validation study 
The aim of the study was to determine the validity and reliability of the Norwegian 
version of the Severe Impairment Battery (SIB). The SIB was developed by J. Saxton and 
colleagues to measure cognitive function in people with moderate to severe dementia 
(Saxton and Swihart, 1989). The SIB had not previously been translated into Norwegian, 
and therefore had not been validated and tested for reliability. Three psychiatrists 
translated the English version of the SIB to Norwegian. A fourth psychiatrist made a final 
Norwegian version by compiling the three Norwegian versions into one. A British-born 
colleague who had been living in Norway for several decades translated the final 
Norwegian version back into English, and the re-translated version was virtually identical 
to the original English version.
The study consisted of two parts, a validation study and an inter-rater reliability study. In 
the inter-rater reliability study 30 patients were included. Inclusion criteria were dementia 
of mild, moderate or severe degree, assessed by the CDR, and having given written 
consent. The patients were tested with the SIB twice, by a physician and a registered 
nurse, 1-7 days apart. In the validation study the same 30 patients were included, but the 
cohort was extended with an additional 29 patients. All 59 patients were tested with the 
SIB as well as the CDR, and the correlation between the SIB score and the CDR was 
calculated. 
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4.3.3 The course of NPS in Norwegian nursing homes
In the study 210 patients were included, where 169 patients had dementia defined as a 
CDR score > 0.5. The inclusion criteria were that the patient was living in the nursing 
home and had given written consent. All patients included in the study were assessed by 
the NPI, the CDR, the CSDD and the PSMS at baseline and every fourth month for 16 
months, totalling five assessments. In the paper we report the course of the NPS as 
assessed by the NPI, where a clinically significant NPS (CS-NPS) was defined as a NPI 
score>3 on an individual item. We calculated point prevalence at each assessment, 
cumulative prevalence over 16 months, incidence between two assessments (four months) 
and cumulative incidence for the whole study period (16 months). We also assessed 
persistence and resolution. Persistence is the ratio of residents with CS-NPS at follow up 
to residents with CS-NPS at the previous assessment, and resolution is the ratio of 
residents without CS-NPS at follow up to the residents with CS-NPS at the previous 
assessment.
4.3.4 The withdrawal of antipsychotics and antidepressants from patients with dementia 
and BPSD living in nursing homes – an open pilot study
The study was an open study with two groups of eleven and twelve patients. Patients were 
recruited from nursing homes in Oppland and Hedmark. In group 1 the patients 
discontinued antipsychotics; in group 2 the patients discontinued antidepressants. The 
antidepressive or antipsychotic medication was tapered out over one week. On the basis of 
previous studies, the drop-out rate was estimated to be 30%. All the patients included in 
the study were recruited from nursing homes, and were believed to be living under similar 
conditions as regards quality of care, environment and medical follow-up during the study 
period of 24 weeks. Patients were examined by standardised assessment tools at baseline, 
and after 3 weeks, 6 weeks, 12 weeks and 24 weeks. The project leader made a follow-up
telephone call to the nursing homes two weeks after the study drug was discontinued, 
concerning patient safety and adverse symptoms. Throughout the entire study period the 
project leader was in contact with the staff of the nursing homes to ensure the well-being 
of the patients. To ensure a correct dementia diagnosis, all current patients had a review of 
clinical data and medical history before entering the study. The inclusion and exclusion 
criteria were:
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Inclusion Criteria:
1) Dementia in Alzheimer's disease and / or vascular dementia.
2) Clinical Dementia Rating (CDR) 1, 2 or 3
3) Nursing home resident for three months or more
4) Group 1: Regular prescription of antipsychotics of any kind for three months or
more
5) Group 2: Regular prescription of antidepressants of the SSRI type for three months 
or more
Exclusion Criteria:
1) Other dementia disease
2) Schizophrenia, depression or other psychiatric diagnosis
3) Expected survival less than 3 months
4) Acute infection 10 days before inclusion
5) Uncontrolled Diabetes Mellitus (DM)
6) Terminal illness
7) Group 1: Antipsychotic medications used to control nausea
Data collection
All the interviews with the patients and the carers, and all the rest of the data collection, 
were done by the project leader. The patients were interviewed and assessed for cognitive 
function and quality of life by means of the SIB and the QoL-AD. The rest of the 
assessment tools were administered by means of interviews with the registered nurse or 
health care worker most familiar with the patient. At baseline and after 24 weeks the 
patients were examined with the SIB, the NPI, the CSDD, the CDR, the UPDRS six-item 
version, and the PSMS. At three, six and twelve weeks the patients were assessed with the 
NPI and the UPDRS. At baseline demographic data and information on psychotropic drug 
use were gathered from the medical records and the carers.
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4.3.5 Discontinuation of antidepressants in patients suffering from dementia and NPS 
in Norwegian nursing homes – the DESEP study
Organisation of the project
One project leader (MD) and one project coordinator (registered nurse) held full-time 
positions at the Centre for Old Age Psychiatry Research, Innlandet Hospital Trust. Sixteen 
study centres in 14 counties in Norway cooperated with the project leader and the project 
coordinator to select patients. Every study centre provided one principle investigator (a 
geriatric psychiatrist or general practitioner trained in geriatric psychiatry) and one to three 
research nurses. The study centres were either old age psychiatry departments at hospital 
trusts or nursing homes with a special interest in geriatric psychiatry. Each study centre 
recruited patients from nearby nursing homes. Patients were recruited from 52 nursing 
homes.
Study design
The DESEP study was a 25-week, double-blind parallel group, randomised placebo 
controlled discontinuation trial of four SSRIs; escitalopram, citalopram, sertraline and 
paroxetine. Participants were nursing home residents (men and women). 
The inclusion criteria were:
1) Patients with a diagnosis of dementia in Alzheimer Disease (AD), Vascular 
Dementia (VaD) or mixed AD/VaD (as defined in the International Classification 
of Diseases, version 10, diagnostic criteria for research)
2) Clinical Dementia Rating 1, 2 or 3.
3) Nursing home residents for more than four weeks
4) Regular prescription of risperidone, escitalopram, citalopram, paroxetine or 
sertraline for the last three months.
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The exclusion criteria were:
1) Dementia of any other origin
2) A clinical history of a depressive disorder or schizophrenia
3) Severe somatic disease or terminal illness
4) Not being able to take tablets/capsules as prescribed
5) Expected survival less than three months.
6) Poorly controlled Diabetes Mellitus.
7) Acute infections within the past 10 days
No changes in the dose of the current antidepressant medication were allowed in the last 
four weeks before inclusion and throughout the study period. Changes in the prescription 
of psychotropic drugs other than antidepressants during the study period were allowed. 
The first week after baseline assessment, the antidepressants were either tapered off and 
replaced by a placebo (antidepressant discontinuation group, ADG) or replaced by a study 
drug containing active medication (same kind and same dose) as before inclusion
(antidepressant continuation group, ACG). 
Randomisation and masking
The patients were randomised by a computer generated randomisation process (1:1) in 
blocks of four. The randomisation lists were prepared at the Department of Statistics, Oslo 
University Hospital. Name and date of birth for included patients were sent to the Hospital 
Pharmacy, Innlandet Hospital Trust, and the packs of study medication were prepared 
there according to the randomisation lists. The randomisation was kept hidden from the 
participants, the carers and the assessors until the completion of the data collection and the 
statistical analyses had been done. Randomisation was done across study centres and 
nursing homes. 
Assessments and outcomes
The project leader and the project coordinator trained all the research nurses about the 
study protocol and the questionnaires in a one-day training course. A geriatric psychiatrist 
or general practitioner trained in geriatric psychiatry studied the participants’ medical 
records and if necessary examined the patient, to ensure correct diagnosis of dementia and 
to ensure exclusion of patients with a depressive disorder. The research nurses collected 
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all the data from the nursing homes, closely supervised by the project leader and the 
project coordinator to ensure reliable data collection. 
Assessments were done at baseline, and at day 28 (+/- 2 days), 49 (+/- 3 days), 91 (+/- 5
days) and 175 (+/- 7 days). Table 5 shows which assessments instruments that were 
administrated at the various assessment times.
Table 5. Overview over assessments instruments that were administrated at the various 
assessment times
Efficacy assessments were made at baseline, and at four, seven, 13 and 25 weeks. Primary 
endpoints were changes in the CSDD and the NPI after 25 weeks. The CSDD (minimum 
score zero, maximum score thirty-eight) assesses the depressive symptoms of the patients 
with dementia. In Norway a score of eight points and above is regarded as a sign of a 
depressive disorder, while a score of thirteen and above is regarded as a sign of a severe 
Assessment scale Baseline
Day
28
Day
49
Day
91
Day
175
Neuropsychiatric Inventory X X X X X
Clinical Dementia Rating X X
Severe Impairment Battery X X
Quality of Life – Alzheimer Disease X X
Cornell’s Scale of Depression in Dementia X X X X X
Lawton & Brody's PSMS X X
Unified Parkinson’s Disease Rating Scale X X X X X
PSMS = Physical Self-Maintenance Scale
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depressive disorder (Barca et al., 2010). The CSDD was divided into two sub-scales, 
mood (sadness, anxiety, pessimism, suicidal thoughts, poor self-esteem and delusion) and 
non-mood (the remaining 13 symptoms); according to a recent Norwegian factor analysis 
(Barca et al., 2008). The NPI 10-item version assesses the NPS, and includes the sub-
items; delusions, hallucinations, agitation/aggression, depression, anxiety, apathy, 
irritability, euphoria, disinhibition and aberrant motor behaviour. The frequency scores are 
multiplied by the severity scores. If the resulting score is equal to or greater than 4, the 
symptom is regarded as clinically relevant. If the score is equal to or greater than 9, the 
symptom is regarded as severe (Steinberg et al., 2004). The NPI was divided into the 
following sub-syndromes: Affective (NPI-depression and NPI-anxiety), Psychosis (NPI-
hallucinations and NPI-delusions), Agitation (NPI-agitation, NPI-irritability and NPI-
disinhibition) and Apathy (NPI-apathy) (Selbaek and Engedal, 2011).
The secondary endpoints were changes after twenty-five weeks on the UPDRS, QoL-AD, 
the PSMS, the SIB and the CDR. The SIB was used on the patients unless they were 
unable to communicate or refused testing. The QoL-AD was given to both the patients and 
the carers. The additional assessments were given to one of the nurses at the nursing 
home. 
4.4 Statistics
The data was analysed using the Statistical Program for Social Science (SPSS) vs 15.0, 
and the significant p-value is 0.05.
4.4.1 The Severe Impairment Battery validation study 
To test for differences between the patients’ characteristics we used the t-test for 
independent groups and the chi-square test. The Cronbach’s alpha was calculated to 
evaluate internal consistency of SIB. The Spearman’s correlation coefficient between the 
SIB and the CDR was calculated. We used the Spearman’s rho test to analyse inter-rater 
reliability for the total SIB score and all the sub-scores, and the Mann–Whitney U-test to 
assess differences in the total SIB scores for different stages of CDR. Finally, a Receiver 
Operating Characteristic (ROC) curve was used to calculate sensitivity, specificity and 
accuracy, and a Likelihood Ratio for a positive test (LR+) and for a negative test (LR-) for 
the SIB score. The likelihood ratio is an estimate of how much a test result will change the 
odds of having a disease, in our example the association between a cut-off value of the 
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SIB and CDR groups. The likelihood ratio of a positive test result (LR+) is sensitivity 
divided by (1- specificity), while the likelihood ratio of a negative test result (LR-) is (1-
sensitivity) divided by specificity. The ROC curve was used to calculate the probability of 
correctly labelling the severity of the dementia and to find the cut-off values between 
different CDR groups.
4.4.2 The course of NPS in Norwegian nursing homes
First, we did an exploratory analysis, and the differences between patients with complete 
and incomplete data were analysed with an independent student’s t-test and Chi-square 
test for continuous and categorical data, respectively. Non-parametric statistics were used 
for data that was not normally distributed. We calculated point prevalence, cumulative 
prevalence, incidence, cumulative incidence, and persistence and resolution rates for each 
of the 12 items of the NPI. Point prevalence is the proportions of patients with a CS-NPS 
at each assessment, and cumulative prevalence is the proportions of patients with a CS-
NPS on at least one of the five assessments. Incidence is the proportion of patients who 
were symptom free at one assessment, but developed a CS-NPS at the next assessment. 
Cumulative incidence is the proportion of patients who were symptom free at baseline but 
developed a CS-NPS at one of the following assessments. Persistence is the ratio of 
residents with CS-NPS at follow up to residents with CS-NPS at the previous assessment, 
and resolution is the ratio of residents without CS-NPS at follow up to the residents with 
CS-NPS at the previous assessment. To analyse the variation in severity of the NPI-score 
over time, we used the linear multiple level model (MLM). MLM is a good statistical 
technique for analysing hierarchically organised data with repeated assessments, and also 
for use when data are missing (Field, 2009).
4.4.3 The withdrawal of antipsychotics and antidepressants from patients with dementia 
and BPSD living in nursing homes – an open pilot study
We did an exploratory analysis, and the baseline characteristics were analysed with the 
independent Student’s t-test for parametric data, the Mann–Whitney U-test for non-
parametric data and chi-square statistics or Fischer’s exact test for categorical data. 
Differences between baseline and 24 weeks were analysed with the Student’s t-test for 
parametric data, the Mann–Whitney U-test for non-parametric data and chi-square 
statistics or Fischer’s exact test for categorical data.
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4.4.4 The discontinuation of antidepressants in patients with dementia and NPS in 
Norwegian nursing homes – the DESEP study
The power calculation was based on the only published pilot study on the discontinuation
of antidepressants in persons with dementia (Bergh and Engedal, 2008). Based on a 
statistical power of 80%, a two-tailed significance level of 0.05 and a drop-out rate of 
33%, 45 patients had to be included in each group to ensure enough statistical power to 
detect a 30% change in the CSDD score. The corresponding numbers were 76 patients in 
each group to detect a 30% change in the NPI score. We had planned to enrol 152 patients 
in the study, but the inclusion rate was slow, and only 128 patients were included. 
All 128 patients were included in the safety analysis, and all the patients with at least one 
assessment after the baseline (117 patients) were included in the efficacy analysis. The 
last-observation-carried-forward method (LOCF) was used to impute values if follow-up
data were missing. We also analysed the patients with complete data (n=81) for changes in 
the primary endpoints, presented as observed cases. Assessment scales which lacked more 
than 20% of the data were not analysed. Analyses were done across study centres without 
sub-analyses of each study centre, as ten study centres were small (they had less than ten 
patients each).
The baseline characteristics were analysed with the independent Student’s t-test for
parametric data, Mann–Whitney U-test for non-parametric data and chi-square statistics or 
Fischer’s exact test for categorical data. The two study groups were compared with an 
independent Student’s t-test for the difference between baseline and 25 weeks for the two 
primary outcomes; CSDD and NPI. Differences between the two groups after 25 weeks 
were analysed with the Student’s t-test for parametric data, the Mann–Whitney U-test for 
non-parametric data and chi-square statistics or Fischer’s exact-test for categorical data. 
For the primary outcomes Analysis of Covariance with correction for baseline data of the 
CSDD and the NPI was done. A post hoc test comparing the two study groups’ changes in 
the CSDD and the NPI at visit 2, 3 and 4 was done.
4.5 Ethics
In all research that makes use of patients there are ethical dilemmas that have to be 
considered and discussed. The pros and cons of the study for each individual patient, the 
group of patients and the society should be discussed. The disadvantages for the patients 
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enrolled in the study should be avoided or kept at a minimum compared to the benefits for 
the patients. Treatment and intervention studies should be compared with the results of the 
best treatments known at the time of the trial. A placebo controlled trial should not be 
carried out if there is a good tried and tested treatment for a disease. The persons included 
in the study should give written, informed and voluntary consent to participate. Many
patients with dementia have limited insight into their illness and have a limited capacity to 
understand the information relating to a study. In Norwegian nursing homes 80.5% of the 
patients have dementia, and 26.7% have moderate and 33.6% have severe dementia 
(Selbaek et al., 2007). A considerable proportion of these patients will have a reduced 
ability to give informed consent because they lack the capacity. In our studies, carried out 
among nursing home patients, the staff together with the consultants assessed whether a 
patient had the capacity to give informed consent or not. Patients who could give informed 
consent gave written consent. If not, we informed the next of kin, and the next of kin 
could refuse participation in the studies on behalf of the patient. 
As we wanted to study the course of the NPS as well as the effect of the withdrawal of 
antidepressants on NPS in patients with dementia, all our studies included patients with 
dementia. Our studies could not, therefore, be carried out among patients without
dementia. Failing to do studies among patients with dementia because they cannot give 
consent would be unethical because the patients would miss the opportunity of receiving 
evidence based treatment. For the SIB validation study and the study on the course of NPS 
in nursing homes, the patients were assessed with standardised questionnaires which 
contributed to the patients’ having a better medical investigation than they usually would 
have had. There were no disadvantages for the patients in taking part in the study apart 
from the collection of potentially sensitive data and the time the patients were occupied 
with the interviews, and we judged that the benefit of being in the studies exceeded the 
disadvantages.
For the two drug discontinuation studies special ethical considerations had to be taken into 
account. Usually withdrawals of well-established treatments are questionable, especially if 
the evidence for their effects is well documented. We wanted to study the effect of the 
discontinuation of drug treatment for NPS in patients with dementia. According to 
evidence-based reviews, such as Cochrane reviews, the effects of antidepressant and 
antipsychotic medication for NPS are not well documented. Besides, treatments with such 
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drugs are reported to have serious adverse effects and interactions with other drugs make 
drug treatment complicated in the elderly. Without having solid evidence for significant 
effects of psychotropic drugs on patients with dementia, it may be unethical to prescribe 
antidepressants and antipsychotics for elderly patients with dementia. Based on previous 
discontinuation studies and our pilot study, our hypothesis was that the patient’s 
symptoms would be unchanged or improve after discontinuation of antidepressants. 
The studies were approved by the Norwegian Medicines Agency, the Regional Committee 
of Medical Research Ethics and the Norwegian Directorate of Health. They were 
conducted according to the standard of Good Clinical Practice (GCP), and the DESEP was 
monitored by independent persons from Oslo University Hospital. The procedures were 
conducted in accordance with the Helsinki Declaration as revised in 1983.
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5 Abstracts of the papers with additional results
Paper I
Reliability and validity of the Norwegian version of the Severe Impairment Battery 
(SIB)
Objective: The Severe Impairment Battery (SIB) is developed to test cognitive function in 
patients with dementia of moderate to severe degree. We have conducted a study to assess 
the inter-rater reliability and the validity of the Norwegian version of SIB. 
Methods: The reliability study comprised 30 patients, and the validity study 59 patients in 
nursing homes. We assessed Cronbach’s alpha coefficient of the scale and the inter-rater 
reliability for the total SIB score and its nine sub scores between two testers by means of 
the Spearman’s correlation coefficients. In the validity study we compared the SIB scores 
with the scores on the Clinical Dementia Rating Scale.
Results: The mean SIB score was 72.10 (SD 25.37). The Cronbach’s alpha was 0.97, and 
the inter-rater reliability of total SIB score was Spearman’s rho 0.85, and ranged from 0.46 
to 0.76 for the nine sub-scores. The mean SIB score for patients with a CDR score<2 was 
84.2(13.4), whereas total scores for patients with CDR 2 and 3 were 74 (18.9) and 48.4 
(33.3), respectively. A cut-off point of 80.5 points gave the highest accuracy in 
discriminating between patients with CDR 2 and CDR 3, while a cut-off point of 87.5 best 
discriminated between CDR<2 and CDR 3.
Conclusion: The study indicates that the Norwegian version of SIB is a reliable and valid 
test with which to evaluate the cognition in patients with dementia of moderate to severe 
degree. 
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Paper II
The course of neuropsychiatric symptoms in patients with dementia in Norwegian 
nursing homes
Background: Neuropsychiatric symptoms (NPS) are common in patients with dementia, 
and cause distress for patients. Studies on the prevalence, incidence, persistence and 
resolution of NPS in patients living in nursing homes are sparse. The aim of this study was 
to evaluate the course of NPS in patients with dementia living in Norwegian nursing 
homes.
Methods: 169 patients from seven Norwegian nursing homes were assessed five times 
over a period of 16 months with the Neuropsychiatric Inventory (NPI). The severity and 
the frequency of the NPI were analyzed.
Results: 91.7% of the patients had at least one clinically significant NPS at one or more 
assessments over the 16 months. Irritability (63.5%), agitation (51.0%) and disinhibition
(50.0%) had the highest cumulative prevalence, while irritability (42.6%), disinhibition 
(37.8%) and depression (31.5%) showed the highest cumulative incidence. Delusion, 
agitation and irritability were enduring symptoms while the other symptoms had high
resolution rates. The severity of the NPS did not vary significantly over time.
Conclusion: Almost every patient in Norwegian nursing homes had at least one clinically 
significant NPS over 16 months, but individual NPS show a fluctuating course. This 
should influence how we monitor and treat NPS in patients with dementia.
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Paper III
The withdrawal of antipsychotics and antidepressants from patients with dementia 
and BPSD living in nursing homes – an open pilot study
Introduction: The prevalence of dementia in Norwegian nursing homes (NH) is 80%, 
72% of those have Behavioural and Psychological Symptoms of Dementia (BPSD), and 
25.8% were prescribed antipsychotics and 39.0% antidepressants. Five double blind 
randomised trials (DB RCT) have evaluated the effects of the withdrawal of 
antipsychotics from patients with BPSD. None of these studies report changes in the 
patients’ symptoms after withdrawal. No DB RCT has studied withdrawal of 
antidepressants in patients with BPSD. The aim of the open pilot study was to examine 
BPSD and depression after withdrawal of antipsychotic or antidepressant medication in 
patients with dementia and BPSD.
Methods: We conducted a 24-week open antidepressant and antipsychotic withdrawal 
study with 23 patients. Medication was tapered out over 1 week. Patients were examined 
at baseline and after 24 weeks by means of the Neuropsychiatry Inventory (NPI), Severe 
Impairment Battery (SIB), Quality of Life–Alzheimer Disease (QoL-AD), Cornell’s 
Depression Scale (CSDD), Lawton’s PADL, the Unified Parkinson Disease Rating Scale 
(UPDRS) and the Clinical Dementia Rating Scale (CDR). In addition, assessment of the 
NPI and the UPDRS were done at weeks 3, 6 and 12.
Results: Mean age was 84.1 (SD 6.59) years, and 91.3% were women. Three patients 
were rated as CDR 1, 11 as CDR 2 and nine as CDR 3. Ten patients completed 24 weeks, 
six in the AP and four in the AD group. The NPI scores increased slightly in both groups 
after discontinuation of medication, but showed minor changes at the end of the study 
period. The CSDD were unchanged in the antipsychotic group, but decreased in the 
antidepressant withdrawal group. This trend was confirmed when analysing the sub items 
depression and anxiety of the NPI.
Conclusion: Although our findings are not statistically significant and the number of 
patients is small, the present study does show a trend towards decreased depressive and 
BPSD symptoms after the withdrawal of antidepressants. We plan to carry out a DB RCT 
of the withdrawal of antidepressants.
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Paper IV
A double blind, randomized placebo controlled discontinuation trial of 
antidepressants in persons with dementia and neuropsychiatric symptoms – the 
DESEP study
Background: Forty percent of nursing home residents in Norway are prescribed 
antidepressants, but with unclear indications. Twenty percent of patients with dementia 
have clinically significant depressive symptoms. The evidence for the efficacy of 
antidepressants for Neuropsychiatric Symptoms (NPS) is weak.
Methods: A twenty-five week double-blind antidepressant discontinuation RCT 
was performed, on nursing-home residents with dementia and NPS, without a 
depressive disorder (According to ICD-10 criteria). The primary outcomes were 
changes on the Cornell Scale of Depression in Dementia (CSDD) and the 10-items 
version of the Neuropsychiatric Inventory (NPI) after 25 weeks, while secondary 
outcomes were changes on the Clinical Dementia Rating Scale, the Unified 
Parkinson Disease Rating Scale, the Quality of Life – Alzheimer Disease, the Lawton 
& Brody's Physical Self-Maintenance scale and the Severe Impairment Battery. 
Findings: There was a significantly different mean change between baseline and 25 
weeks between the two groups in the CSDD score, 2·53 (SD 5·61, worsening) in the 
antidepressant discontinuation group (ADG) and minus 0·43 (SD 3·61, improving) in the 
antidepressant continuation group (ACG), p=0·001. The mean total score for the NPI-10
increased by 5·93 (SD 19·41, worsening) in the ADG and decreased by 1·39 (SD 15·26) 
in the ACG, p=0·023. A non-response analysis (>30% worsening on the CSDD) 
confirmed these results, as significantly more patients in the ADG (22·0%) worsened 
compared to the ACG (10·3%), p=0·006. No statistically significant differences between 
the groups were found for secondary outcomes. 
Interpretation: Patients in the ADG experienced more depressive symptoms assessed by 
the Cornell Scale of Depression in Dementia and more NPS assessed with the 
Neuropsychiatric Inventory.
Funding: The study was funded by unrestricted grants from the Innlandet Hospital Trust, 
the Research Council of Norway and the South-Eastern Norway Regional Health 
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Authority. H. Lundbeck A/S provided the study with escitalopram tablets and placebos 
free of charge.
Additional results: A post-hoc analysis, with the independent student’s T-test, of the 
changes in the mean total CSDD score from baseline to assessment 2 (four weeks), 
assessment 3 (seven weeks) and assessment 4 (thirteen weeks) showed the following. 
Visit 2: ADG = +0.39 (SD 3.86), ACG = -0.77 (SD 3.28), p=0.097
Visit 3: ADG = +1.61 (SD 5.39), ACG = -0.88 (SD 3.15), p=0.003
Visit 4: ADG = +2.33 (SD 5.69), ACG = -0.21 (SD 4.46), p=0.009
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6 Discussion
The overall objective of the project was to study the neuropsychiatric symptoms (NPS) of 
patients with dementia in nursing homes, the course of the symptoms and the effect of 
withdrawal of antidepressive medication. To be able to evaluate changes in cognitive 
function over time in patients with moderate and severe dementia, the Severe Impairment 
Battery (SIB) was translated into Norwegian. This thesis is based on the research project 
and its four articles. A discussion of the four main objectives of the project is to be found 
in chapter 6.1 to chapter 6.5.
6.1 The validity and reliability of the Norwegian version of the SIB 
The Norwegian version of the SIB was translated from the English version in traditional 
ways with a translation and then a re-translation back into English. We report a high 
Cronbach’s alpha, in agreement with previous studies, indicating a good internal 
consistency of the cognitive test. Furthermore, we report the inter-rater reliability with a 
Spearman correlation coefficient of 0.85 (p-value<0.001) for the total SIB score, while the 
Spearman correlation coefficient for the SIB subscales ranged from 0.46 to 0.76. This 
indicates a lower inter-rater reliability in our study for the Norwegian versions of the SIB 
compared to versions in other languages, as other studies report a Spearman correlation 
coefficient of 0.97 to 0.99 for the inter-rater reliability (Panisset et al., 1994;Suh and 
Kang, 2006;Llinas et al., 1995;Pippi et al., 1999;Ahn et al., 2006). These five studies 
reporting a higher correlation all used a different methodology to study the inter-rater 
reliability than that which we used. In our study the project leader and a registered nurse 
tested the patients on different days, at least one day apart and maximum seven days apart. 
In the other five studies one rater tested the patients while another rater was present at the 
same interview and scored the SIB simultaneously. The difference in methodology may 
explain the differences in the Spearman correlation coefficients between the studies, as our 
test procedure was a mix of an inter-rater and a test-retest reliability study. The other 
studies report a test-retest reliability correlation coefficient between 0.81 and 0.97, which 
corresponds with our inter-rater reliability correlation coefficient. There were also 
differences in the severity of the dementia and dementia diagnosis of the patients between 
the studies, which could explain the differences in the correlation coefficients. We 
included patients with mild, moderate and severe dementia independent of the aetiological 
dementia diagnosis. Suh et al. and Ahn et al. included patients with moderate and severe 
85
AD (Suh and Kang, 2006;Ahn et al., 2006) and Panisset et al. included patients with AD 
with a mean Mini Mental State Examination (MMSE) score of 10.7 (Panisset et al., 1994).
In the study by Pippi et al. patients with different kinds of dementia disorders were 
included, and they reported the weakest inter-rater test correlation coefficient of the five 
studies (Pippi et al., 1999).
In the validation study we compared the SIB score with the CDR score, and reported a 
Spearman correlation coefficient of -0.55, indicating a lower score on the SIB as the CDR 
score increased. Suh et al. reported a Spearman correlation coefficient of -0.67 comparing 
the SIB score and the CDR score, which was slightly higher than in our study. The 
difference is probably explained by the fact that the Korean population was more 
homogeneous than ours. The other four studies compared the SIB score with the MMSE 
score, reporting a Spearman correlation coefficient between 0.73 and 0.87.
We reported a statistically significant difference in the SIB score between the patients with 
CDR 1, CDR 2 and CDR 3, indicating that the SIB could discriminate between the three 
severities of dementia. Using a Receiver Operating Characteristic (ROC) curve analysis 
and a cut-off point of 80/81 we could discriminate between patients with CDR 2 and CDR 
3 very well, and using a cut-off point of 87/88 we could discriminate between patients 
with CDR < 2 and CDR 2. Ahn et al. reported a cut-off point of 62/63 to discriminate 
between patients with CDR 2 and CDR 3, indicating that patients in the Korean study with 
moderate and severe dementia on average performed less well on the SIB compared to the 
Norwegian patients. The differences in the cut-off point may be explained by differences 
in the translation and the implementation of the Korean and the Norwegian versions of the 
SIB and the CDR. Another explanation could be differences in the interpretation of the 
CDR scale between researchers in the two countries, as there is some room for subjectivity 
when scoring the assessment scale.
Other cognitive tests, such as the MMSE, have a floor effect when used in patients with 
moderate and severe dementia. A floor effect of a test exists if more than 15% of the 
respondents achieved the minimum score of the test (McHorney and Tarlov, 1995), and 
therefore the tests are not useful in testing cognitive function in patients with severe 
dementia. The SIB has been used for evaluating the effect of donepezil treatment on 
cognition in patients with dementia in several large RCT (Winblad et al., 2006;Feldman et 
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al., 2001), and has been found to be able to detect changes in cognitive function over time 
in a group of patients.
The Norwegian version of the SIB is valid and reliable and may be used for patients with 
moderate and severe dementia. We conclude that the SIB is useful in evaluating the effect 
of treatment on the cognitive function of patients, as well as in assessing the course of 
cognitive function in the patients.
6.2 The prevalence and distribution of NPS in patients with dementia in 
Norwegian nursing homes
In our study we report the prevalence, incidence, persistence and resolution of NPS in 
patients with dementia in Norwegian nursing homes. Prevalence may be reported as point 
prevalence, at inclusion or at a later time of assessment, or as a cumulative prevalence 
defined as the presence of a symptom at one or more assessments during the study period. 
Point prevalence may vary between studies because of differences in assessment 
instruments or study population. Cumulative prevalence may differ between studies 
because of the time period studied and the frequency of assessments, as well as differences 
in assessment instruments and the study population. Comparisons of our results with other 
studies are difficult because of substantial differences in methodology, use of assessment 
instruments, the severity of the dementia and dementia diagnosis in the patients studied. 
We report that irritability (35.1%), agitation (32.3%) and disinhibition (25.9%) were the 
most prevalent NPS in Norwegian nursing homes, assessed as point prevalence at 
baseline. These findings correspond well with other studies (Ballard et al., 2001a;Selbaek
et al., 2007;Zuidema et al., 2007;Wetzels et al., 2010b). The similarity in the prevalence 
of NPS in nursing homes in different countries could indicate that the prevalence of NPS 
is correlated with the dementia disease rather than environmental factors or differences 
between the nursing homes studied. 
Wetzels et al. reported similar cumulative prevalence for most of the NPI sub-items over a 
24 month study period as we did over a 16 month study period, but for four of the sub-
items (delusion, hallucination, depression and disinhibition) the cumulative prevalence in 
the Dutch study was 50% lower than the cumulative prevalence in our study (Wetzels et 
al., 2010b). The patients in the study by Wetzels et al. had more severe degree of 
dementia than those in our study. The mean MMSE score was 7.6 (SD 7.1) in the Dutch 
87
study vs. a mean MMSE score of 14.5 (SD 6.0) in our study. More severe dementia is 
usually associated with a higher prevalence of NPS (Selbaek et al., 2007), but in the Dutch 
study both the point prevalence and the cumulative prevalence of delusion, hallucination, 
depression and disinhibition were lower than in our study. Both studies included patients 
with dementia, independent of aetiological dementia diagnosis, the patients lived in 
nursing homes, age and gender were comparable between the studies and both studies 
used the NPI for assessment of the symptoms. What could the reasons be for the 
differences? 
One explanation could be differences in the analysis of the data from patients where 
questions in the questionnaire were answered with the "not applicable" (N/A) – option. In 
our study, data from patients where questions were answered “not applicable” were 
excluded from the prevalence analysis; while in the Dutch study symptoms that could not 
be evaluated (due to the patients’ language or communication problems) were scored as 
zero and the data were included in the prevalence analysis (Wetzels, personal 
communication). As answering questions about the presence of delusion or hallucinations 
may be difficult for patients with dementia, evaluating these symptoms may be unreliable. 
Scoring symptoms impossible to evaluate as zero will reduce the prevalence rate of the 
symptoms in that cohort of patients.
Another explanation for the difference in the occurrence of depressive symptoms between 
the two studies could be differences in the prescription of psychotropic medication. 
However, this is probably less likely, since the patients in our study used antidepressants 
and anxiolytics drugs more frequently than patients in the Dutch study. Conversely, 
patients in the Dutch study were more frequently prescribed antipsychotic drugs than 
patients in the Norwegian study, which could explain the lower prevalence of psychosis 
and disinhibition in the study by Wetzels et al. (Wetzels et al., 2010b). In another Dutch 
study, by Zuidema et al., the prevalence rates of the NPS are comparable to the prevalence 
rates we report, except for delusion and hallucination which have lower prevalence figures 
in the Dutch study than in our study (Zuidema et al., 2007). Our study and the study by 
Zuidema et al. were comparable in terms of the mean age of participants, male/female 
distribution, types of nursing homes and assessment instruments used in the study. The 
Dutch study scored symptoms that were impossible to evaluate as zero, in the same way as 
the study by Wetzels, which could explain the differences between Zuidema et al.’s study 
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and ours. The differences in the frequency of psychotic symptoms could also be explained 
by the more frequent use of antipsychotic medication in Dutch nursing homes (Zuidema et 
al., 2007).
The present study has yielded improved knowledge of prevalence rates of NPS in 
Norwegian nursing homes. This knowledge can prepare the municipalities (which are 
responsible for nursing-home care in Norway) in their planning for the health care system 
of the future. Our study population was from seven nursing homes in two counties of 
south-eastern Norway, and the nursing homes were chosen for reasons of convenience and 
not by random selection. We should, therefore, be careful when generalizing the results of 
our study to all the patients living in nursing homes in Norway. However, the prevalence 
rates of the NPS in our study were directly comparable with the prevalence rates in 
another large Norwegian nursing-home study, which included a representative sample of 
1,163 patients from 26 nursing homes in 18 municipalities and four counties. This might 
indicate that the other results in our study are reliable as well. 
6.3 The course of NPS in patients with dementia in Norwegian nursing 
homes
Comparison of studies on the course of NPS in nursing homes is perhaps even more 
difficult than the comparison of studies on the prevalence of NPS. There are huge 
differences in the number of assessments and the time between assessments, among 
studies on the course of NPS in patients with dementia living in nursing homes. In 
addition, differences in the severity and aetiology of the dementia in the patients, 
differences in the assessment instruments used in the study, different cut-off points used to 
classify a NPS as a clinically significant symptom, and different prescription rates of 
psychotropic drugs in the nursing homes make comparison of studies difficult. The seven 
studies on the course of NPS in nursing homes are summarized in table 4 in chapter 3.2, 
and, as can be seen there, the studies vary in terms of assessment instruments, time 
between assessments and the number of assessments (Wagner et al., 1995;Burton et al.,
1995;Ballard et al., 2001a;Payne et al., 2002;Wancata et al., 2003;Selbaek et al.,
2008;Wetzels et al., 2010b). The studies of Ballard et al., Selbæk et al. and Wetzels et al.
are, however, the studies most comparable to our study, as they included patients with 
various dementia disorders living in nursing homes. The patients had similar demographic 
data as in our study, and they were assessed with the NPI. 
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In our study delusions, agitation/aggression, depression, disinhibition, irritability and 
aberrant motor behaviour showed the highest persistence rates over the five assessments, 
corresponding with the results of other studies (Wetzels et al., 2010b;Ballard et al.,
2001a;Selbaek et al., 2008). Wetzels et al. reported that agitation/aggression, disinhibition 
and irritability were the most persistent NPS (Wetzels et al., 2010b), Selbæk et al.
reported that irritability, agitation/aggression and apathy were the most persistent NPS 
(Selbaek et al., 2008), while Ballard et al. reported that the persistence rate of 
agitation/aggression and delusions were higher than the persistence rate of hallucinations
and depression (Ballard et al., 2001a).
In our study, appetite and eating disorder, sleep and night-time behaviour disorder and 
euphoria had the highest resolution rate, which did not correspond to the findings of the 
other studies. Ballard et al. reported that hallucinations and depression had high resolution 
rates (Ballard et al., 2001a), Selbæk et al. found that euphoria, aberrant motor behaviour 
and hallucinations had highest resolution rates (Selbaek et al., 2008) and Wetzels et al.
reported that delusions, disinhibition and euphoria had the highest resolution rates 
(Wetzels et al., 2010b). Explanation for this variation in resolution rates could be due to 
the dropout rates during the study period, the differences in time between assessments, the 
number of assessments during the study period and the differences in the use of 
psychotropic drugs. Several studies indicate, however, that the NPS fluctuate over time 
irrespective of psychotropic drug use, and the correlation between the frequency of NPS 
and the use of psychotropic drugs is low (Selbaek et al., 2008;Ballard et al., 2001a).
Caution should be taken in the interpretation of the association between the prevalence 
and the course of the NPS and the psychotropic drug, as the studies referred to are 
observational studies. 
We reported no statistically significant differences in the severity of NPS during the 
follow-up period. Other studies have found a decrease in the severity of symptoms with 
increasing severity of the dementia (Wetzels et al., 2010b;Selbaek et al., 2008).
Explanations for the different results could be (1) increased awareness of the patients’ 
NPS among the nursing-home staff, which caused the staff to report higher prevalence and 
severity of the NPS during the study period, (2) the study period in our study was too short 
to demonstrate changes in the severity of the symptoms, (3) patients with severe dementia 
died during the study period, which caused a stable distribution of the NPI score for the 
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study population; and (4) the increased severity of dementia is associated with the 
increased use of psychotropic drugs, which could camouflage the symptoms. 
We conclude that individual NPS fluctuate over time and this fluctuation should have 
clinical implications for the treatment of patients with dementia. Psychotropic drug use 
should be monitored closely in patients with dementia and the drugs should be 
discontinued if the NPS are not present any more.
6.4 The effect of discontinuation of antidepressive medication in patients 
with dementia and NPS in Norwegian nursing homes 
We have published a small open pilot study on the discontinuation of antidepressant and 
antipsychotic medication in patients with dementia and NPS. As the study was open, with 
no control group, the results of the study should be interpreted with caution. The biggest 
lesson learned from the pilot study was that it was feasible to withdraw psychotropic 
drugs, as this was safe for the patients. Further, we learned that the assessment instruments 
used in the study were reliable and valid for the design chosen. We report trends from our 
study indicating no changes in the NPS after discontinuation of antipsychotic medication, 
which were in line with previous antipsychotic discontinuation studies (Bridges-Parlet et 
al., 1997;Cohen-Mansfield et al., 1999;van Reekum et al., 2002;Ballard et al., 2004;Ruths
et al., 2004;Ruths et al., 2008;Ballard et al., 2008;Ballard et al., 2009). In the group of 
patients whose antidepressants were discontinued, we found a 50% reduction in the 
depressive symptoms assessed with the Cornell Scale of Depression in Dementia (CSDD), 
which raises some questions. Was the higher prevalence and severity of depressive 
symptoms at inclusion an expression of the adverse effects of the antidepressant 
prescribed? Did the carers in the nursing homes report a decrease in depressive symptoms 
after 25 weeks, because our hypothesis was that nursing-home patients in Norway were 
over-medicated? Anyway, the results encouraged us to conduct a double blind randomized 
controlled trial (DB RCT) on the discontinuation of antidepressants.
As far as we know, we have conducted the first double blind RCT discontinuation study of 
antidepressant medication on patients with dementia and NPS living in nursing homes, 
meaning that our results have to be discussed in the light of the results in clinical trials on 
the initiation of antidepressant drug therapy rather than discontinuation studies. Ulfvarson 
et al. have published a single blind antidepressant discontinuation study of patients 
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without dementia and with no known depressive disorder (Ulfvarson J et al., 2003). The 
clinicians treating the patients were aware of the discontinuation of antidepressants in half 
of the patients, but the raters were blinded to whether or not an individual patient had 
discontinued treatment. They found no differences between the discontinuation group and 
the continuation group. 
In our DB RCT discontinuation study we found an increase in depressive symptoms in the 
group of patients discontinuing their antidepressant medication. Several DB RCT studies 
on the effect of antidepressants for depression in patients with dementia have been 
published. Some studies have published positive results (Roth et al., 1996;Lyketsos et al.,
2003), but mostly studies have published negative results (Banerjee et al., 2011;Rosenberg
et al., 2010;Weintraub et al., 2010). One study has indicated a positive effect of 
antidepressants for NPS, especially emotional bluntness, confusion, irritability, anxiety, 
fear/panic, depressed mood and restlessness (Nyth and Gottfries, 1990), but this result has 
not been reproduced. None of our patients had a depressive disorder at inclusion, and we 
ensured that patients were excluded if there was a history of depression or documented 
depressive disorder in the medical record of the patients. At inclusion the median score on 
the CSDD was 4 in the antidepressant discontinuation group (ADG) and 5 in the
antidepressant continuation group (ACG), indicating no depressive disorder at inclusion. 
After 25 weeks the mean change in CSDD score was 2.53 (increasing depressive 
symptoms) in the ADG and -0.43 (decreasing depressive symptoms) in the ACG, a highly 
statistically significant result. Nevertheless, the CSDD scores after 25 weeks were still not 
an indication of a depressive disorder. Comparison of our results with studies on the effect 
of antidepressants for a depressive disorder is, therefore, difficult. All the same it is 
interesting that removing a treatment, for which there is weak evidence in the literature, 
significantly changes the CSDD score in the patients in a small cohort of patients. 
One obvious difference between our discontinuation study and studies of the effect of 
antidepressants is the cohort of included patients. We included patients who had been 
prescribed antidepressants for more than three months, and, although the indication for 
prescribing the medication in the first place was poorly documented in the patients’ 
medical records, there is a chance that the prescribing doctor had observed depressive 
symptoms justifying the prescription. The cohort studied for the effect of antidepressants 
had a documented depressive disorder at inclusion, indicating that our study cohort was 
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different from the study cohort in studies of the effectiveness of antidepressants for a 
depressive disorder. 
Another explanation for divergence between the results of our study and previous studies 
of the effect of antidepressants for depression is the doses of antidepressant used in the 
different studies. In our study the mean antidepressant dosage at inclusion was 15.9 
mg/day for citalopram (79.5% of defined daily dose, DDD), 25.0 mg/day for paroxetine 
(125% of DDD), 65.0 mg/day for sertraline (130% of DDD) and 10.6 mg/day for 
escitalopram (106% of DDD). In two studies on the effects of antidepressant for 
depression the mean sertraline dose was 70 mg/day (Banerjee et al., 2011) and 90 mg/day 
(Rosenberg et al., 2010). In the study by Nyth et al. patients in the treatment group 
received 20-30 mg citalopram per day (Nyth and Gottfries, 1990), substantially higher 
doses than the patients were prescribed at inclusion in our study. In conclusion, the 
patients in our study were prescribed lower doses of antidepressants at inclusion than 
patients in studies of the effectiveness of antidepressant for depression. It is unlikely that 
the negative effects of the described studies are caused by too high daily doses of the 
antidepressants, and the differences in mean daily dose of antidepressants cannot explain 
the disparity between the studies. 
In our study we tapered out the antidepressant medication over one week in a blinded way, 
and discontinued the medication at day seven. This discontinuation period is shorter than 
clinicians would have chosen for patients in a usual nursing-home setting. Could the quick 
one-week discontinuation period have led to the increasing depressive symptoms in the 
ADG? Analysing the CSDD score, in the patients completing the 25-week study period, at 
the five assessments (baseline, four, seven, thirteen and twenty-five weeks), showed that 
the changes from baseline to the following assessments were statistically significant at 
assessment three (week seven), assessment four (week 13) and assessment 5 (week 25). 
The small increase in the mean CSDD score from 5.25 at baseline to 5.73 after four weeks 
in the ADG could hardly support the notion that quick discontinuation leads to increasing 
depressive symptoms.
The DB RCT discontinuation study we have presented is unique because it is the only 
discontinuation study of antidepressants in patients with dementia and NPS. The results 
contradict other studies, which was probably caused by differences in the study 
populations. The clinical interpretation of the study is that patients using antidepressive 
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drugs for NPS are affected by the medical treatment, and they will deteriorate if the 
antidepressants are discontinued. A large DB RCT study including patients not previously 
prescribed antidepressants for NPS should be conducted, to find evidence for the effect of 
antidepressants for NPS.
6.5 Methodological issues 
The studies have some general methodological limitations. No aetiologic dementia 
diagnoses were made for the patients included in the two first studies. The classification of 
patients into no dementia and mild, moderate and severe dementia was based on 
categorical scores on the Clinical Dementia Rating Scale (CDR). However, previous 
studies in Norwegian nursing-home patients have revealed a good correlation between 
CDR scores and the dementia diagnosis based on clinical examination of the patients 
(Engedal, 1993;Nygaard and Ruths, 2003). For the two antidepressant discontinuation 
studies all patients were examined by the nursing-home clinician and an aetiological 
dementia diagnosis was made.
Several assessors were involved in the project. For the study on the prevalence and course 
of the NPS in nursing homes, the assessors were registered nurses from the nursing 
homes, who assessed patients in their own nursing home. In the validation study of the 
SIB, all patients were examined by the project leader and one registered nurse. For the 
pilot discontinuation study, the only assessor was the project leader, and for the DESEP 
antidepressant discontinuation study there were 16 study centres with minimum one to 
three research nurses. All assessors underwent a one-day training course, and they were all 
supervised during the project period. Nevertheless, there is a chance that inter-tester bias 
may have arisen during testing as there could have been small individual differences in the 
manner in which tests and assessment scales were applied to the patients, although inter-
rater reliability is good for all the assessment scales used in the project. 
To be able to generalise the results of the studies, the cohorts have to be representative of 
the general nursing-home population. To assure representativeness in the DESEP 
antidepressant discontinuation study, a multicentre approach with 16 study centres in 14 
counties was chosen. In the remaining three studies the nursing homes were chosen for 
their convenience. In the validation study of the SIB effort was made to include patients 
with mild, moderate and severe dementia, based on the CDR score. Patients in the pilot 
discontinuation study, the study on the course of the NPS and the validation study of the 
94
SIB were recruited from nursing homes in two counties (Oppland and Hedmark) situated 
in the south-eastern part of Norway. The counties are rural areas, comprise a few middle-
sized towns and lack the multi-ethnicity found in larger cities. For the SIB validation 
study, the representativeness of the nursing homes is of less significance to the validity of 
the study, but, to be able to generalize the results in the study on the prevalence and course 
of the NPS in nursing homes from the studied cohort to the general nursing-home 
population, we should have used a more representative sample. Nevertheless our results 
on the course of the NPS in patients with dementia are comparable with previous studies 
in Norway and internationally (Selbaek et al., 2007;Selbaek et al., 2008;Wetzels et al.,
2010b), indicating that the courses of the symptoms are a result of the dementia disease 
itself rather than environmental factors that vary between nursing homes. 
6.6 Further directions for research
Much research has been done on dementia, depression in dementia, neuropsychiatric 
symptoms in dementia and the treatment for different symptoms of dementia. 
Nevertheless, there are several topics that should be studied further.
As mentioned, a large DB RCT studying the effect of antidepressants for NPS should be 
conducted. The evidence for the effects of antidepressants for depression in patients with 
dementia is weak, and the evidence for the use of antidepressants for the treatment of NPS 
is virtually non-existent. Theoretically, SSRI could be effective for depressive symptoms 
in dementia, as decreased levels of serotonin are found in patients with AD and FTD 
(Salmon, 2007).
A further classification of patients with fluctuating and persistent NPS should be carried 
out, and studies on genetic polymorphism in patients with or without persistent NPS 
should be conducted. To prevent severe and persistent NPS in patients with dementia, risk 
factors for NPS should be identified. Therefore, longitudinal studies on patients with 
dementia should be carried out, preferably from MCI to severe dementia, taking into 
account potential biological, psychological and social triggers. Linking the NPS and 
dementia to diseases and symptoms earlier in life is essential to identify risk factors for 
dementia as well as NPS. 
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As the evidence for medical treatment for depression in dementia and NPS in dementia is 
weak, research into non-medical treatment for depression and NPS in dementia should be 
carried out. 
There are several studies on the Quality of Life in dementia, but more studies are needed. 
One step would be to agree on a definition for Quality of Life in dementia. The Quality of 
Life in persons with dementia in relation to depression has been studied, but more studies 
on the relation between the treatment of depression or NPS and the Quality of Life are 
needed. 
The concept of depression in dementia should be studied for the better understanding of 
the differences between depression in the elderly, depressive symptoms in patients with 
dementia and a depressive disease in patients with dementia. Further, studies on the 
treatment, both medical and psycho-social, options for depression in dementia should be 
conducted.  
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7 Conclusions
We have studied the validity and reliability of the Norwegian version of the Severe 
Impairment Battery (SIB). This cognitive test was found both valid and reliable when used 
on patients with moderate and severe dementia living in Norwegian nursing homes. 
Furthermore, we studied the prevalence and the course of neuropsychiatric symptoms 
(NPS) in patients with dementia in Norwegian nursing homes. We found that NPS were 
prevalent and that most of the patients had at least one NPS at all times. The three NPS 
with highest cumulative prevalence were irritability (63.5%), agitation (51.0%) and 
disinhibition (50.0%). The individual NPS followed a fluctuating course, but delusion, 
agitation and irritability were the most persistent NPS. This should be taken into account 
when treating patients with NPS in dementia. 
Finally, we conducted a DB RCT antidepressants discontinuation study in patients with 
dementia and NPS, but no depressive disorder. After 25 weeks the group of patients 
discontinuing antidepressant treatment had a significant increase in their depressive 
symptoms assessed by the Cornell Scale of Depression in Dementia (CSDD), compared to 
the group of patients continuing antidepressant medication, who had a small decrease in 
their depressive symptoms. 
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ABSTRACT
Background: Neuropsychiatric symptoms (NPS) are common in patients with dementia, and cause distress for
patients. Studies on the prevalence, incidence, persistence and resolution of NPS in patients living in nursing
homes are sparse. The aim of this study was to evaluate the course of NPS in patients with dementia living in
Norwegian nursing homes.
Methods: 169 patients from seven Norwegian nursing homes were assessed ﬁve times over a period of 16
months with the Neuropsychiatric Inventory (NPI). The severity and the frequency of the NPI were analyzed.
Results: 91.7% of the patients had at least one clinically signiﬁcant NPS at one or more assessments over
the 16 months. Irritability (63.5%), agitation (51.0%) and disinhibition (50.0%) had the highest cumulative
prevalence, while irritability (42.6%), disinhibition (37.8%) and depression (31.5%) showed the highest
cumulative incidence. Delusion, agitation and irritability were enduring symptoms while the other symptoms
had high resolution rates. The severity of the NPS did not vary signiﬁcantly over time.
Conclusion: Almost every patient in Norwegian nursing homes had at least one clinically signiﬁcant NPS over
16 months, but individual NPS show a ﬂuctuating course. This should inﬂuence how we monitor and treat
NPS in patients with dementia.
Key words: Neuropsychiatric Inventory, prevalence, incidence, resolution, persistence
Introduction
According to a recently published study, 80.5%
of persons living in Norwegian nursing homes
have dementia (Selbaek et al., 2007). In addition
to cognitive decline, neuropsychiatric symptoms
(NPS) are disturbing symptoms in all dementia
diseases. Of the patients with dementia in
Norwegian nursing homes, 71% have at least
one clinically signiﬁcant neuropsychiatric symptom
as measured by the Neuropsychiatric Inventory
(Selbaek et al., 2007). Neuropsychiatric symptoms
cause distress for the patients, their relatives and
nursing home staff (Sourial et al., 2001), and
increase the incidence of physical restraints in the
nursing homes (Werner et al., 1989; Kirkevold et al.,
2004) and the prescription of psychotropic drugs
(Bartels et al., 2003).
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As dementia becomes more severe, the NPS
occur more frequently (Selbaek et al., 2007).
Not surprisingly therefore, the prevalence of NPS
among community-dwelling patients with dementia
is lower (Lyketsos et al., 2002; Aalten et al., 2005;
Savva et al., 2009) than among patients living
in nursing homes (Ballard et al., 2001; Selbaek
et al., 2007; Zuidema et al., 2007). Previous
studies assessing the course of NPS have included
community-dwelling patients (Devanand et al.,
1997; Marin et al., 1997; Haupt et al., 2000;
Aalten et al., 2005; Ryu et al., 2005) and nursing
home patients (Burton et al., 1995; Wagner et al.,
1995; Ballard et al., 2001; Wancata et al., 2003;
Selbaek et al., 2008b;Wetzels et al., 2010). Although
the studies differ in terms of their assessment
instruments, length of the follow-up period and
number of assessments within the follow-up period,
they have some results in common. Most of
the patients with dementia have at least one
neuropsychiatric symptom present at all times, but
it seems that the speciﬁc NPS have a ﬂuctuating
course. Only one study on the course of NPS in
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nursing home patients has a longer follow-up period
than one year (Wetzels et al., 2010). Therefore, there
is a lack of long-term follow-up studies focusing
on the course of NPS. The aim of our study was
to assess the prevalence, incidence, resolution and
persistence of NPS, and to study the severity of
NPS with frequent assessments during a 16-month
follow-up period in a group of nursing homes
patients.
Methods
Patients
Patients were recruited between April 2008 and
April 2010 from seven nursing homes in two
counties in the south-eastern part of Norway. The
seven nursing homes were non-randomly invited to
take part in the study. They contain special care
units and regular units and are a mix of small and
big nursing homes. All 271 patients in these nursing
homes were invited to take part in the study, and the
inclusion criterion was that the patient or a relative
consented to participation. Sixty-one patients were
not included in the study, leaving 210 patients for
inclusion. Of the 61 who were not included, 29
declined to participate, 25 relatives declined on
behalf of the patients, two patients moved out of the
nursing home before data collection commenced,
one patient was in a terminal stage of life, and four
patients were not asked to participate because it
was deemed improper to ask for the consent by
the nursing home care workers. Fifty-seven patients
(27.1%) lived in a Special Care Unit (SCU) and
153 patients (72.9%) lived in Ordinary Units (OU).
Of the 210 patients, 169 patients (80.5%) had
dementia deﬁned as a Clinical Dementia Rating
Scale (CDR) score > 0.5. An analysis was done
using data collected from these 169 patients with
dementia.
Procedure and assessments
The patients were assessed every four months
for 16 months, a total of ﬁve assessments (T0–
T4) by 25 registered nurses from the nursing
homes. All assessors attended a two-day course
on the use of the assessment scales prior to
the data collection and were experienced in
administering tests to patients with dementia.
The assessors interviewed professional caregivers
(registered nurses or assistants) at the nursing
homes, and the same assessor interviewed the same
professional caregiver at each assessment. T0 refers
to the baseline assessment, while the other four
assessments are referred to as T1 to T4, respectively.
The mean time between the assessments was 140.2
days, SD 19.6 (T0–T1), 140.1 days, SD 22.2 (T1–
T2), 130.7 days, SD 15.9 (T2–T3) and 129.7 days,
SD 17.7 (T3–T4).
Assessments scales
The NPS were assessed with the Neuropsychiatric
Inventory (NPI) (Cummings et al., 1994). We
used the 12-item version (Cummings, 1997), which
includes the following neuropsychiatric symptoms:
delusions, hallucinations, agitation, depression,
anxiety, apathy, irritability, euphoria, disinhibition,
aberrant motor behavior, night time behavior
disturbance and appetite and eating abnormalities.
For each symptom, the severity and the
frequency were scored based on a structured
interview with the professional caregivers in the
nursing homes. The severity (1–3 points) and
frequency (1–4 points) for each symptom were
multiplied to get the score for each symptom (1–
12 points). A score above three on an individual
symptom was deﬁned as a clinically signiﬁcant
symptom (CS-NPS) (Steinberg et al., 2004). The
total NPI score (0–144 points) was obtained by
summing the scores of the 12 symptoms. The
validity and reliability of the NPI have been
established (Cummings and McPherson, 2001), as
have the reliability and the validity of the Norwegian
version of NPI (Selbaek et al., 2008a).
In addition to the NPI, the Mini-Mental State
Examination (MMSE) (Folstein et al., 1975) and
the CDR (Hughes et al., 1982; Berg, 1988) were
administered to the patients. MMSE was used to
assess the cognitive function of the patients, and
CDR to assess the severity of the dementia. No
etiological dementia diagnoses were established.
The validity and inter-tester reliability for each
assessment scale has been established.
Demographics and information on psychotropic
drug use were collected from the patients’
records. We used the Anatomical Therapeutic
Chemical (ATC) classiﬁcation system to select ﬁve
groups of psychotropic drugs: antipsychotics, anti-
depressants, tranquilizers (sedatives and anxiolyt-
ics), cognitive enhancers and other.
Statistical analysis
Statistical analyses were performed with Statistical
Package for Social Science (SPSS), version 15.0.
We did an exploratory analysis, and the differences
between patients with complete and incomplete
data were analyzed with independent student’s t-
test and χ2 test for continuous and categorical
data, respectively. Non-parametric statistics were
used for non-normally distributed data. We
calculated point prevalence, cumulative prevalence,
incidence, cumulative incidence, and persistence
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and resolution rates for each of the 12 items of the
NPI. Point prevalence is the proportions of patients
with a CS-NPS at each assessment, and cumulative
prevalence is the proportions of patients with a
CS-NPS on at least one of the ﬁve assessments.
Incidence is the proportion of patients who were
symptom free at one assessment, but developed
a CS-NPS at the next assessment. Cumulative
incidence is the proportion of patients who were
symptom free at baseline but developed a CS-NPS
at one of the following assessments. Persistence is
the ratio of residents with CS-NPS at follow-up to
residents with CS-NPS at the previous assessment,
and resolution is the ratio of residents without
CS-NPS at follow-up to the residents with CS-
NPS at the previous assessment. To analyze the
variation in severity of the NPI over time, we used
the linear multiple level model (MLM). MLM is a
good statistic technique for analyzing hierarchically
data with repeated assessments, also when data are
missing (Field, 2009).
Ethical and legal considerations
Patients or their next of kin gave their informed
consent, depending on the severity of the patient’s
dementia. The study was approved by the Regional
Ethics Committee for Medical Research in South-
Eastern Norway and by the Data Inspectorate and
the Norwegian Directorate of Health.
Results
Demographic characteristics
Table 1 shows the demographic data of the included
patients at baseline (T0). The number of patients
lost to follow-up were 19 (11.2%), 37 (21.9%), 53
(31.3%) and 73 (43.2%) for assessments two to ﬁve
(T1–T4), respectively. Sixty-eight patients (40.2%)
died during the follow-up period and ﬁve patients
(3.0%) moved to another nursing home. Premature
discontinuations from the study due to moving to
another nursing home were at 3, 12, 19, 24 and
36 weeks. The mean age of the included patients
was 84.9 years (SD 6.7), 69.2% were women and
the median length of stay in the nursing home was
673 days, minimum 28 days and maximum 6087
days (inter-quartile range, IQR, 249–1372). For
the 61 patients not included in the study, their
mean age was 84.9 years (SD 9.9), 63.9% were
women and the median length of stay was 658 days
(IQR 314–1568). The age, the gender, the length
of the stay and the NPI score were not signiﬁcantly
different in the two groups. The average MMSE
score at baseline was 14.5 (SD 6.0). The group of
patients who completed the ﬁve assessments had
an MMSE score of 15.3 (SD 6.1) at baseline and
the group of patients who did not complete the ﬁve
assessments had a MMSE score of 13.0 (SD 5.7)
(p<0.05). Regarding the use of psychotropic drugs
we found a statistical difference between the groups:
90.4% of patients lost to follow-up and 78.1%
of the completers used at least one psychotropic
medication, p = 0.033. The groups also differed
in terms of CDR with the group of patients who
completed ﬁve assessments having a signiﬁcantly
lower CDR score (p<0.05).
Prevalence and cumulative prevalence rates
Table 2 shows the prevalence and the cumulative
prevalence rates of the individual CS-NPS. The
prevalence of any CS-NPS varied between 62.9%
and 72.0% over the ﬁve assessments. The three
most prevalent CS-NPS were irritability, agitation
and apathy (T0 and T1), irritability, agitation
and disinhibition (T2 and T3) and depression,
disinhibition and irritability (T4). The three CS-
NPS with the highest cumulative prevalence
were irritability (63.5%), agitation (51.0%) and
disinhibition (50.0%). In all, 91.7% of the patients
had at least oneCS-NPS at one ormore assessments
over the 16 months.
Incidence and cumulative incidence rates
The incidence and the cumulative incidence rates
are shown in Table 3. The NPS with the
highest incidence rate were irritability, apathy
and agitation (T0–T1) disinhibition, irritability
and apathy (T1–T2), irritability, delusions and
aberrant motor behavior (T2–T3) and irritability,
apathy and agitation (T3–T4). Irritability (42.6%),
disinhibition (37.8%) and depression (31.5%)
showed the highest cumulative incidence.
Persistence and resolution
The persistence and the resolution rates of the CS-
NPS are shown in Table 4. The three CS-NPS
with the highest persistence rates were agitation,
irritability and disinhibition for the ﬁrst (T0–T1)
and second (T1–T2) follow-up period. For the third
(T2–T3) follow-up period disinhibition, apathy and
irritability showed highest persistence rates, while
for the last follow-up period (T3–T4) the three
CS-NPS with the highest persistence rates were
hallucination, depression and anxiety. On the other
hand, the three CS-NPS with the highest resolution
rates were euphoria, eating change and night-time
behavior (T0–T1) and (T1–T2), eating change,
hallucination and delusion (T2–T3) and eating
change, euphoria and apathy (T3–T4).
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Table 1. Demographic characteristics at baseline for all included patients, patients completing the study
period and patients lost-to-follow up, with statistical comparison of patients with and without complete
data
PATIENTS LOST PATIENTS WITH
TOTAL GROUP TO FOLLOW UP COMPLETE DATA
n = 169 n = 73 n = 96 p-value
................................................................................................................................................................................................................................................................................................................
Age in years - mean (SD)a) 84.9 (6.7) 85.6 (5.6) 84.4 (7.4) 0.538
Female gender (%)b) 117 (69.2) 56 (76.7) 61 (63.5) 0.066
Length of stay in days - median (IQR)c) 673 (249–1372) 746 (343–1451) 623 (169–1335) 0.211
CDR = 1 (%)b) 35 (20.7) 8 (6.8) 27 (28.1) 0.016
CDR = 2 (%) 63 (37.3) 28 (38.4) 35 (36.5)
CDR = 3 (%) 71 (43.4) 37 (50.7) 34 (35.4)
MMSE - mean (SD)a) 14.5 (6.0) 13.0 (5.7) 15.3 (6.1) 0.045
NPI – one or more symptoms (%)b) 154 (91.1) 70 (95.9) 84 (87.5) 0.839
NPI - one or more clin. sign. symptoms∗ (%)b) 119 (70.4) 52 (71.2) 67 (69.8) 0.193
Use of psychotropic drug (%)b) 141 (83.4) 66 (90.4) 75 (78.1) 0.033
Use of antidepressants (%)b) 72 (42.6) 34 (46.6) 38 (39.6) 0.363
Use of antipsychotic (%)b) 37 (21.9) 19 (26.0) 18 (18.8) 0.257
Use of tranquilizers (%)b) 94 (55.6) 40 (54.8) 54 (56.3) 0.850
Use of cognitive enhancers (%)b) 35 (20.7) 16 (21.9) 19 (19.8) 0.372
Use of any other psychotropic drug (%)b) 18 (10.7) 6 (8.2) 12 (12.5) 0.735
CDR = Clinical Dementia Ratio, MMSE = Mini Mental State Examination, NPI = Neuropsychiatric Inventory, IQR = Interquartile
Range.
SD = Standard Deviation.
∗ Clinical Signiﬁcant Neuropsychiatric Symptoms = NPI > 3.
a) Independent Student’s t-test, b) Pearson Chi-square test c) Mann-Whitney U test.
Table 2. Prevalence and cumulative prevalence of Clinically Signiﬁcant Neuropsychiatric Symptoms∗
(%)
CUMULATIVE T0 T1 T2 T3 T4
PREVALENCE n = 169 n = 150 N = 132 N = 116 N = 96
SYMPTOMS T0 - T4 PREV1 PREV2 PREV3 PREV4 PREV5
...................................................................................................................................................................................................................................................................................................
Delusion 44.9 25.5 23.4 26.2 26.1 26.1
Hallucination 17.7 12.0 11.2 10.4 9.7 7.8
Agitation 51.0 32.3 34.9 32.1 27.0 29.2
Depression 45.8 20.4 21.3 17.1 21.4 29.3
Anxiety 35.4 20.0 20.9 21.3 14.9 18.3
Euphoria 18.7 5.4 3.4 3.1 7.0 8.3
Apathy 44.8 25.9 28.0 26.6 26.3 22.1
Disinhibition 50.0 16.5 22.4 32.3 31.0 29.5
Irritability 63.5 35.1 36.9 37.2 36.2 37.2
Ab motor behaviour 45.8 23.6 21.5 22.1 23.7 16.8
Night time behaviour 32.3 13.7 14.2 14.6 15.7 16.8
Eating change 32.3 13.3 7.4 13.0 10.6 12.6
At least one CS-NPS∗ 91.7 70.4 72.0 70.5 62.9 68.8
∗ Clinically Signiﬁcant Neuropsychiatric Symptoms = NPI > 3.
T0 = Baseline/ﬁrst assessment, T1 = second assessment, T2 = third assessment, T3 = fourth assessment, T4 = ﬁfth assessment.
1, 2, 3,4 and 5 Prevalence among all patients completing the ﬁrst, second, third, fourth and ﬁfth assessment, respectively.
Severity over time
We calculated the multilevel linear models statistics
for the ﬁrst-, second- and third-order polynomial
growth curve of the individual NPI items. Analysis
of the severity of the individual NPI items over time
did not show signiﬁcant differences for individual
NPI items, reported as the linear, quadratic or
cubic trend best describing the pattern of the data
over time: delusion F(1, 287.92) = 0.59, p =
0.44; hallucination F(1, 300.73) = 1.09, p = 0.28;
agitation F(1, 319.15) = 2.47, p = 0.12; depression
F(1, 277.67) = 2.71, p = 0.10; anxiety F(1,
310.78) = 0.20, p = 0.65; euphoria F(1, 311.39) =
0.57, p = 0.45; apathy F(1, 284.70) = 1.53,
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Table 3. Cumulative incidence and Incidence of Clinically Signiﬁcant Neuropsychiatric Symptoms∗ (%)
CUMULATIVE INCIDENCE INCIDENCE INCIDENCE INCIDENCE
INCIDENCE n = 150 n = 132 N = 116 N = 96
SYMPTOMS T1 - T4 T0 -T1 T1 -T2 T2 -T3 T3 -T4
......................................................................................................................................................................................................................................................................................................................
Delusion 26.6 11.2 13.5 14.3 12.3
Hallucination 10.8 5.0 5.5 5.1 2.4
Agitation 24.2 13.7 11.0 10.0 14.1
Depression 31.5 11.0 7.4 12.0 12.7
Anxiety 22.4 10.7 13.1 4.4 6.5
Euphoria 13.3 2.9 3.2 5.4 5.7
Apathy 27.8 17.6 13.8 9.8 13.3
Disinhibition 37.8 13.6 18.8 9.3 11.6
Irritability 42.6 18.5 14.1 16.4 17.7
Ab motor beh. 27.5 9.4 12.4 13.0 2.9
Night time beh. 21.3 9.6 9.8 7.3 8.8
Eating change 22.0 3.1 10.7 7.1 9.5
At least one CS-NPS∗ 82.9 44.2 32.4 19.4 40.4
∗ Clinically Signiﬁcant Neuropsychiatric Symptoms = NPI > 3.
T0 = Baseline/ﬁrst assessment, T1 = second assessment, T2 = third assessment, T3 = fourth assessment, T4 = ﬁfth assessment.
p = 0.22; disinhibition F(1, 297.89) = 0.21, p =
0.65; irritability F(1, 283.85) = 0.02, p = 0.90;
aberrant motor behavior F(1, 276.72) = 1.33,
p = 0.25; night-time behavior F(1, 311.90) = 2.22,
p = 0.14; and eating change F(1, 296.62) = 0.32,
p = 0.57.
Use of psychotropic drugs
Of the 169 patients analyzed in the study, 83.4%
used at least one psychotropic drug on a daily
basis at the baseline registration; 42.6% used
an antidepressant, 21.9% used an antipsychotic,
55.6% used a tranquilizer and 20.7% used a
cognitive enhancer.
Of the 96 patients completing the ﬁve
assessments, 82 (85.4%) used one or more
psychotropic drug at least at one assessment.
Sixty-two out of the 90 patients (75.6%) had a
persistent use as they used at least one psychotropic
drug at four or ﬁve out of ﬁve assessments.
Tranquilizers were the group of psychotropic drug
most frequently prescribed. Sixty-three out of 97
patients (75.6%) used a tranquilizer at least at one of
the assessments during the follow-up period, and 37
of these 63 (58.7%) used a tranquilizer at four or ﬁve
assessments during the period. Thirty-two out of 96
patients (33.3%) used an antipsychotic at least at
one assessment, and 10 of these 32 (31.3%) used the
antipsychotic at four or ﬁve assessments. Fifty out
of the 96 patients (52.1%) used an antidepressant at
least at one assessment during the follow-up period,
and 26 of these 50 (52.0%) used the antidepressant
at four or ﬁve assessments.
Discussion
We report the prevalence, incidence, persistence
and resolution of neuropsychiatric symptoms of
patients living in Norwegian nursing homes. Our
cohort consisted of 210 patients (from a total of
271) living in seven nursing homes. Of these, 169
patients had dementia according to a CDR rating
of 1 and above, and results from these patients were
analyzed.
Prevalence
We found that irritability, agitation and disinhibition
are the most prevalent NPS in nursing homes,
which correspond to other studies (Ballard et al.,
2001; Selbaek et al., 2007; Wetzels et al., 2010).
In contrast, apathy, depression and aberrant
motor behavior are found to be more prevalent
among outpatients (Aalten et al., 2005). Owing to
differences in assessment instruments, the studies
by Wancata et al. (2003) and Wagner et al. (1995)
are difﬁcult to compare with ours, but Wancata et al.
report a cumulative prevalence over six months of
depression 32.6%, delusion 9.3% and hallucination
2.4%. The studies by Aalten et al. (2005) and
Wetzels et al. (2010) are comparable to our study
using the same design, following a cohort of patients
with dementia over ﬁve consecutive assessments
with the NPI. However, the two Dutch studies
differ from our study as the time between each
assessment in their studies was six months not four.
We report that the cumulative prevalence of any CS-
NPS over 16 months is 91.7% compared to 96.6%
in a nursing home population in the Netherlands
6 S. Bergh et al.
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(Wetzels et al., 2010). When looking at single
NPI symptoms, Wetzels et al. report that delusion,
hallucination, depression and disinhibition are
approximately half as prevalent as we report in our
study. In the study by Aalten et al. (2005) on Dutch
outpatients they reported similar ﬁgures to ours on
the cumulative prevalence of individual clinically
signiﬁcant NPS. Our drop-out rate was 43.2%,
caused by death (68 patients) and moving from the
nursing home (ﬁve patients). Aalten et al. (2005)
reported a drop-out rate of 50%, with 24% due to
death and 26% refusing to participate. Wetzels et al.
(2010) reported a drop-out rate of 60% (54% due
to death and 6% moving to another nursing home).
At inclusion our patients had a mean MMSE score
of 14.5 points, whereas those in the study by Aalten
et al. (2005) had a mean MMSE score of 18.1 (SD
4.7) and those in the study by Wetzels et al. (2010)
had a mean MMSE score of 7.6 (SD 7.1). These
MMSE differences and the differences in drop-out
rates should be regarded as a possible explanation
for the difference in the results. The follow-up
periods in their studies was eightmonths longer than
in our study, with the same number of assessments,
which also could explain the difference in the
results. In addition, pharmacological treatment and
non-pharmacological interventions could also have
inﬂuenced the results of the three studies, but
we do not have sufﬁcient information of such
variables to make any conclusions. In our study
the nursing homes received extra attention from the
department of Old Age Psychiatry during the study.
They were given extensive information on dementia
and the different assessment scales. Parallel with
the assessment of the NPS the nursing homes
were encouraged to create their own small research
project to improve the quality of their care. This
extra attention might therefore have improved the
quality of care in the nursing homes, which could
explain some of the differences between our study
and other similar studies.
Incidence
We report that irritability (42.6%), disinhibition
(37.8%) and depression (31.5%) showed the
highest cumulative incidence. A previous Swiss
study has reported an incidence after six months
of 10.5% for depression, 4.7% for delusion and
0.0% for hallucination (Wancata et al., 2003), while
a previous Norwegian study reported that agitation,
apathy and irritability have the highest cumulative
incidence after one year (Selbaek et al., 2008b). This
result was conﬁrmed in the study from the Nether-
lands by Wetzels et al. (2010), which also found
that depression (19.6%) and disinhibition (16.7%)
had a fairly low cumulative incidence. Why this
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difference? Selbæk and colleagues report data for
a large number of patients on two assessments over
one year, but do not have information on the symp-
toms experienced by the patients between the two
assessments. Both Wetzels’ study and our own have
a remarkably higher cumulative incidence rate than
that reported by Selbæk and colleagues, indicating
that the NPS show a rapid cycling in their course.
The study by Wetzels and colleagues was based
on patients with dementia living in Special Care
Units (SCU), and their dementia was more severe
than in other studies. As the dementia progresses
the presentation of the NPS changes. This could
contribute to the differences between the stud-
ies. Delusion, hallucination, agitation/aggression,
apathy, disinhibition and aberrant motor behavior
all signiﬁcantly increase in frequency with more
severe dementia (Selbaek et al., 2007).
Persistence, resolution and possible inﬂuence
of psychotropic drug use
In our study delusions, agitation, depression,
disinhibition, irritability and aberrant motor
behavior showed high persistence over the ﬁve
assessments, which correspond with the results
from a previous study on nursing home patients who
reported agitation/aggression and aberrant motor
behavior to be the most persistent NPS (Wetzels et
al., 2010). In the Swiss study (Wancata et al., 2003),
depression was persistent in 63.3%, delusion in
50.0% and hallucination in 50.0%. In outpatients,
depression, apathy and aberrant motor behavior
were the NPS with highest persistence (Aalten et al.,
2005). Compared to the two Dutch studies it seems
that patients with dementia living at home differ in
their symptom expression from the nursing home
patients with dementia. This difference could be
due to dementia severity, but also to environmental
factors, caregiver burden and pharmacological and
non- pharmacological interventions (Rozzini et al.,
2006).
We noted that the use of psychotropic drugs was
very common among our study subjects; 83.4% of
them used at least one psychotropic drug at one
assessment during the 16 months period. Almost
76% of the patients used one or more psychotropic
drugs at four or ﬁve out of the ﬁve assessments. We
did not speciﬁcally compare the persistent use of
psychotropic drugs with the persistence of the CS-
NPS. However, as the persistent use of psychotropic
drugs generally is very high, we assume that the
persistence of NPS is not inﬂuenced to a signiﬁcant
degree by the drug use. According to the results
of two previous studies of nursing home patients,
the severity of dementia and factors associated with
being institutionalized most probably explain the
persistence of the NPS (Selbaek et al., 2008b;
Wetzels et al., 2010).
Severity over time
We did not ﬁnd any signiﬁcant change in the
severity of the NPS during the 16-month follow-
up period. This contradicts the ﬁndings of Aalten
et al. (2005) in their two-year study of NPS in
outpatients and Wetzels et al. (2010) in their nursing
home cohort. Aalten et al. reported signiﬁcantly
decreased severity of depression and increased
severity of aberrant motor behavior and apathy,
while Wetzels et al. reported signiﬁcant reduction
in depression and anxiety. We do not know how
to explain these contradictory ﬁndings, although
differences in statistical methods may play a role.
Wetzels et al. used Friedman test to analyze change
in NPI severity score over time, whereas Aalten et al.
used analyses of variance (ANOVA) with repeated
measurements; in our study we used the Multiple
Level Method.
Clinical implications and treatment options
Our study conﬁrms the ﬁndings from previous
studies. Most of the patients with dementia,
living either in nursing homes or in their own
homes, will experience at least one NPS over the
course of 16 to 24 months. Individual symptoms
have a ﬂuctuating course, with high resolution
and incidence rate throughout the period. As
clinicians we should monitor our patients well,
with repeated assessments with the NPI or another
systematic tool for the NPS. In the same way
as we monitor the blood sugar and adjust the
treatment in patients with Diabetes Mellitus we
should monitor and adjust the treatment in patients
with dementia and NPS. According to our results,
delusion, hallucinations, disinhibition, agitation
and irritability have a resolution rate between
assessments varying from 30 to 40%, indicating that
approximately one-third of the patients with these
symptoms are symptom-free four months later. At
the same time, we know that 75% of patients with
dementia using an antipsychotic are still prescribed
the same antipsychotic 12 months later (Selbaek
et al., 2008b). We see the same trend concerning
the symptoms of depression, anxiety, apathy and
irritability. The resolution rates for these symptoms
are between 26% and 50% while the persistence
rates for antidepressant prescription is 79.2% over
12 months (Selbaek et al., 2008b).
There are several weaknesses in the present
study. The nursing homes taking part in the
study were a convenience sample of nursing homes
from the south-eastern part of Norway. There was
no randomization or stratiﬁcation when inviting
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nursing homes to take part in the study, and the
patients in our study may not be representative of
the Norwegian nursing home population. In fact,
we believe that the nursing homes taking part in
the study were among the better nursing homes
in the region, according to their knowledge of,
education and interest in dementia. It is likely that
knowledge of and interest in dementia among the
professional caregivers in the nursing homes will
reduce NPS among the nursing home residents,
and our study may underestimate the prevalence
of NPS in Norwegian nursing homes. Dementia
was diagnosed based on a CDR scale score of
1, 2 or 3, but we did not make any etiological
dementia diagnosis which could improve the quality
of our study. We were therefore unable to perform
regression analysis adjusted for dementia diagnosis;
however, previous studies have demonstrated that
staging dementia based on the CDR score is a valid
substitute for a dementia diagnosis (Nygaard and
Ruths, 2003). We did not make any adjustments for
use of psychotropic drugs and somatic or psychiatric
comorbidity, nor did we adjust for differences in
nursing staff and type of ward in the nursing homes.
The patients were assessed by several assessors,
and although they all attended a two-day training
course and the Norwegian version of the NPI has
been found to have good inter-rater reliability, the
relatively high number of assessors could bias the
results. Almost all the patients lost to follow-up
died during the follow-up period, and as shown
in the analysis, the patients lost to follow-up
had signiﬁcantly more severe dementia than the
patients completing the follow-up period. In our
study, as well as in other studies (Selbaek et al.,
2008b;Wetzels et al., 2010), changes in symptoms
may partly be due to the Hawthorn effect whereby
the symptoms of the patients taking part in the
study can improve just because they are taking part
(Roethlisberger et al., 1939).
The strength of our study is the relatively large
number of included patients, and the relatively low
drop-out rate (43.2%) compared to other nursing
home studies. We made assessments of the patients
every four months, a shorter interval than other
reported studies.
Conclusion
We report a high prevalence of neuropsychiatric
symptoms in Norwegian nursing homes. Only 8%
of the patients did not experience a CS-NPS over
the 16-month follow-up period. The most prevalent
NPS were irritability, agitation and disinhibition,
and these also had the highest persistence. Most of
the NPS are ﬂuctuating in their course, and very few
symptoms are present continuously for more than
eight months.
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
Table 1. Demographic characteristics at baseline for all included patients (n=128), with 
statistical analysis of differences between antidepressant discontinuation group (ADG) and 
antidepressant continuation group (ACG).  
ADG ACG   
  
n = 63 n = 65  p-
value 
Age in years  - mean (SD) a) 85.3 (8.2) 86.1 (6.7) 0.543 
Female gender (%) b) 49 (77.8) 47 (72.3) 0.475 
Diagnosis b)    
     AD (%)  32 (50.8) 38 (58.5) 0.193 
     VaD (%) 16 (25.4) 10 (15.4) 0.159 
     Mixed AD/VaD (%) 15 (23.8) 17 (26.2) 0.759 
Clinical Dementia Rating b)    
     CDR = 1 (%)  8 (12.5) 8 (12.3) 0.947 
     CDR = 2 (%) 32 (50.0) 31 (47.7) 0.726 
     CDR = 3 (%) 23 (35.9) 26 (40.0) 0.684 
SIB  - median (IQR) c) 78 (64.5 - 91.5) n=50 81 (68 - 94) n=52 0.721 
       - mean (SD) 72.5 (19.5) 70.9 (25.6) 
 
CSDD - median (IQR) c) 4 (1.5 - 6.5) n=61 5 (1.5 - 8.5) n=64 0.278 
       - mean (SD) 5.03 (4.15) 5.89 (4.62)   
CSDD - mood - median (IQR) c) 1 (0 - 2) n=63 1 (-1 - 3) n=64 0.228 
       - mean (SD) 1.28 (1.71) 1.95 (2.40)  
CSDD - non Mood - median (IQR) c) 3 (1 - 5) n=62 2.5 (0 - 5) n=64 0.931 
       - mean (SD) 3.44 (3.30) 3.32 (2.90)  
NPI10 - Sum - median (IQR) c) 13 (3.5 - 22.5) 16 (6.5 - 25.5) 0.678 
       - mean (SD) 17.78 (16.75) 17.63 (14.09)  
PSMS - median (IQR) c) 18 (14.5 - 21.5) 19 (9 - 29) 0.329 
       - mean (SD) 17.25 (4.67) 18.14 (5.45) 
 
QoL-AD - patient's rating, mean (SD) a)  33.67 (5.03) n=46 34.38 (5.05) n=50 0.494 
QoL-AD - caregivers' rating, mean (SD) a) 31.06 (5.57) 30.72 (5.05) 0.715 
UPDRS - median (IQR) c) 2 (0 - 4) 3 (0.5 - 5.5) 0.117 
       - mean (SD) 3.08 (2.84) 4.38 (4.06)  
Weight - mean (SD) a) 66.46 (15.06) n=54 66.33 (11.78) n=58 0.958 
Other psychotropic medication   
       - median (IQR) c) 2 (1.5 - 2.5) 2 (1 - 3) 0.407 
       - mean (SD) 1.94 (1.01) 2.11 (1.11)  
Falls/day last 21 days before inclusion    
       - median (IQR) c) 0 (0 - 0) 0 (0 - 0) n=64 0.820 
       - mean (SD) 0.02 (0.09) 0.01 (0.03)  
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Mg oxazepam/day last 21 days 
 before inclusion    
       - median (IQR) c) 0 (0 - 0) 0 (0 - 0) 0.831 
       - mean (SD) 0.67 (3.63) 0.18 (0.55)  
ADG = Antidepressant Discontinuation Group, ACG = Antidepressant Continuation Group, SD = 
Standard Deviation, IQR = Interquartile Range,  AD = Alzheimer's Disease, VaD = Vascular 
Dementia, CDR = Clinical Dementia Rating Scale, SIB = Severe Impairment Battery, CSDD = the 
Cornell Scale of Depression in Dementia, NPI10 = Neuropsychiatric Inventory 10 items version, 
PSMS = Lawton and Brody's Physical Self-Maintenance scale, QoL-AD = Quality of Life - Alzheimer 
Disease, UPDRS = Unified Parkinson's Disease Rating Scale, six-item version 
a) Independent Student’s t-test, b) Pearson Chi-square test c) Mann-Whitney U test 
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Table 2. Results of the efficacy analysis at week 25 
 
ADG ACG   
  
n = 59 n = 58  p-value 
Primary efficacy analysis    
Change in CSDD score, mean (SD) LOCF a) '79)=975">C9; - 0.43 (3.61) 0.001* 
Change in CSDD score, mean (SD) OC a) 379'=)7:">C)) - 0.98 (3.63) n=46 0.085 
Change in CSDD score, mean (SD) LOCF c) '74M=3795>C9; -0.38 (0.56) < 0.001* 
Change in NPI-10 score, mean (SD) LOCF a)  5.93 (19.41) -1.39 (14.31) n=57 0.023* 
Change in NPI-10 score, mean (SD) OC a)  0.80 (17.25) n=35 -1.59 (12.07) n=46 0.466 
Change in NPI-10 score, mean (SD) LOCF c) 5.82 (1.95) -1.27 (1.98) 0.012* 
    
Secondary efficacy variables    
Change in CSDD mood score, mean (SD) a) 37;9="7M9>C9) -0.25 (1.85) n=51 0.006* 
Change in CSDD non-mood score, mean (SD) a) "7:4=97"5>C99 0.42 (3.30) n=57 0.074 
CSDD responders (%) b)     
     > 30 % improvement ")=''73> 19 (32.8) 0.193 
     30 % improvement to 30 % deterioration "4=')7;> 22 (37.9) 0.096 
     > 30 % deterioration )'=947'> 17 (29.3) 0.006* 
Change in NPI – Affective subsyndrom, mean (SD) a) 1.59 (6.23) - 0.69 (4.62) 0.026* 
NPI - Affective subsyndrom, responders (%) b)     
     > 30 % improvement 18 (30.5) 18 (31.0) 0.951 
     30 % improvement to 30 % deterioration 28 (47.5) 34 (58.6) 0.226 
     > 30 % deterioration 13 (22.0) 6 (10.3) 0.087 
Change in NPI - agitation subsyndrom, mean (SD) a)  "7:M=;7M3> 0.41 (7.39) 0.266 
Change in NPI - psychotic subsyndrom - mean (SD) a) "73;=979M> 0.09 (3.04) 0.240 
Change in NPI - apathy - mean (SD) a) 37;)=)7:3> -0.12 (3.58) n=57 0.224 
Clinical Dementia Rating b)   
     Missing (%) 3 (5.1) 7 (12.1) 0.177 
     CDR = 0.5 (%)  0 (0.0) 1 (1.7) 0.311 
     CDR = 1 (%) 6 (10.2) 7 (12.1) 0.744 
     CDR = 2 (%) 23 (39.0) 19 (32.8) 0.483 
     CDR = 3 (%) 27 (45.8 24 (41.4) 0.633 
Change in SIB  - mean (SD) a) -0.87 (14.74) n=31 -1.95 (17.41) n=39 0.784 
Change in UPDRS, mean (SD) a) 3793='75;>C9M 0.07 (2.73) 0.392 
Change in PSMS, mean (SD) a) 0.89 (3.27) n=56 1.06 (2.69) n=53 0.777 
Change in weight, mean (SD) a) -1.51 (3.66) n=37 -0.04 (3.62) n=46 0.071 
Change in QoL-AD - patient's rating - mean (SD) a)  -0.50 (5.04) n=28 0.24 (4.99) n=33 0.567 
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Change in QoL-AD - caregivers' rating - mean (SD) a) -2.26 (5.19) n=54 -1.90 (5.20) n=52 0.725 
Change in falls/day, mean (SD) a) -0.01 (0.08) n=56 0.01 (0.03) n=53 0.055 
Change in mg oxazepam/day, mean (SD) a) 0.40 (2.43) n=54 0.07 (0.34) n=54 0.336 
Change in psychotropic medication, median (IQR) 0 (0-0) n=56 0 (0-0) n=54 0.190 
                                                            - mean (SD) -0.13 (0.605) -0.20 (0.562)  
  
 
ADG = Antidepressant Discontinuation Group, ACG = Antidepressant Continuation Group, CSDD = the 
Cornell Scale of Depression in Dementia, LOCF = last observation Carried Forward, OC = Observed Cases, 
SD = Standard Deviation, IQR = Interquartile Range, NPI-10 = the Neuropsychiatric Inventory 10 items 
version, CDR = the Clinical Dementia Rating Scale, SIB = Severe Impairment Battery, QoL-AD = Quality of 
Life - Alzheimer Disease, UPDRS=Unified Parkinson’s Disease Rating Scale, six-item version, PSMS = 
Lawton's Physical Self-Maintenance scale 
a)
 Independent Student’s t-test, b) Pearson Chi-square test c) Analyze of Covariance, with baseline values as 
covariate, * p<0.05 
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Table 3. Number of patients completing twenty-five weeks intervention and number of 
patients discontinued intervention prematurely 
ADG ACG   
  
n = 63 n = 65  p-
value 
Completed 25 weeks intervention, no (%) 1) 35 (55.6) 46 (70.8) 0.074 
Discontinued intervention, no (%)    
     Death, somatic disease or hospitalization 2) 7 (11.1) 7 (10.8) 1.000 
     Withdrawal of consent 2) 5 (7.9) 4 (6.2) 0.742 
     Increased symptoms 2) 13 (20.6) 4 (6.2) 0.019* 
     Could not swallow the study capsules 2) 2 (3.2) 1 (1.5) 0.616 
     Moved from the nursing home 2) 1 (1.6) 1 (1.5) 1.000 
     Did not take the study medication as prescribed 2) 0 (0.0) 2 (3.1) 0.496 
        
ADG = Antidepressant Discontinuation Group, ACG = Antidepressant Continuation Group 
1)
 Pearson Chi-square test 2) Fisher's Exact test, * p<0.05 
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